CN105452224A - Multifunctional quinoline derivatives as anti-neurodegenerative agents - Google Patents

Multifunctional quinoline derivatives as anti-neurodegenerative agents Download PDF

Info

Publication number
CN105452224A
CN105452224A CN201380075030.2A CN201380075030A CN105452224A CN 105452224 A CN105452224 A CN 105452224A CN 201380075030 A CN201380075030 A CN 201380075030A CN 105452224 A CN105452224 A CN 105452224A
Authority
CN
China
Prior art keywords
alcohol
base
quinoline
chloro
methyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN201380075030.2A
Other languages
Chinese (zh)
Other versions
CN105452224B (en
Inventor
陈基旺
黄振玮
张佩德
塔立卡·R·S
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ricky Biotechnology New Pharmaceutical Co.,Ltd.
Original Assignee
Annji Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Annji Pharmaceutical Co Ltd filed Critical Annji Pharmaceutical Co Ltd
Publication of CN105452224A publication Critical patent/CN105452224A/en
Application granted granted Critical
Publication of CN105452224B publication Critical patent/CN105452224B/en
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/24—Oxygen atoms attached in position 8
    • C07D215/26—Alcohols; Ethers thereof
    • C07D215/28—Alcohols; Ethers thereof with halogen atoms or nitro radicals in positions 5, 6 or 7
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/24—Oxygen atoms attached in position 8
    • C07D215/26—Alcohols; Ethers thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Abstract

Novel quinolone derivatives are disclosed. Also disclosed are synthesis and use thereof for treating neurodegenerative diseases. In an aspect, the invention relates to a composition comprising a therapeutically effective amount of the compound as aforementioned, or a pharmaceutically acceptable salt, a solvate or hydrate, a prodrug, or a metabolite thereof and a pharmaceutically acceptable diluent or carrier. Further in another aspect, the invention relates to a composition comprising a compound as aforementioned, or a pharmaceutically acceptable salt, a solvate or hydrate, a prodrug, or a metabolite thereof, and a pharmaceutically acceptable diluent or carrier to use in treating a neurodegenerative disease. Yet in another aspect, the invention relates to a use of a compound as aforementioned in the manufacture of a medicament for treating a neurodegenerative disease. In one embodiment, the medicament is for treating Alzheimer's disease.

Description

As the multi-functional quinoline of anti-nerve degeneration agent
Technical field
The present invention is about a kind of compound or its medical acceptable salt, solvate or hydrate, prodrug or the metabolite that are used for the treatment of neurodegenerative disorders.
Background technology
United States Patent (USP) the 7th, 439, No. 243 and the 7th, 452, No. 888 are disclosed a series of quinoline, and it is abnormal that it can be used for treatment CNS, comprises Alzheimer's disease.United States Patent (USP) the 7th, records a series of quinoline for 009, No. 053 and can be used for treatment Alzheimer's disease, Heng Dingdunshi disease, Parkinson's disease, amyotrophic lateral sclerosis, apoplexy, local asphyxia, traumatic brain injury, Spinal injury or osteoarthritis.
Summary of the invention
In one side, the present invention is about a kind of formula (I) compound or its medical acceptable salt, solvate or hydrate, prodrug or metabolite:
Wherein
R 1for hydrogen, (C 1-C 8) alkyl, (C 1-C 8) stretch alkyl (C 3-C 8) cycloalkyl, (C 1-C 8) alkylhalide group or (C 1-C 8) stretch alkyl (C 6-C 20) aryl;
R 2for hydrogen or halogen;
R 3for hydrogen, halogen, (C 1-C 8) alkyl or (C 1-C 8) alkoxyl group;
R 4for hydrogen, halogen, (C 1-C 8) alkyl, (C 1-C 8) alkoxyl group or (C 1-C 8) alkylhalide group;
R 5for hydrogen or (C 1-C 20) alkanol;
R 6for hydrogen; And
R 7for hydrogen, (C 1-C 20) alkanol, (C 1-C 8) stretch alkyl (C 3-C 8) heterocyclic radical (C 1-C 20) alkanol, (C 1-C 8) stretch alkyl (C 3-C 8) heterocyclic radical (C 1-C 20) alkyl, (C 1-C 8) stretch alkyl (C 1-C 6) alkyl amine group (C 1-C 6) alkynyl, (C 1-C 8) stretch alkyl amine group (C 1-C 20) alkanol or (C 1-C 8) stretch alkyl amine group (C 1-C 20) alkanol (C 1-C 8) stretch alkyl replace (C 3-C 20) heteroaryl.
In another aspect, the present invention is about a kind of method preparing aforesaid compound, and the method comprises:
(1) by formula (II) compound
Wherein:
R 2, R 3, R 4, R 5and R 6respective is independently hydrogen; Or
R 2, R 4, R 5and R 6independently be hydrogen and R separately 3for CH 3; Or
R 2, R 3, R 5and R 6independently be hydrogen and R separately 4for CH 3, F, Cl or Br; Or
R 2, R 5, R 6respective is independently hydrogen, R 3for OCH 3and R 4for Cl; Or
R 2, R 4for Cl and R 3, R 5, R 6respective is independently hydrogen,
With toluene bromide, methyl iodide, iodoethane, 2-N-PROPYLE BROMIDE or methylene radical Cyclopropyl Bromide in an alkalescence
React at about room temperature is to about 80 DEG C in liquid, to obtain formula (III) compound,
Wherein:
R 1for CH 3, CH 2cH 3, CH (CH 3) 2, CH 2cH (CH 3) 2or phenmethyl; And
R 2, R 3, R 4, R 5and R 6respective is independently hydrogen; Or
R 2, R 4, R 5and R 6independently be hydrogen and R separately 3for CH 3; Or
R 2, R 3, R 5and R 6independently be hydrogen and R separately 4for CH 3, F, Cl or Br; Or
R 2, R 5, R 6respective is independently hydrogen, R 3for OCH 3and R 4for Cl; Or
R 2, R 4for Cl and R 3, R 5, R 6respective is independently hydrogen;
(2) formula (III) compound and two (trimethyl silicon based) amido lithium and monobromo (C1-C20) alkanol are reacted, to obtain formula (I) compound in tetrahydrofuran (THF) at 0 DEG C
Wherein:
R 1for CH 3, CH 2cH 3, CH (CH 3) 2, CH 2cH (CH 3) 2or phenmethyl;
R 2, R 3, R 4, R 5and R 6respective is independently hydrogen; Or
R 2, R 4, R 5and R 6independently be hydrogen and R separately 3for CH 3; Or
R 2, R 3, R 5and R 6independently be hydrogen and R separately 4for CH 3, F, Cl or Br; Or
R 2, R 5, R 6respective is independently hydrogen, R 3for OCH 3and R 4for Cl; Or R 3for Cl and R 4for OCH 3or
R 2, R 4for Cl and R 3, R 5, R 6respective is independently hydrogen; And
R 7for (CH 2) 9oH, (CH 2) 10oH, (CH 2) 11oH, (CH 2) 12oH, (CH 2) 13oH or (CH 2) 15oH,
(3) wherein R is incited somebody to action 1for formula (I) compound of phenmethyl, at room temperature reacted in methyl alcohol by palladium carbon under pressure with hydrogen, or react at 0 DEG C in methylene dichloride with boron trichloride, to obtain formula (I) compound
R 1, R 2, R 3, R 4, R 5and R 6respective is independently hydrogen; Or
R 1, R 2, R 4, R 5and R 6independently be hydrogen and R separately 3for CH 3; Or
R 1, R 2, R 3, R 5and R 6independently be hydrogen and R separately 4for CH 3, F, Cl or Br; Or
R 1, R 2, R 5, R 6respective is independently hydrogen, R 3for OCH 3and R 4for Cl; Or
R 2, R 4for Cl and R 1, R 3, R 5, R 6respective is independently hydrogen; And
R 7for (CH 2) 9oH, (CH 2) 10oH, (CH 2) 11oH, (CH 2) 12oH, (CH 2) 13oH or (CH 2) 15oH; Or
(4) wherein R is incited somebody to action 1, R 2, R 3, R 4, R 5and R 6independently be hydrogen and R separately 7for (CH 2) 11formula (I) compound of OH, at room temperature reacts in methyl chloride with N-chloro-succinimide, to provide formula (I) compound, wherein R 1, R 3, R 5and R 6respective is independently hydrogen, R 2and R 4independently be chlorine and R separately 7for (CH 2) 11oH; Or
(5) wherein R is incited somebody to action 1for methyl, R 2, R 3, R 4, R 5and R 6independently be hydrogen and R separately 7for (CH 2) 11oH, (CH 2) 12oH or (CH 2) 13formula (I) compound of OH, with concentrated hydrochloric acid, ICl 3and glacial acetic acid reacts, to provide formula (I) compound, wherein R 1for methyl, R 2, R 3, R 5and R 6respective is independently hydrogen, R 4for Cl and R 7for (CH 2) 10oH, (CH 2) 11oH, (CH 2) 12oH, (CH 2) 13oH, (CH 2) 15oH, (CH 2) 10oCOCH 3, (CH 2) 11oCOCH 3, (CH 2) 12oCOCH 3or (CH 2) 13oCOCH 3; Or
(6) 2-amino-phenol and methyl vinyl ketone are reacted in hydrochloric acid, to obtain formula (INT-1) compound
(7) formula (INT-1) compound and methyl iodide, iodoethane, 2-N-PROPYLE BROMIDE, methylene radical Cyclopropyl Bromide or toluene bromide are reacted in basic solution, to provide formula (III) compound
Wherein R 10for methyl, ethyl, 2-propyl group, methylene radical cyclopropyl or phenmethyl;
(8) wherein R is incited somebody to action 10for formula (III) compound of methyl, ethyl, 2-propyl group, methylene radical cyclopropyl or phenmethyl, react at 0 DEG C in tetrahydrofuran (THF) with two (trimethyl silicon based) amido lithium and the bromo-1-decanol of 10-or the bromo-1-undecyl alcohol of 11-, to obtain formula (I) compound, wherein R 1for methyl, ethyl, 2-propyl group, methylene radical cyclopropyl or phenmethyl; R 2, R 3, R 4, R 6and R 7respective is independently hydrogen; And R 5for (CH 2) 11oH or (CH 2) 12oH;
(9) wherein R is incited somebody to action 1for phenmethyl; R 2, R 3, R 4, R 6and R 7respective is independently hydrogen; And R 5for (CH 2) 11oH or (CH 2) 12formula (I) compound of OH, is at room temperature reacted by palladium carbon under pressure with hydrogen in methyl alcohol, to obtain formula (I) compound, wherein R 1for hydrogen; R 2, R 3, R 4, R 6and R 7respective is independently hydrogen; And R 5for (CH 2) 11oH or (CH 2) 12oH; Or
(10) 2-trifluoro-methoxyaniline and crotonic aldehyde are reacted, to obtain 2-methyl-8-trifluoromethoxy quinoline, by it with two (trimethyl silicon based) amido lithium and monobromo (C 1-C 20) alkanol processes, to obtain formula (I) compound, wherein R in tetrahydrofuran (THF) at 0 DEG C 1for trifluoromethyl; R 2, R 3, R 4, R 5and R 6respective is independently hydrogen; And R 7for (CH 2) 10oH, (CH 2) 11oH, (CH 2) 12oH, (CH 2) 13oH or (CH 2) 15oH; Or
(11) by the 8-hydroxy-2-methylquinoline compound of the same form (IV), wherein R 1for hydrogen, methyl, ethyl, 2-propyl group or methylene radical cyclopropyl
React at an elevated temperature in dioxan with tin anhydride, to provide the same form (VI) compound, R 1for hydrogen, methyl, ethyl, 2-propyl group or methylene radical cyclopropyl
(12) wherein R is incited somebody to action 1for formula (VI) compound of hydrogen, methyl, ethyl, 2-propyl group or methylene radical cyclopropyl, react with N-methyl-prop ynamine, to obtain the same form (I) compound, wherein R 1for hydrogen, CH 3, CH 2cH 3, CH 2cH (CH 3) 2, CH 2cH (CH 2) 2or CH (CH 3) 2, R 2, R 3, R 4, R 5and R 6respective is independently hydrogen; And R 7for CH 2n (CH 3) CH 2c ≡ CH; Or
(13) by R 1for formula (VI) compound of hydrogen, methyl, ethyl, 2-propyl group or methylene radical cyclopropyl, react with 2 (piperazine-1-base) ethanol, to obtain the same form (I) compound, wherein R 1for hydrogen, CH 3, CH 2cH 3, CH 2cH (CH 3) 2, CH 2cH (CH 2) 2or CH (CH 3) 2, R 2, R 3, R 4, R 5and R 6respective is independently hydrogen; And R 7for CH 2(N (CH 2cH 2) 2n) CH 2cH 2oH; Or
(14) by formula (VI) compound and an amido (C 1-C 20) alkanol carries out reacting to obtain the same form (I) compound, wherein R 1for hydrogen, CH 3, CH 2cH 3, CH 2cH (CH 3) 2, CH 2cH (CH 2) 2or CH (CH 3) 2; R 2, R 3, R 4, R 5and R 6respective is independently hydrogen; And R 7for CH 2nH (CH 2) 8oH or CH 2n ((CH 2) 6oH) CH 2(8-methoxy quinoline-2-base).
In another aspect, the present invention is about a kind of constituent, and it comprises aforesaid compound or its medical acceptable salt, solvate or hydrate, prodrug or the metabolite of a treatment significant quantity, and medical acceptable thinner or a supporting agent.
In another aspect, the present invention is about a kind of constituent, it comprises an aforesaid compound or its medical acceptable salt, solvate or hydrate, prodrug or metabolite, and medical acceptable thinner or a supporting agent, can be used for treatment one neurodegenerative disorders.
In more on the one hand, the present invention is about the purposes of a kind of aforesaid compound for the preparation of neurodegenerative disorders medicine for treatment thing.In an embodiment, this medicine is for being used for the treatment of Alzheimer's disease.
Explanation by following preferred embodiment is coordinated following accompanying drawing and has gained some understanding by these and other aspect, but can carry out changing and revising under the spirit not deviating from novel concept of the present invention and scope.
Subsidiary accompanying drawing illustrates one or more specific embodiment of the invention, coordinates invention description can illustrate principle of the present invention.If likely, identical Ref. No. is to represent the identical of specific embodiment or like for whole accompanying drawing.
Accompanying drawing explanation
Figure 1A-B shows Compound C 12 morphological analysis for the impact that fA β is formed and fA β s is separated under zine ion presence or absence condition.
Fig. 2 show Compound C 12 zine ion not in the presence of suppress the polymerization of A β.
Fig. 3 A-B shows Compound C 12 as the neuroprotective for fA β.
Fig. 4 shows the axon growth that quinoline brings out.
Fig. 5 shows the performance that quinoline increases GAP43 (marker of axon growth).
Fig. 6 shows the result of roller-test.
Fig. 7 A-D shows the result of Morris water maze test.
After Fig. 8 is shown in Compound C 12 treatment, in dysmnesia fA β diseased mice, GAP43 increase and fA β reduce.
Embodiment
Unless context has clear indicating, otherwise " one " of singulative and " being somebody's turn to do " comprises the situation of plural number.
Not at two letters or intersymbol dash "-" in order to represent a part or substituent tie point.For example ,-CONH 2part is for connect by carbon atom.
Term " amido " expression-NH 2.Amido can be substituted arbitrarily, as the definition " be substituted " for term herein.Term " alkyl amine group " expression-NR 2, wherein at least one R is alkyl and second R is alkyl or hydrogen.Term " acyl group amido " represents N (R) C (=O) R, and wherein each R is independently hydrogen, alkyl or aryl.
Term " alkyl " represents containing normal chain, secondary, three grades or ring carbon atom C 1– C 18hydrocarbon.Example is methyl, ethyl, 1 – propyl group, 2 – propyl group, 1 – butyl, 2 – Jia Ji – 1 – propyl group (isobutyl-， – CH 2cH (CH 3) 2), 2 – butyl (the second butyl ， – CH (CH 3) CH 2cH 3), 2 – Jia Ji – 2 – propyl group (tributyl ， – C (CH 3) 3), 1 – amyl group, 2 – amyl groups, 3 – amyl groups, 2 – Jia Ji – 2 – butyl, 3 – Jia Ji – 2 – butyl, 3 – Jia Ji – 1 – butyl, 2 – Jia Ji – 1 – butyl, 1 – hexyl, 2 – hexyls, 3 – hexyls, 2 – Jia Ji – 2 – amyl groups, 3 – Jia Ji – 2 – amyl groups, 4 – Jia Ji – 2 – amyl groups, 3 – Jia Ji – 3 – amyl groups, 2 – Jia Ji – 3 – amyl groups, 2,3 – bis-Jia Ji – 2 – butyl, 3,3 – bis-Jia Ji – 2 – butyl.Alkyl can be monovalent hydrocarbon group, described above and illustration, or it can be divalent hydrocarbyl mission (namely stretching alkyl).This alkyl can replace through one or more following groups arbitrarily: alkoxyl group, halogen, alkylhalide group, hydroxyl, hydroxyalkyl, aryl, heteroaryl, heterocycle, cycloalkyl, alkyloyl, alkoxy carbonyl, amido, imido grpup, alkyl amine group, acyl group amido, nitro, trifluoromethyl, trifluoromethoxy, carboxyl, carboxyalkyl, ketone group, thioketones base, alkylthio, alkyl sulphinyl, alkyl sulphonyl, cyano group, acetamido, acetoxyl group, ethanoyl, benzoylamino, benzenesulfinyl, benzene sulfonamido, benzenesulfonyl, benzenesulfonyl amido, benzoyl, benzoyl amido, benzoyloxy, phenmethyl, benzyloxy, Benzyloxycarbonyl, benzylthio, amine formyl, amine formyloxy, isocyanato (isocyannato), sulfamic, amine sulfinyl, sulfino, sulfonic group, sulfonic acid amido, thiosulfo, NR xr yand/or COOR x, wherein each R xand R yindependent is H, alkyl, thiazolinyl, aryl, heteroaryl, heterocycle, cycloalkyl or hydroxyl.This alkyl can arbitrarily with one or more non-hydroperoxy groups (– O –), sulfenyl (– S –), amido (– N (H) –), methylenedioxy (– OCH 2o –), carbonyl (– C (=O) –), carboxyl (– C (=O) O –), carbonylic dioxo base (– OC (=O) O –), carboxylic foundation (– OC (=O) –), imido grpup (C=NH), sulfinyl (SO) or alkylsulfonyl (SO 2) interrupt.In addition, this alkyl can be arbitrarily at least part of unsaturation, therefore provides a kind of thiazolinyl.
Term " is stretched alkyl " to represent saturated, the side chain of a kind of 1-18 carbon atom or straight chain or cyclic hydrocarbon group, and have on the identical or different carbon atom by female alkanes and remove two hydrogen atoms and derivative two monovalent radical centers.Typical case stretches alkyl group and includes but not limited to methylene radical (– CH 2–), 1,2 – stretch ethyl (– CH 2cH 2–), 1,3 – stretch propyl group (– CH 2cH 2cH 2–), 1,4 – stretch butyl (– CH 2cH 2cH 2cH 2–) etc.This is stretched alkyl and can replace through one or more following groups arbitrarily: alkoxyl group, halogen, alkylhalide group, hydroxyl, hydroxyalkyl, aryl, heteroaryl, heterocycle, cycloalkyl, alkyloyl, alkoxy carbonyl, amido, imido grpup, alkyl amine group, acyl group amido, nitro, trifluoromethyl, trifluoromethoxy, carboxyl, carboxyalkyl, ketone group, thioketones base, alkylthio, alkyl sulphinyl, alkyl sulphonyl, cyano group, acetamido, acetoxyl group, ethanoyl, benzoylamino, benzenesulfinyl, benzene sulfonamido, benzenesulfonyl, benzenesulfonyl amido, benzoyl, benzoyl amido, benzoyloxy, phenmethyl, benzyloxy, Benzyloxycarbonyl, benzylthio, amine formyl, amine formyloxy, isocyanato, sulfamic, amine sulfinyl, sulfino, sulfonic group, sulfonic acid amido, thiosulfo, NR xr yand/or COOR x, wherein each R xand R yindependent is H, alkyl, thiazolinyl, aryl, heteroaryl, heterocycle, cycloalkyl or hydroxyl.In addition, this stretch alkyl can arbitrarily with one or more non-hydroperoxy groups (– O –), sulfenyl (– S –), amido (– N (H) –), methylenedioxy (– OCH 2o –), carbonyl (– C (=O) –), carboxyl (– C (=O) O –), carbonylic dioxo base (– OC (=O) O –), carboxylic foundation (– OC (=O) –), imines (C=NH), sulfinyl (SO) or alkylsulfonyl (SO 2) interrupt.In addition, this stretches alkyl can be at least part of unsaturation arbitrarily, therefore provides one to stretch thiazolinyl.
Term " alkynyl " represents a kind of single group branched chain or unbranched hydrocarbon chain, and it has a complete unsaturation part (i.e. a carbon-to-carbon sp triple bond).In a specific embodiment, alkynyl can have 2 to 10 carbon atoms, or 2 to 6 carbon atoms.In another specific embodiment, alkynyl can have 2 to 4 carbon atoms.This term can be illustrated by following group: ethynyl, 1-proyl, 2-propynyl, ethyl acetylene base, 2-butyne base, 3-butynyl, 1-hexin base, 2-hexin base, 3-hexin base, 1-octyne base etc.Alkynyl can be and is substituted or the person of being unsubstituted.
Term " alkoxyl group " represents the group of Wan Ji – O –, and wherein alkyl is as definition herein.Preferably alkoxyl group comprises such as methoxyl group, oxyethyl group, positive propoxy, isopropoxy, n-butoxy, the 3rd butoxy, the second butoxy, n-pentyloxy, positive hexyloxy, 1,2-dimethyl butoxy etc.Alkoxyl group can replace through one or more following groups arbitrarily: halogen, alkylhalide group, hydroxyl, hydroxyalkyl, aryl, heteroaryl, heterocycle, cycloalkyl, alkyloyl, alkoxy carbonyl, amido, imido grpup, alkyl amine group, acyl group amido, nitro, trifluoromethyl, trifluoromethoxy, carboxyl, carboxyalkyl, ketone group, thioketones base, alkylthio, alkyl sulphinyl, alkyl sulphonyl, cyano group, acetamido, acetoxyl group, ethanoyl, benzoylamino, benzenesulfinyl, benzene sulfonamido, benzenesulfonyl, benzenesulfonyl amido, benzoyl, benzoyl amido, benzoyloxy, phenmethyl, benzyloxy, Benzyloxycarbonyl, benzylthio, amine formyl, amine formyloxy, isocyanato, sulfamic, amine sulfinyl, sulfino, sulfonic group, sulfonic acid amido, thiosulfo, NR xr yand/or COOR x, wherein each R xand R yindependent is H, alkyl, thiazolinyl, aryl, heteroaryl, heterocycle, cycloalkyl or hydroxyl.
Term " alkanol " represents the compound of general formula R OH, and wherein R is alkyl, and its definition as above.
Term " aryl " represents the unsaturation aromatic carbocyclic group with 6 to 20 carbon atoms of monocycle (such as phenyl) or multiple condensation (condensing) ring, and wherein at least one ring is aromatic ring (such as naphthyl, dihydrophenanthrenyl, fluorenyl or anthryl).Preferably aryl comprises phenyl, naphthyl etc.This aryl can be arbitrarily divalent group, thus provides one to stretch aryl.Aryl can replace through one or more following groups arbitrarily: alkyl, thiazolinyl, alkoxyl group, halogen, alkylhalide group, hydroxyl, hydroxyalkyl, aryl, heteroaryl, heterocycle, cycloalkyl, alkyloyl, alkoxy carbonyl, amido, imido grpup, alkyl amine group, acyl group amido, nitro, trifluoromethyl, trifluoromethoxy, carboxyl, carboxyalkyl, ketone group, thioketones base, alkylthio, alkyl sulphinyl, alkyl sulphonyl, cyano group, acetamido, acetoxyl group, ethanoyl, benzoylamino, benzenesulfinyl, benzene sulfonamido, benzenesulfonyl, benzenesulfonyl amido, benzoyl, benzoyl amido, benzoyloxy, phenmethyl, benzyloxy, Benzyloxycarbonyl, benzylthio, amine formyl, amine formyloxy, isocyanato, sulfamic, amine sulfinyl, sulfino, sulfonic group, sulfonic acid amido, thiosulfo, NR xr yand/or COOR x, wherein each R xand R yindependent is H, alkyl, thiazolinyl, aryl, heteroaryl, heterocycle, cycloalkyl or hydroxyl.
Term " aryloxy " and " alkoxy aryl " respectively represent bond to the aryl of Sauerstoffatom and in moieties bond to the aralkyl of Sauerstoffatom.Example includes but not limited to phenoxy group, naphthyloxy and benzyloxy.
Term " carbocyclic ring " represents saturated, unsaturation or aromatic ring, and it has 3 to 8 carbon atoms is monocycle, and 7 to 12 carbon atoms are dicyclo, and about 30 carbon atoms are many rings at the most.Monocycle carbocyclic ring generally has 3 to 6 annular atomses, is more typically 5 or 6 annular atomses.Bicyclic carbocyclic has 7 to 12 annular atomses, such as, be arranged as dicyclo [4,5], [5,5], [5,6] or [6,6] system, or 9 or 10 annular atomses are arranged as dicyclo [5,6] or [6,6] system.The example of carbocyclic ring comprises cyclopropyl, cyclobutyl, cyclopentyl, 1-ring penta-1-thiazolinyl, 1-ring penta-2-thiazolinyl, 1-ring penta-3-thiazolinyl, cyclohexyl, 1-hexamethylene-1-thiazolinyl, 1-hexamethylene-2-thiazolinyl, 1-hexamethylene-3-thiazolinyl, phenyl, volution base and naphthyl.This carbocyclic ring can replace through the group of above-mentioned substitutable alkyl group arbitrarily.
If a substituting group is designated as one or more atom of specified person, time " or a key ", in the configuration of this substituting group representated by " key ", the specified substituent group of next-door neighbour for by chemically reasonably bond configuration be connected to each other directly.
Term " cycloalkyl " represents the cyclic alkyl of 3 to 20 carbon atoms, and it has monocycle or many cyclic condensations ring.This cycloalkyl comprises, and for example, single ring architecture is such as cyclopropyl, cyclobutyl, cyclopentyl, ring octyl group etc., or polynuclear plane is such as adamantyl etc.Cycloalkyl can replace through one or more following groups arbitrarily: alkyl, thiazolinyl, alkoxyl group, halogen, alkylhalide group, hydroxyl, hydroxyalkyl, aryl, heteroaryl, heterocycle, cycloalkyl, alkyloyl, alkoxy carbonyl, amido, imido grpup, alkyl amine group, acyl group amido, nitro, trifluoromethyl, trifluoromethoxy, carboxyl, carboxyalkyl, ketone group, thioketones base, alkylthio, alkyl sulphinyl, alkyl sulphonyl, cyano group, acetamido, acetoxyl group, ethanoyl, benzoylamino, benzenesulfinyl, benzene sulfonamido, benzenesulfonyl, benzenesulfonyl amido, benzoyl, benzoyl amido, benzoyloxy, phenmethyl, benzyloxy, Benzyloxycarbonyl, benzylthio, amine formyl, amine formyloxy, isocyanato, sulfamic, amine sulfinyl, sulfino, sulfonic group, sulfonic acid amido, thiosulfo, NR xr yand/or COOR x, wherein each R xand R yindependent is H, alkyl, thiazolinyl, aryl, heteroaryl, heterocycle, cycloalkyl or hydroxyl.Cycloalkyl can be arbitrarily at least part of unsaturation, thus provides a kind of cycloalkenyl group.In addition, cycloalkyl can be arbitrarily divalent group, thus provides one to stretch cycloalkyl.
Term " significant quantity " represent be enough to produce favourable or for the quantity of result.In order to be familiar with medical science, person can determine the significant quantity of specific dispensing.
Term " halogen " represents fluorine-based, chloro, bromo and iodo.In the same manner, term " halogen " represents fluorine, chlorine, bromine and iodine.
Term " alkylhalide group " represents the alkyl replaced through 1 –, 4 halogens, and each halogen can be identical or different.Representational alkylhalide group comprises trifluoromethyl, 3 – fluorine dodecyls, 12,12,12 – trifluorododecyl, 2 – bromine octyl groups, 3 – Xiu – 6 – chlorine heptyl etc.
Term " heteroaryl " is containing one, two or three aromatic ring and containing the monocycle of at least one nitrogen, oxygen or sulphur atom, dicyclo or three-ring system in aromatic ring, and it can be and is unsubstituted or the person of being substituted.Heteroaryl can be arbitrarily divalent group, thus provides one to stretch heteroaryl.The example of heteroaryl includes but not limited to 2H-pyrryl, 3H-indyl, 4H-quinolizinyl, 4H-carbazyl, acridyl, benzo [b] thienyl, benzothiazolyl, β-carboline base, carbazyl, chromenyl, cinnolines base (cinnaolinyl), dibenzo [b, d] furyl, furan a word used for translation base, furyl, imidazolyl (imidazolyl), imidazolyl (imidizolyl), indazolyl, indolizine base (indolisinyl), indyl, isobenzofuran-base, pseudoindoyl, isoquinolyl, isothiazolyl, isoxazolyl, naphthyridinyl, naphthalene [2,3-b], oxazolyl, pah pyridine base, phenanthridinyl, phenanthroline base, phenarsazine base, phenazinyl, phenothiazinyl, phenoxazine thiophene base, Phenazoxine base, phthalazinyl, pteridine radicals, purine radicals, piperazine is muttered base, pyrazinyl, pyrazolyl, pyridazinyl, pyridyl, pyrimidyl, pyrryl, quinazolyl, quinolyl, quinoxalinyl, thiadiazolyl group, thianthrenyl, thiazolyl, thienyl, triazolyl and xanthenyl.In one embodiment, term " heteroaryl " represents the monocyclic aromatic ring containing five or six annular atomses, and carbon containing and 1,2,3 or 4 are independently selected from the heteroatoms of non-peroxidation oxygen, sulphur and N (Z), wherein Z does not exist or is H, O, alkyl, phenyl or benzyl.In another specific embodiment, heteroaryl represents that about eight to ten are rolled into a ball spread out survivor by the o-fused bicyclic heterocycle, particularly benzene-derivative of its derivative annular atoms or by condensing to stretch propyl group or stretch butyl double-basis.
Heteroaryl can replace through one or more following groups arbitrarily: alkyl, thiazolinyl, alkoxyl group, halogen, alkylhalide group, hydroxyl, hydroxyalkyl, aryl, heteroaryl, heterocycle, cycloalkyl, alkyloyl, alkoxy carbonyl, amido, imido grpup, alkyl amine group, acyl group amido, nitro, trifluoromethyl, trifluoromethoxy, carboxyl, carboxyalkyl, ketone group, thioketones base, alkylthio, alkyl sulphinyl, alkyl sulphonyl, cyano group, acetamido, acetoxyl group, ethanoyl, benzoylamino, benzenesulfinyl, benzene sulfonamido, benzenesulfonyl, benzenesulfonyl amido, benzoyl, benzoyl amido, benzoyloxy, phenmethyl, benzyloxy, Benzyloxycarbonyl, benzylthio, amine formyl, amine formyloxy, isocyanato, sulfamic, amine sulfinyl, sulfino, sulfonic group, sulfonic acid amido, thiosulfo, NR xr yand/or COOR x, wherein each R xand R yindependent is H, alkyl, thiazolinyl, aryl, heteroaryl, heterocycle, cycloalkyl or hydroxyl.
Term " heterocycle " or " heterocyclic radical " represent a saturated or unsaturated member ring systems of part, and it contains the heteroatoms that at least one is selected from oxygen, nitrogen and sulphur, and arbitrarily through alkyl or C (=O) OR breplace, wherein R bfor hydrogen or alkyl.Typical heterocycle is contain one or more heteroatomic monocycle being selected from oxygen, nitrogen and sulphur, dicyclo or three cyclic groups.Heterocyclic radical also can containing the ketone group (=O) being connected to this ring.The limiting examples of heterocyclic radical comprises 1,3-Dihydrobenzofuranes, 1,3-dioxolane, 1,4-dioxan, Isosorbide-5-Nitrae-dithiane, 2H-piperazine are muttered, 2-pyrazoline, 4H-piperazine are muttered, chromanyl, imidazolidine base, imidazolinyl, indoline base, isochroman base, isoindoline base, morpholine, piperazinyl, piperidines, piperidyl, pyrazoles pyridine, pyrazoles pyridine base, pyrazolinyl, Pyrrolizidine, pyrroline, rubane and thiomorpholine.This heterocyclic radical can be arbitrarily divalent group, thus provides one to stretch heterocyclic radical.Heterocycle can replace through one or more following groups arbitrarily: alkyl, thiazolinyl, alkoxyl group, halogen, alkylhalide group, hydroxyl, hydroxyalkyl, aryl, heteroaryl, heterocycle, cycloalkyl, alkyloyl, alkoxy carbonyl, amido, imido grpup, alkyl amine group, acyl group amido, nitro, trifluoromethyl, trifluoromethoxy, carboxyl, carboxyalkyl, ketone group, thioketones base, alkylthio, alkyl sulphinyl, alkyl sulphonyl, cyano group, acetamido, acetoxyl group, ethanoyl, benzoylamino, benzenesulfinyl, benzene sulfonamido, benzenesulfonyl, benzenesulfonyl amido, benzoyl, benzoyl amido, benzoyloxy, phenmethyl, benzyloxy, Benzyloxycarbonyl, benzylthio, amine formyl, amine formyloxy, isocyanato, sulfamic, amine sulfinyl, sulfino, sulfonic group, sulfonic acid amido, thiosulfo, NR xr yand/or COOR x, wherein each R xand R yindependent is H, alkyl, thiazolinyl, aryl, heteroaryl, heterocycle, cycloalkyl or hydroxyl.
The example of nitrogen heterocyclic and heteroaryl includes but not limited to pyrroles, imidazoles, pyrazoles, pyridine, pyrazine, pyrimidine, pyridazine, indolizine, isoindole, indoles, indazole, purine, quinolizine, isoquinoline 99.9, quinoline, phthalazines, naphthlypyridine, quinoxaline, quinazoline, cinnolines, to talk endlessly pyridine, carbazole, carboline, phenanthridines, acridine, phenanthroline, isothiazole, azophenlyene, isoxzzole, Phenazoxine, thiodiphenylamine, imidazolidine, tetrahydroglyoxaline, piperidines, piperazine, indoline, morpholinyl, piperidyl, tetrahydrofuran base etc. and the N-alkoxyl group-nitrogen containing heterocycle.
Term " hydrate " represents that solvent molecule is the mixture of water.
Term " individuality ", " main body ", " experimenter " and " sufferer " can be used alternatingly, and represent a Mammals, include but not limited to primate, comprise ape and monkey and the mankind.
Term " metabolite " represents from female medicine or its prodrug in vivo or in vitro manufactured any formula (I) compound.
The acceptable salt of medicine of compound as herein described can be synthesized into by traditional chemical routes by parent compound, and wherein parent compound contains alkalescence or an acidic moiety.Generally speaking, by the free acid of these compounds or alkali form, can carry out reacting in water or organic solvent or the mixture of the two with stoichiometric suitable alkali or acid and prepare this kind of salt; Generally speaking, preferably is Non-aqueous vehicles, such as ether, ethyl acetate, ethanol, Virahol or acetonitrile.The list of many applicable salts is found in Remington:TheScienceandPracticeofPharmacy, 21 stedition, Lippincott, Williams & Wilkins, (2005).
The acceptable prodrug of medicine represents that a compound forming formula (I) compound in main body after such as hydrolysis or the metabolism such as oxidation.The functional moieties that the representative instance of prodrug is included in active compound has the compound of biological instability blocking group.Prodrug comprise can oxidized, reduction, amination, go amination, hydroxylation, go hydroxylation, hydrolysis, dehydration, alkylation, alkylation removal, acylations, removal of acylation, phosphorylation, dephosphorylation to be to produce the compound of active compound.
Prodrug can use means known in the art to be prepared easily by formula (I) compound.For example, refer to Publication about Document: Notari, R.E., " TheoryandPracticeofProdrugKinetics, " MethodsinEnzymology, 112:309323 (1985); Bodor, N., " NovelApproachesinProdrugDesign, " DrugsoftheFuture, 6 (3): 165182 (1981); AndBundgaard, H., " DesignofProdrugs:Bioreversible-DerivativesforVariousFunc tionalGroupsandChemicalEntities; " inDesignofProdrugs (H.Bundgaard, ed.), Elsevier, N.Y. (1985); Burger ' sMedicinalChemistryandDrugChemistry, FifthEd., Vol.1, pp.172178,949982 (1995).
Term " solvate " represents the various stoichiometric mixture formed by a solute (for formula (I) compound or its salt class or physiology have functional derivative in the present invention) and a solvent.With regard to object of the present invention, this solvent can't affect the biological activity of this solute.The limiting examples of appropriate solvent includes but not limited to water, methyl alcohol, ethanol and acetic acid.This preferred solvents is medical acceptable solvent.The limiting examples of the acceptable solvent of medicine comprises water, ethanol and acetic acid.
Temperature within the scope of term " room temperature " expression about 20 DEG C to about 30 DEG C.
Term " is substituted " for referring to that one or more hydrogen on specified atom is to be selected from specified group displacement, and prerequisite is that specified atom does not exceed normal valence mumber, and this replacement produces a stable compound.Suitable specified group comprises, such as alkyl, thiazolinyl, alkylidene group, alkenylene, alkoxyl group, halogen, alkylhalide group, hydroxyl, hydroxyalkyl, aryl, heteroaryl, heterocycle, cycloalkyl, alkyloyl, acyloxy, alkoxy carbonyl, amido, imido grpup, alkyl amine group, acyl group amido, nitro, trifluoromethyl, trifluoromethoxy, carboxyl, carboxyalkyl, ketone group, thioketones base, alkylthio, alkyl sulphinyl, alkyl sulphonyl, cyano group, acetamido, acetoxyl group, ethanoyl, benzoylamino, benzenesulfinyl, benzene sulfonamido, benzenesulfonyl, benzenesulfonyl amido, benzoyl, benzoyl amido, benzoyloxy, phenmethyl, benzyloxy, Benzyloxycarbonyl, benzylthio, amine formyl, amine formyloxy, isocyanato, sulfamic, amine sulfinyl, sulfino, sulfonic group, sulfonic acid amido, thiosulfo, NR xr yand/or COOR x, wherein each R xand R yindependent is H, alkyl, thiazolinyl, aryl, heteroaryl, heterocycle, cycloalkyl or hydroxyl.When substituting group be ketone group (namely=O) or thioketones base (namely=S) time, then two hydrogen on atom are replaced.
Term " treatment " represents effect on the desirable pharmacology of acquisition and/or physiology.Just prevent with regard to a disease or its symptom wholly or in part, this effect can be preventative effect, and/or with regard to the detrimentally affect of partially or completely curing a disease and/or being attributable to this disease, this effect can be therapeutic efficacy.
The present invention is about multi-functional quinoline, and it has following characteristic: metal-chelating, scavenging capacity oxygenate, anticoagulation, axon growth and neurone hyperplasia.It can be used for treating and oxidative pressure and other neurotoxicity caused with the relevant imbalance of abnormal unfolded protein aggegation and the related neurodegenerative disorders of exception.In zootype, serious toxicity can not be caused through finding the quinoline (B3 or C12) of abdominal injection 1 to 100mg/kg every day (being preferably 1 to 10mg/kg) that mouse memory can be improved.
In one side, the present invention is about a kind of formula (I) compound or its medical acceptable salt, solvate or hydrate, prodrug or metabolite:
Wherein
R 1for hydrogen, (C 1-C 8) alkyl, (C 1-C 8) stretch alkyl (C 3-C 8) cycloalkyl, (C 1-C 8) alkylhalide group or (C 1-C 8) stretch alkyl (C 6-C 20) aryl;
R 2for hydrogen or halogen;
R 3for hydrogen, halogen, (C 1-C 8) alkyl or (C 1-C 8) alkoxyl group;
R 4for hydrogen, halogen, (C 1-C 8) alkyl, (C 1-C 8) alkoxyl group or (C 1-C 8) alkylhalide group;
R 5for hydrogen or (C 1-C 20) alkanol;
R 6for hydrogen; And
R 7for hydrogen, (C 1-C 20) alkanol, (C 1-C 8) stretch alkyl (C 3-C 8) heterocyclic radical (C 1-C 20) alkanol, (C 1-C 8) stretch alkyl (C 3-C 8) heterocyclic radical (C 1-C 20) alkyl, (C 1-C 8) stretch alkyl (C 1-C 6) alkyl amine group (C 1-C 6) alkynyl, (C 1-C 8) stretch alkyl amine group (C 1-C 20) alkanol or (C 1-C 8) stretch alkyl amine group (C 1-C 20) alkanol (C 1-C 8) stretch alkyl replace (C 3-C 20) heteroaryl.
In the present invention one specific embodiment, wherein
R 1for hydrogen, CH 3, CH 2cH 3, CH (CH 3) 2, CH 2cH (CH 3) 2, CF 3or phenmethyl;
R 2for hydrogen, F or Cl;
R 3for hydrogen, F, Cl, CH 3or OCH 3;
R 4for hydrogen, F, Cl, Br, CH 3, OCH 3or CF 3;
R 5for hydrogen, (CH 2) 11oH or (CH 2) 12oH;
R 6for hydrogen; And
R 7for hydrogen, (CH 2) 9oH, (CH 2) 10oH, (CH 2) 11oH, (CH 2) 12oH, (CH 2) 13oH, (CH 2) 14oH, (CH 2) 15oH, CH 2(N (CH 2cH 2) 2n) CH 2cH 2oH, CH 2(N (CH 2cH 2) 2n) CH 2cH 3, CH 2n (CH 3) CH 2c ≡ CH, CH 2nH (CH 2) 8oH or CH 2n ((CH 2) 6oH) CH 2(8-methoxy quinoline-2-base).
In another specific embodiment of the present invention, wherein
R 1for hydrogen, CH 3, CH 2cH 3, CH (CH 3) 2, CH 2cH (CH 3) 2, CH 2cH (CH 2) 2, CF 3or phenmethyl;
R 2, R 3, R 4, R 5and R 6respective is independently hydrogen; And
R 7for (CH 2) 9oH, (CH 2) 10oH, (CH 2) 11oH, (CH 2) 12oH, (CH 2) 13oH, (CH 2) 14oH, (CH 2) 15oH, CH 2(N (CH 2cH 2) 2n) CH 2cH 2oH or CH 2n (CH 3) CH 2c ≡ CH.
In another specific embodiment of the present invention, wherein
R 1for hydrogen, CH 3, CH 2cH 3, CH 2cH (CH 3) 2, CH 2cH (CH 2) 2or CH (CH 3) 2;
R 2, R 3, R 5and R 6respective is independently hydrogen;
R 4for CH 3, F, Cl, Br, CF 3or OCH 3; And
R 7for (CH 2) 9oH, (CH 2) 10oH, (CH 2) 11oH, (CH 2) 12oH, (CH 2) 13oH, (CH 2) 15oH, (CH 2) 10oCOCH 3, (CH 2) 11oCOCH 3, (CH 2) 12oCOCH 3, (CH 2) 13oCOCH 3, CH 2nH (CH 2) 8oH, CH 2(N (CH 2cH 2) 2n) CH 2cH 2oH, CH 2(N (CH 2cH 2) 2n) CH 2cH 3or CH 2n (CH 3) CH 2c ≡ CH.
In another specific embodiment of the present invention, wherein
R 1for hydrogen, CH 3, CH 2cH 3, CH (CH 2) 2or CH 2cH (CH 2) 2;
R 2, R 4respective is independently Cl;
R 3, R 5and R 6respective is independently hydrogen; And
R 7for (CH 2) 11oH, CH 2nH (CH 2) 8oH or CH 2n (CH 3) CH 2c ≡ CH.
In another specific embodiment of the present invention, wherein
R 1for hydrogen, CH 3, CH 2cH 3, CH 2cH (CH 3) 2, CH 2cH (CH 2) 2, CH (CH 3) 2or phenmethyl;
R 2, R 3, R 4, R 6and R 7respective is independently hydrogen; And
R 5for (CH 2) 11oH or (CH 2) 12oH.
In another specific embodiment of the present invention, wherein
R 1for CH 3;
R 2, R 5and R 6respective is independently hydrogen;
R 3and R 4respective is independently OCH 3or Cl; And
R 7for (CH 2) 11oH.
In another specific embodiment of the present invention, this compound is selected from following formed group: 9-(8-(benzyloxy) quinoline-2-base)-1-alcohol in the ninth of the ten Heavenly Stems, 10-(8-(benzyloxy) quinoline-2-base)-1-alcohol in the last of the ten Heavenly stems, 11-(8-(benzyloxy) quinoline-2-base) 11-1-alcohol, 12-(8-(benzyloxy) quinoline-2-base) 12-1-alcohol, 13-(8-(benzyloxy) quinoline-2-base) 13-1-alcohol, 14-((8-(benzyloxy) quinoline-2-base) 14-1-alcohol, 15-(8-(benzyloxy) quinoline-2-base) 15-1-alcohol, 11-(8-(benzyloxy)-5-toluquinoline-2-base) 11-1-alcohol, 11-(8-(benzyloxy)-6-toluquinoline-2-base) 11-1-alcohol, 11-(8-(benzyloxy)-5-fluorine quinoline-2-base) 11-1-alcohol, 11-(8-(benzyloxy)-5-chloroquinoline-2-base) 11-1-alcohol, 2-(9-hydroxyl nonyl) quinoline-8-alcohol, 2-(10-hydroxy decyl) quinoline-8-alcohol, 2-(11-hydroxyl undecyl) quinoline-8-alcohol, 2-(12-hydroxyl dodecyl) quinoline-8-alcohol, 2-(13-hydroxyl tridecyl) quinoline-8-alcohol, 2-(14-hydroxyl tetradecyl) quinoline-8-alcohol, 2-(15-hydroxyl pentadecyl) quinoline-8-alcohol, 2-(11-hydroxyl undecyl)-5-toluquinoline-8-alcohol, 2-(11-hydroxyl undecyl)-6-toluquinoline-8-alcohol, the chloro-2-of 5-(11-hydroxyl undecyl) quinoline-8-alcohol, 9-(8-methoxy quinoline-2-base)-1-alcohol in the ninth of the ten Heavenly Stems, 10-(8-methoxy quinoline-2-base)-1-alcohol in the last of the ten Heavenly stems, 11-(8-methoxy quinoline-2-base) 11-1-alcohol, 12-(8-methoxy quinoline-2-base) 12-1-alcohol, 13-(8-methoxy quinoline-2-base) 13-1-alcohol, 14-((8-methoxy quinoline-2-base) 14-1-alcohol, 15-(8-methoxy quinoline-2-base) 15-1-alcohol, 11-(8-methoxyl group-5-toluquinoline-2-base) 11-1-alcohol, 11-(the fluoro-8-methoxy quinoline of 5--2-base) 11-1-alcohol, 12-(the fluoro-8-methoxy quinoline of 5--2-base) 12-1-alcohol, 9-(the chloro-8-methoxy quinoline of 5--2-base)-1-alcohol in the ninth of the ten Heavenly Stems, 11-(the chloro-8-methoxy quinoline of 5--2-base) 11-1-alcohol, 15-(the chloro-8-methoxy quinoline of 5--2-base) 15-1-alcohol, 11-(the bromo-8-methoxy quinoline of 5--2-base) 11-1-alcohol, 11-(8-methoxyl group-5-(trifluoromethyl) quinoline-2-base) 11-1-alcohol, 11-(5,8-dimethoxy-quinoline-2-base) 11-1-alcohol, 11-(8-methoxyl group-6-toluquinoline-2-base) 11-1-alcohol, 11-(the fluoro-8-methoxy quinoline of 6--2-base) 11-1-alcohol, 11-(the chloro-8-methoxy quinoline of 6--2-base) 11-1-alcohol, 11-(the fluoro-8-methoxy quinoline of 7--2-base) 11-1-alcohol, 11-(the chloro-8-methoxy quinoline of 7--2-base) 11-1-alcohol, 11-(chloro-6, the 8-dimethoxy-quinoline-2-bases of 5-) 11-1-alcohol, 11-(chloro-5, the 8-dimethoxy-quinoline-2-bases of 6-) 11-1-alcohol, 11-(the chloro-8-methoxy quinoline of 5,7-bis--2-base) 11-1-alcohol, 9-(8-ethoxyquinoline-2-base)-1-alcohol in the ninth of the ten Heavenly Stems, 10-(8-ethoxyquinoline-2-base)-1-alcohol in the last of the ten Heavenly stems, 11-(8-ethoxyquinoline-2-base) 11-1-alcohol, 12-(8-ethoxyquinoline-2-base) 12-1-alcohol, 13-(8-ethoxyquinoline-2-base) 13-1-alcohol, 14-((8-ethoxyquinoline-2-base) 14-1-alcohol, 15-(8-ethoxyquinoline-2-base) 15-1-alcohol, 11-(8-oxyethyl group-5-toluquinoline-2-base) 11-1-alcohol, 11-(8-oxyethyl group-5-fluorine quinoline-2-base) 11-1-alcohol, 9-(the chloro-8-ethoxyquinoline of 5--2-base)-1-alcohol in the ninth of the ten Heavenly Stems, 11-(the chloro-8-ethoxyquinoline of 5--2-base) 11-1-alcohol, 15-(the chloro-8-ethoxyquinoline of 5--2-base) 15-1-alcohol, 11-(the bromo-8-ethoxyquinoline of 5--2-base) 11-1-alcohol, 11-(the chloro-8-ethoxyquinoline of 5,7-bis--2-base) 11-1-alcohol, 9-(8-isopropoxy quinoline-2-base)-1-alcohol in the ninth of the ten Heavenly Stems, 10-(8-isopropoxy quinoline-2-base)-1-alcohol in the last of the ten Heavenly stems, 11-(8-isopropoxy quinoline-2-base) 11-1-alcohol, 12-(8-isopropoxy quinoline-2-base) 12-1-alcohol, 13-(8-isopropoxy quinoline-2-base) 13-1-alcohol, 14-((8-isopropoxy quinoline-2-base) 14-1-alcohol, 15-(8-isopropoxy quinoline-2-base) 15-1-alcohol, 11-(8-isopropoxy-5-toluquinoline-2-base) 11-1-alcohol, 11-(5-fluoro-8-isopropoxy quinoline-2-base) 11-1-alcohol, 9-(5-chloro-8-isopropoxy quinoline-2-base)-1-alcohol in the ninth of the ten Heavenly Stems, 11-(5-chloro-8-isopropoxy quinoline-2-base) 11-1-alcohol, 15-(5-chloro-8-isopropoxy quinoline-2-base) 15-1-alcohol, 11-(5-bromo-8-isopropoxy quinoline-2-base) 11-1-alcohol, 15-(5-chloro-8-isopropoxy quinoline-2-base) 15-1-alcohol, 11-(5-bromo-8-isopropoxy quinoline-2-base) 11-1-alcohol, 11-(5,7-bis-chloro-8-isopropoxy quinoline-2-base) 11-1-alcohol, 9-(8-(cyclo propyl methoxy) quinoline-2-base)-1-alcohol in the ninth of the ten Heavenly Stems, 10-(8-(cyclo propyl methoxy) quinoline-2-base)-1-alcohol in the last of the ten Heavenly stems, 11-(8-(cyclo propyl methoxy) quinoline-2-base) 11-1-alcohol, 12-(8-(cyclo propyl methoxy) quinoline-2-base) 12-1-alcohol, 13-(8-(cyclo propyl methoxy) quinoline-2-base) 13-1-alcohol, 14-((8-(cyclo propyl methoxy) quinoline-2-base) 14-1-alcohol, 15-(8-(cyclo propyl methoxy) quinoline-2-base) 15-1-alcohol, 11-(8-(cyclo propyl methoxy)-5-toluquinoline-2-base) 11-1-alcohol, 11-(8-(cyclo propyl methoxy)-5-fluorine quinoline-2-base) 11-1-alcohol, 9-(the chloro-8-of 5-(cyclo propyl methoxy) quinoline-2-base)-1-alcohol in the ninth of the ten Heavenly Stems, 11-(the chloro-8-of 5-(cyclo propyl methoxy) quinoline-2-base) 11-1-alcohol, 15-(the chloro-8-of 5-(cyclo propyl methoxy) quinoline-2-base) 15-1-alcohol, 11-(the bromo-8-of 5-(cyclo propyl methoxy) quinoline-2-base) 11-1-alcohol, 11-(the chloro-8-of 5,7-bis-(cyclo propyl methoxy) quinoline-2-base) 11-1-alcohol, the chloro-2-of 5,7-bis-(11-hydroxyl undecyl) quinoline-8-alcohol, 10-(the chloro-8-methoxy quinoline of 5--2-base)-1-alcohol in the last of the ten Heavenly stems, acetic acid 10-(the chloro-8-methoxy quinoline of 5--2-base) ester in the last of the ten Heavenly stems, 11-(the chloro-8-methoxy quinoline of 5--2-base) 11-1-alcohol, acetic acid 11-(the chloro-8-methoxy quinoline of 5--2-base) 11 esters, 12-(the chloro-8-methoxy quinoline of 5--2-base) 12-1-alcohol, acetic acid 12-(the chloro-8-methoxy quinoline of 5--2-base) ten diester, 13-(the chloro-8-methoxy quinoline of 5--2-base) 13-1-alcohol, acetic acid 13-(the chloro-8-methoxy quinoline of 5--2-base) 13 esters, 11-(8-methoxy quinoline-4-(-Ji) 11-1-alcohol, 11-(8-ethoxyquinoline-4-(-Ji) 11-1-alcohol, 11-(8-isopropoxy quinoline-4-(-Ji) 11-1-alcohol, 11-(8-(cyclo propyl methoxy) quinoline-4-(-Ji) 11-1-alcohol, 11-(8-(benzyloxy) quinoline-4-(-Ji) 11-1-alcohol, 12-(8-(benzyloxy) quinoline-4-(-Ji) 12-1-alcohol, 4-((11-hydroxyl undecyl) quinoline-8-alcohol, 4-((12-hydroxyl dodecyl) quinoline-8-alcohol, 9-(8-(trifluoromethoxy) quinoline-2-base)-1-alcohol in the ninth of the ten Heavenly Stems, 11-(8-(trifluoromethoxy) quinoline-2-base) 11-1-alcohol, 14-((8-(trifluoromethoxy) quinoline-2-base) 14-1-alcohol, 15-(8-(trifluoromethoxy) quinoline-2-base) 15-1-alcohol, 2-((4-((2-hydroxyethyl) piperazine-1-base) methyl) quinoline-8-alcohol, 2-(4-(((the chloro-8-methoxy quinoline of 5--2-base) methyl) piperazine-1-base) ethanol, 2-(4-(((the chloro-8-ethoxyquinoline of 5--2-base) methyl) piperazine-1-base) ethanol, 2-(4-(((5-chloro-8-isopropoxy quinoline-2-base) methyl) piperazine-1-base) ethanol, 2-(4-(((the chloro-8-of 5-(cyclo propyl methoxy) quinoline-2-base) methyl) piperazine-1-base) ethane, 2-(4-(((the chloro-8-methoxy quinoline of 5,7-bis--2-base) methyl) piperazine-1-base) ethanol, 2-(4-(((the chloro-8-of 5,7-bis-(cyclo propyl methoxy) quinoline-2-base) methyl) piperazine-1-base) ethanol, 2-((methyl (Propargyl) amido) methyl) quinoline-8-alcohol, the chloro-2-of 5-((methyl (Propargyl) amido) methyl) quinoline-8-alcohol, N ((the chloro-8-methoxy quinoline of 5--2-base) methyl)-N-methyl-prop-2-alkynes-1-amine, N ((the chloro-8-ethoxyquinoline of 5--2-base) methyl)-N-methyl-prop-2-alkynes-1-amine, N ((5-chloro-8-isopropoxy quinoline-2-base) methyl)-N-methyl-prop-2-alkynes-1-amine, N ((the chloro-8-of 5-(cyclo propyl methoxy) quinoline-2-base) methyl)-N-methyl-prop-2-alkynes-1-amine, N ((the chloro-8-methoxy quinoline of 5,7-bis--2-base) methyl)-N-methyl-prop-2-alkynes-1-amine, N ((the chloro-8-of 5,7-bis-(cyclo propyl methoxy) quinoline-2-base) methyl)-N-methyl-prop-2-alkynes-1-amine, 8-((5-chloro-8-methoxy quinoline-2-base) methyl amido) pungent-1-alcohol, 8-((5-chloro-8-ethoxyquinoline-2-base) methyl amido) pungent-1-alcohol, 8-((5-chloro-8-isopropoxy quinoline-2-base) methyl amido) pungent-1-alcohol, 8-((the chloro-8-of 5-(cyclo propyl methoxy) quinoline-2-base) methyl amido) pungent-1-alcohol, 8-((5,7-bis-chloro-8-methoxy quinoline-2-base) methyl amido) pungent-1-alcohol, 8-((the chloro-8-of 5,7-bis-(cyclo propyl methoxy) quinoline-2-base) methyl amido) pungent-1-alcohol and the own-1-alcohol of 6-(two ((8-methoxy quinoline-2-base) methyl) amido).
In another aspect, the present invention is about a kind of constituent, and it comprises above-claimed cpd or its medical acceptable salt, solvate or hydrate, prodrug or metabolite, and medical acceptable thinner or a supporting agent, is used for the treatment of neurodegenerative disorders.
In the present invention one specific embodiment, this neurodegenerative disorders is selected from the group be made up of following disease: Alzheimer's disease, amyotrophic lateral sclerosis (ALS), cataract, cognitive dissonance, ischemia apoplexy, cerebral paralysis, apoplexy, hemorrhagic stroke, storehouse Jia Shi disease, spongiform encephalopathy becomes, mad cow syndrome, dementia, melancholia, Down syndrome, epilepsy, post-traumatic epilepsy, Frontotemporal Dementia, Tourette syndrome, Ha Sishi disease (Hallerboden-Spatzdisease), Heng Dingdunshi disease, Lewy body disease, Parkinson's disease, cognitive disorder, learning disorder, macular diseases, dysmnesia, multiple sclerosis, multiple systems atrophy, motor neurone disease, kirschner disease, gradual core is benumbed, pseudodementia disease, retinopathy, senile dementia, the nerve degeneration that schizophrenia transient anoxia brings out, pain, traumatic brain injury and Spinal injury.
Chemistry
Embodiment 1 – prepares (8-benzyloxy quinoline-2-base) and (oxine-2-base) alkyl alcohol
Reagent and condition: (a) BnBr, KOH, EtOH, backflow, 15h.; (b) 1) LHMDS, THF, 0 DEG C, 1h.; 2) Br (CH 2) n-1oH, rt, 16-36h.; (c) H 2, Pd/C, MeOH, rt, 6 to 10h.; (d) BCl 3, CH 2cl 2, 0 DEG C to rt, 3h.
Method: the document [Tetrahedron, 1996,52,4659-4672] see people such as G.Serratrice carries out Benzylation.Under reflux conditions, toluene bromide (6.45g, 37.7mmol) is added into the 60mlEtOH stirred solution containing 2-methyl quinaldine red (5.0g, 31.4mmol) and KOH (1.95g, 34.8mmol).After 15 hours, filter reaction mixture vacuum removes filtrate.Utilized by resistates flash column chromatography chromatography method to carry out purifying with Hex/EA (6:1), and in hexane recrystallize to obtain intermediate.LHMDS (2.2 to 2.5 equivalent) is processed 1 hour with the 20mlTHF containing stirred solution (1 equivalent) at 0 DEG C.By the Br (CH of correspondence 2) n-1oH (1.0 to 1.2 equivalent) is added into reaction mixture, and makes temperature get back to room temperature (RT) to carry out 15 to 36 hours again.Decompression removes solvent.Flash column chromatography chromatography method is utilized by brown oil resistates to carry out purifying with Hex/EA (3:1 to 2:1) or DCM/EA (15:1 to 9:1), and with hexane/EA recrystallize to provide a series of compd A.Under 10%Pd/C existence condition under hydrogen, at room temperature remove the phenmethyl 6-10 hour of compd A series.Filter reaction mixture, and filtrate utilized flash column chromatography chromatography method to carry out purifying to provide a series of compd B with Hex/EA (4:1 to 3:1).In the 20mlCH containing A11 (0.65g, 1.4mmol) 2cl 2in stirred solution, in ice bath, add 1MBCl 3(2.8ml, 2.8mmol) reaches 3 hours.Reaction mixture is poured in ice bath, and with 50mlCH 2cl 2extraction.In reduced under vacuum organic layer, and resistates is utilized flash column chromatography chromatography method (EA) purifying, to provide product (0.31g, 60%).
9-(8-(benzyloxy) quinoline-2-base)-1-alcohol in the ninth of the ten Heavenly Stems (A1)
Productive rate (YD): 53%. 1hNMR (400MHz, d4-MeOD) δ 8.15 (d, J=8.4Hz, 1H), 7.52 (d, J=6.8Hz, 2H), 7.31 ~ 7.41 (m, 5H), 7.29 (d, J=2.0Hz, 1H), 7.15 (dd, J=7.6,2.0Hz, 1H), 5.40 (s, 2H), 3.52 (t, J=6.8Hz, 2H), 3.00 (t, J=8.0Hz, 2H), 1.80 (quin, J=6.8Hz, 2H), 1.50 (t, J=7.2Hz, 2H), 1.28-1.42 (br, 11H); MS.m/z400.0, [M+Na] +.
10-(8-(benzyloxy) quinoline-2-base)-1-alcohol in the last of the ten Heavenly stems (A2)
YD:41％. 1HNMR(400MHz,d4-MeOD)δ8.14(d,J＝8.4Hz,1H),7.52(d,J＝7.6Hz,2H),7.32-7.42(m,5H),7.28(t,J＝7.2Hz,1H),7.14(dd,J＝7.6,1.2Hz,1H),5.38(s,2H),3.51(t,J＝6.8Hz,2H),2.98(t,J＝8.0Hz,2H),1.79(quin,J＝7.2Hz,2H),1.49(t,J＝6.8Hz,2H),1.29-1.40(br,13H)；MS.m/z414.0,[M+Na] +。
11-(8-(benzyloxy) quinoline-2-base) 11-1-alcohol (A3)
YD:42％. 1HNMR(400MHz,CDCl 3)δ8.02(d,J＝8.4Hz,1H),7.53(d,J＝7.2Hz,2H),7.27-7.39(m,6H),7.02(d,J＝7.6Hz,1H),5.46(s,2H),3.63(t,J＝6.8Hz,2H),3.05(t,J＝8Hz,2H),1.84(q,J＝7.6Hz,3H),1.56(t,J＝7.2Hz,2H),1.29-1.46(m,12H)；MS.m/z428.3,[M+Na] +。
12-(8-(benzyloxy) quinoline-2-base) 12-1-alcohol (A4)
YD:44％. 1HNMR(400MHz,d4-MeOD)δ8.13(d,J＝8.4Hz,1H),7.52(d,J＝7.6Hz,2H),7.31-7.40(m,5H),7.26(d,J＝7.6Hz,1H),7.13(dd,J＝7.6,0.8Hz,1H),5.37(s,2H),3.51(t,J＝6.8Hz,2H),2.98(t,J＝7.6Hz,2H),1.78(quin,J＝7.2Hz,2H),1.49(quin,J＝7.2Hz,2H),1.25-1.41(m,17H)；MS.m/z442.3,[M+Na] +。
13-(8-(benzyloxy) quinoline-2-base) 13-1-alcohol (A5)
YD:40％. 1HNMR(400MHz,CDCl 3)δ7.95(d,J＝8.4Hz,1H),7.45(d,J＝7.6Hz,2H),7.19-7.30(m,5H),6.93(d,J＝7.6Hz,1H),5.40(s,2H),3.55(t,J＝6.8Hz,2H),2.99(t,J＝7.6Hz,2H),1.77(quin,J＝7.6Hz,2H),1.46(t,J＝6.8Hz,2H),1.19-1.38(br,19H)；MS.m/z456.3,[M+Na] +。
14-(8-(benzyloxy) quinoline-2-base) 14-1-alcohol (A6)
YD:51％. 1HNMR(400MHz,d4-MeOD)δ8.14(d,J＝8.4Hz,1H),7.52(d,J＝7.2Hz,2H),7.33-7.42(m,5H),7.28(t,J＝7.2Hz,1H),7.14(d,J＝6.8Hz,1H),5.38(s,2H),3.52(t,J＝6.4Hz,2H),2.98(t,J＝8.0Hz,2H),1.50(quin,J＝6.8Hz,2H),1.47(t,J＝6.8Hz,2H),1.22-1.41(br,21H)；MS.m/z447.3,[M+H] +。
15-(8-(benzyloxy) quinoline-2-base) 15-1-alcohol (A7)
YD:42％. 1HNMR(400MHz,d4-MeOD)δ8.15(d,J＝8.4Hz,1H),7.53(d,J＝7.2Hz,2H),7.35-7.43(m,5H),7.28-7.33(m,1H),7.15(dd,J＝7.6,1.6Hz,1H),5.39(s,2H),3.52(t,J＝6.8Hz,2H),2.99(t,J＝8.0Hz,2H),1.79(quin,J＝6.8Hz,2H),1.51(quin,J＝6.8Hz,2H),1.22-1.41(br,23H)；MS.m/z462.3,[M+H] +。
11-(8-(benzyloxy)-5-toluquinoline-2-base) 11-1-alcohol (A8)
YD:47％. 1HNMR(400MHz,d4-MeOD)δ8.30(d,J＝8.4Hz,1H),7.52(d,J＝7.2Hz,2H),7.44(d,J＝8.8Hz,1H),7.26-7.36(m,3H),7.17(d,J＝8.0Hz,2H),7.02(d,J＝8.0Hz,2H),5.36(s,2H),3.52(t,J＝6.4Hz,2H),3.00(t,J＝7.6Hz,2H),2.55(s,3H),1.80(quin,J＝7.2Hz,2H),1.50(quin,J＝6.8Hz,2H),1.28-1.41(m,15H)；MS.m/z420.3,[M+H] +。
11-(8-(benzyloxy)-6-toluquinoline-2-base) 11-1-alcohol (A9)
YD:40％. 1HNMR(400MHz,d4-MeOD)δ8.03(d,J＝8.4Hz,1H),7.53(d,J＝7.2Hz,2H),7.33-7.37(m,3H),7.26-7.30(m,1H),7.16(s,1H),7.00(d,J＝1.2Hz,2H),5.36(s,2H),3.51(t,J＝6.8Hz,2H),2.95(t,J＝7.6Hz,2H),2.40(s,3H),1.76(q,J＝7.6Hz,2H),1.56(t,J＝7.2Hz,2H),1.29-1.46(m,15H)；MS.m/z442.3,[M+Na] +。
11-(8-(benzyloxy)-5-fluorine quinoline-2-base) 11-1-alcohol (A10)
YD:43％. 1HNMR(400MHz,CDCl 3)δ8.28(d,J＝8.8Hz,1H),7.51(d,J＝7.2Hz,2H),7.33-7.40(m,3H),7.28(t,J＝8.0Hz,1H),6.89～6.98(m,2H),5.42(s,2H),3.61(t,J＝6.4Hz,2H),3.07(t,J＝8Hz,2H),1.83(q,J＝7.6Hz,2H),1.51-1.54(m,2H),1.21-1.45(m,15H)；MS.m/z446.2,[M+Na] +。
11-(8-(benzyloxy)-5-chloroquinoline-2-base) 11-1-alcohol (A11)
YD:43％.HNMR(400MHz,d4-MeOD)δ8.48(d,J＝8.8Hz,1H),7.52-7.57(m,3H),7.46(d,J＝8.4Hz,1H),7.35～7.39(m,2H),7.31(d,J＝7.2Hz,1H),7.14(d,J＝8.4Hz,1H),5.40(s,2H),3.52(t,J＝6.8Hz,2H),3.03(t,J＝7.6Hz,2H),1.81(quin,J＝7.2Hz,2H),1.49(t,J＝6.8Hz,2H),1.28-1.41(m,15H)；MS.m/z462.2,[M+Na] +。
2-(9-hydroxyl nonyl) quinoline-8-alcohol (B1)
YD:85%. 1hNMR (400MHz, d4-MeOD) δ 7.86 (d, J=8.4Hz, 1H), 7.22 (t, J=7.6Hz, 1H), 7.03-7.13 (m, 3H), 3.50 (t, J=6.8Hz, 2H), 2.75 (t, J=8.0Hz, 2H), 1.58 (quin, J=6.8Hz, 2H), 1.44 (quin, J=6.8Hz, 2H), 1.10-1.20 (m, 11H); HRMS (ESI): calculated value [C 18h 25nO 2-Na] +: 310.1778, actual value: 310.1779.
2-(10-hydroxy decyl) quinoline-8-alcohol (B2)
YD:85％. 1HNMR(400MHz,CDCl 3)δ8.01(d,J＝8.4Hz,1H),7.35(t,J＝6.8Hz,1H),7.26-7.28(m,2H),7.11(d,J＝7.2Hz,1H),3.60(t,J＝6.4Hz,2H),2.92(t,J＝7.6Hz,2H),1.79(quin,J＝6.8Hz,2H),1.53(quin,J＝6.8Hz,2H),1.27-1.33(br,14H)；MS.m/z302.2,[M+H] +。
2-(11-hydroxyl undecyl) quinoline-8-alcohol (B3)
YD:77％. 1HNMR(400MHz,CDCl 3)δ8.04(d,J＝8.4Hz,1H),7.38(t,J＝7.8Hz,1H),7.27-7.31(m,2H),7.14(dd,J＝1.2,7.6Hz,1H),3.64(t,J＝6.8Hz,2H),2.95(t,J＝7.8Hz,2H),1.83(quin,J＝7.8Hz,2H),1.55(m,2H),1.28-1.36(br,17H)； 1MS.m/z316.2,[M+H] +。
2-(12-hydroxyl dodecyl) quinoline-8-alcohol (B4)
YD:76％. 1HNMR(400MHz,CDCl 3)δ8.03(d,J＝8.4Hz,1H),7.36(t,J＝8Hz,1H),7.25-7.30(m,2H),7.13(d,J＝7.6Hz,1H),3.62(t,J＝6.4Hz,2H),2.94(t,J＝7.6Hz,2H),1.81(quin,J＝7.6Hz,2H),1.54(quin,J＝6.8Hz,2H),1.29-1.38(br,18H)；MS.m/z330.3,[M+H] +。
2-(13-hydroxyl tridecyl) quinoline-8-alcohol (B5)
YD:84％. 1HNMR(400MHz,CDCl 3)δ8.03(d,J＝8.4Hz,1H),7.36(t,J＝7.6Hz,1H),7.26-7.30(m,2H),7.13(d,J＝7.6Hz,1H),3.62(t,J＝6.8Hz,2H),2.95(t,J＝7.6Hz,2H),1.81(quin,J＝7.2Hz,2H),1.54(quin,J＝6.8Hz,2H),1.25-1.34(br,20H)；MS.m/z344.3,[M+H] +。
2-(14-hydroxyl tetradecyl) quinoline-8-alcohol (B6)
YD:87％. 1HNMR(400MHz,CDCl 3)δ8.02(d,J＝8.8Hz,1H),7.36(t,J＝7.6Hz,1H),7.25-7.29(m,2H),7.12(d,J＝7.2Hz,1H),3.61(t,J＝6.4Hz,2H),2.94(t,J＝7.6Hz,2H),1.80(quin,J＝7.2Hz,2H),1.54(quin,J＝6.8Hz,2H),1.24-1.34(br,24H)；MS.m/z358.3,[M+H] +。
2-(15-hydroxyl pentadecyl) quinoline-8-alcohol (B7)
YD:83％. 1HNMR(400MHz,CDCl 3)δ8.04(d,J＝8.4Hz,1H),7.35(t,J＝7.6Hz,1H),7.26-7.29(m,2H),7.13(d,J＝7.2Hz,1H),3.62(t,J＝6.8Hz,2H),2.95(t,J＝7.6Hz,2H),1.80(quin,J＝7.2Hz,2H),1.54(quin,J＝7.2Hz,2H),1.24-1.37(br,24H)；MS.m/z372.3,[M+H] +。
2-(11-hydroxyl undecyl)-5-toluquinoline-8-alcohol (B8)
YD:83％. 1HNMR(400MHz,d4-MeOD)δ8.26(d,J＝8.4Hz,1H),7.39(d,J＝8.8Hz,1H),7.15(d,J＝7.2Hz,1H),6.93(d,J＝3.2Hz,1H),3.52(t,J＝6.4Hz,2H),2.95(t,J＝8.0Hz,2H),2.53(s,3H),1.81(quin,J＝7.2Hz,2H),1.48(quin,J＝6.8Hz,2H),1.13-1.37(m,15H)；MS.m/z330.3,[M+H] +。
2-(11-hydroxyl undecyl)-6-toluquinoline-8-alcohol (B9)
YD:83％. 1HNMR(400MHz,d4-MeOD)δ7.99(d,J＝8.4Hz,1H),7.29(d,J＝8.8Hz,1H),7.06(s,1H),6.91(s,1H),3.51(t,J＝6.4Hz,2H),2.90(t,J＝8.0Hz,2H),2.41(s,3H),1.77(quin,J＝6.4Hz,2H),1.49(quin,J＝6.8Hz,2H),1.25-1.37(m,19H)；MS.m/z352.2,[M+Na] +。
The chloro-2-of 5-(11-hydroxyl undecyl) quinoline-8-alcohol (B10)
1HNMR(400MHz,d4-MeOD)δ8.39(d,J＝8.8Hz,1H),7.49(d,J＝8.8Hz,1H),7.41(d,J＝8.4Hz,1H),7.01(d,J＝8.0Hz,1H),3.51(t,J＝6.4Hz,2H),2.98(t,J＝8.0Hz,2H),1.81(quin,J＝7.2Hz,2H),1.50(quin,J＝6.8Hz,2H),1.27-1.35(m,15H)；MS.m/z350.2,[M+H] +。
Embodiment 2 – prepares (8-methoxy quinoline-2-base) alkyl alcohol
Reagent and condition: (a) MeI, K 2cO 3, acetone, r.t, 10h.; (b) 1) LHMDS, THF, 0 DEG C, 1h.; 2) Br (CH 2) n-1oH, rt, 12-30h.
Method: under RT, methyl iodide (10.8g, 76.3mmol) is added into containing 2-methyl quinaldine red (1.0g, 6.3mmol) and K 2cO 3the 30ml acetone stirred solution of (5.0g, 36.2mmol) 10 hours.Filter reaction mixture and reduce pressure and remove filtrate.Flash column chromatography chromatography method is utilized by resistates to carry out purifying with Hex/EA (3:1), and with hexane/EA recrystallize to obtain intermediate 8-methoxyl group-2-toluquinoline.LHMDS (2.2 to 2.5 equivalent) is processed 1 hour with the THF containing intermediate (1 equivalent) stirred solution at 0 DEG C.By the Br (CH of correspondence 2) n-1oH (1.0 to 1.2 equivalent) is added into reaction mixture, and makes temperature get back to RT carry out 12 to 30h again.Decompression removes solvent.Flash column chromatography chromatography method is utilized by brown oil resistates to carry out purifying with Hex/EA or DCM/EA, and with Hex/EA recrystallize to provide a series of Compound C.
9-(8-methoxy quinoline-2-base)-1-alcohol in the ninth of the ten Heavenly Stems (C1)
YD:50％. 1HNMR(400MHz,CDCl 3)δ8.05(d,J＝8.4Hz,1H),7.33-7.42(m,3H),7.04(d,J＝6.8Hz,1H),4.08(s,3H),3.62(t,J＝6.4Hz,2H),3.07(t,J＝7.6Hz,2H),1.79(br,2H),1.53(br,2H),1.30-1.42(br,11H)；MS.m/z324.0,[M+Na] +。
10-(8-methoxy quinoline-2-base)-1-alcohol in the last of the ten Heavenly stems (C2)
YD:38％. 1HNMR(400MHz,CDCl 3)δ8.01(d,J＝8.4Hz,1H),7.36(t,J＝7.6Hz,1H),7.30-7.33(m,2H),7.00(d,J＝7.6Hz,1H),4.05(s,3H),3.60(t,J＝6.8Hz,2H),3.01(t,J＝7.6Hz,2H),1.79(quin,J＝8Hz,2H),1.52(quin,J＝6.8Hz,2H),1.30-1.43(br,12H)；MS.m/z316.2,[M+H] +。
11-(8-methoxy quinoline-2-base) 11-1-alcohol (C3)
YD:42％. 1HNMR(400MHz,CDCl 3)δ8.02(d,J＝8.8Hz,1H),7.38(t,J＝7.8Hz,1H),7.31-7.34(m,2H),7.15(d,J＝7.2Hz,1H),4.06(s,3H),3.61(t,J＝6.8Hz,2H),3.02(t,J＝7.8Hz,2H),1.79(quin,J＝7.6Hz,2H),1.54(quin,J＝6.8Hz,2H),1.31-1.42(br,15H)；MS.m/z352.2,[M+Na] +。
12-(8-methoxy quinoline-2-base) 12-1-alcohol (C4)
YD:38％. 1HNMR(400MHz,CDCl 3)δ8.01(d,J＝8.8Hz,1H),7.35(t,J＝7.6Hz,1H),7.30-7.32(m,2H),7.01(d,J＝7.2Hz,1H),4.05(s,3H),3.61(t,J＝6.4Hz,2H),3.01(t,J＝8Hz,2H),1.78(quin,J＝7.6Hz,2H),1.36-1.41(m,2H),1.24-1.33(br,16H)；MS.m/z344.3,[M+H] +。
13-(8-methoxy quinoline-2-base) 13-1-alcohol (C5)
YD:38％. 1HNMR(400MHz,CDCl 3)δ8.01(d,J＝8.4Hz,1H),7.37(t,J＝7.6Hz,1H),7.30-7.33(m,2H),7.01(d,J＝7.6Hz,1H),4.05(s,3H),3.61(t,J＝7.2Hz,2H),3.01(t,J＝8Hz,2H),1.80(quin,J＝7.6Hz,2H),1.54(quin,J＝6.8Hz,2H),1.36-1.43(br,19H)；MS.m/z358.3,[M+H] +。
14-(8-methoxy quinoline-2-base) 14-1-alcohol (C6)
YD:38％. 1HNMR(400MHz,CDCl 3)δ8.02(d,J＝8.4Hz,1H),7.31-7.38(m,3H),7.01(d,J＝7.2Hz,1H),4.06(s,3H),3.61(t,J＝6.8Hz,2H),3.02(t,J＝8Hz,2H),1.79(quin,J＝7.6Hz,2H),1.54(quin,J＝6.8Hz,2H),1.23-1.40(br,21H)；MS.m/z394.3,[M+Na] +。
15-(8-methoxy quinoline-2-base) 15-1-alcohol (C7)
YD:31％. 1HNMR(400MHz,CDCl 3)δ8.01(d,J＝8.4Hz,1H),7.31-7.39(m,3H),7.01(d,J＝7.2Hz,1H),4.06(s,3H),3.63(t,J＝6.8Hz,2H),3.02(t,J＝8Hz,2H),1.79(quin,J＝7.6Hz,2H),1.54(quin,J＝6.8Hz,2H),1.32-1.43(br,23H)；MS.m/z408.3,[M+H] +。
11-(8-methoxyl group-5-toluquinoline-2-base) 11-1-alcohol (C8)
YD:30％. 1HNMR(400MHz,d4-MeOD)δ8.29(d,J＝8.4Hz,1H),7.43(d,J＝8.8Hz,1H),7.24(dd,J＝8.0,0.8Hz,1H),7.01(d,J＝8.0Hz,1H),4.00(s,3H),3.51(t,J＝6.8Hz,2H),2.97(t,J＝8.0Hz,2H),2.56(s,3H),1.76(quin,J＝7.6Hz,2H),1.50(quin,J＝7.2Hz,2H),1.27-1.40(br,15H)；MS.m/z366.2,[M+Na] +。
11-(the fluoro-8-methoxy quinoline of 5--2-base) 11-1-alcohol (C9)
1HNMR(400MHz,d4-MeOD)δ8.34(d,J＝8.8Hz,1H),7.51(d,J＝8.8Hz,1H),7.15(d,J＝7.2Hz,1H),6.93(d,J＝3.2Hz,1H),4.02(s,3H),3.52(t,J＝6.8Hz,2H),2.95(t,J＝8.0Hz,2H),1.81(quin,J＝7.2Hz,2H),1.48(quin,J＝6.8Hz,2H),1.13-1.37(m,15H)；MS.m/z370.2,[M+Na] +。
12-(the fluoro-8-methoxy quinoline of 5--2-base) 12-1-alcohol (C10)
YD:38％. 1HNMR(400MHz,d4-MeOD)δ8.36(d,J＝8.8Hz,1H),7.52(d,J＝8.8Hz,1H),7.17(d,J＝8.8Hz,1H),7.08(dd,J＝8.4,4.8Hz,1H),4.04(s,3H),3.53(t,J＝6.8Hz,2H),3.00(t,J＝8.0Hz,2H),1.78(quin,J＝7.2Hz,2H),1.51(quin,J＝7.2Hz,2H),1.28-1.42(m,17H)；MS.m/z384.2,[M+Na] +。
9-(the chloro-8-methoxy quinoline of 5--2-base)-1-alcohol in the ninth of the ten Heavenly Stems (C11)
YD:38％. 1HNMR(400MHz,d4-MeOD)δ8.47(d,J＝8.8Hz,1H),7.55(d,J＝8.8Hz,1H),7.52(d,J＝8.4Hz,1H),7.11(d,J＝8.8Hz,1H),4.04(s,3H),3.51(t,J＝6.8Hz,2H),3.00(t,J＝8.0Hz,2H),1.77(quin,J＝7.6Hz,2H),1.50(quin,J＝6.8Hz,2H),1.30-1.37(m,11H)；MS.m/z336.2,[M+H] +。
11-(the chloro-8-methoxy quinoline of 5--2-base) 11-1-alcohol (C12)
YD:35％. 1HNMR(400MHz,d4-MeOD)δ8.46(d,J＝8.4Hz,1H),7.54(d,J＝8.8Hz,1H),7.51(d,J＝8.4Hz,1H),7.10(d,J＝8.4Hz,1H),4.04(s,3H),3.51(t,J＝6.8Hz,2H),2.99(t,J＝8.0Hz,2H),1.76(quin,J＝7.6Hz,2H),1.49(quin,J＝6.8Hz,2H),1.27-1.38(br,15H)；MS.m/z386.2,[M+Na] +。
15-(the chloro-8-methoxy quinoline of 5--2-base) 15-1-alcohol (C13)
YD:39％. 1HNMR(400MHz,d4-MeOD+CDCl 3)δ8.44(d,J＝8.4Hz,1H),7.47(d,J＝8.4Hz,1H),7.46(d,J＝8.4Hz,1H),7.01(dd,J＝8.4,4.0Hz,1H),4.03(s,3H),3.52(t,J＝6.8Hz,2H),2.99(t,J＝8.0Hz,2H),1.76(quin,J＝7.6Hz,2H),1.50(quin,J＝6.8Hz,2H),1.22-1.38(m,23H)；MS.m/z442.3,[M+Na] +。
11-(the bromo-8-methoxy quinoline of 5--2-base) 11-1-alcohol (C14)
YD:46％. 1HNMR(400MHz,CDCl 3)δ8.40(d,J＝8.4Hz,1H),7.65(d,J＝8.4Hz,1H),7.44(d,J＝8.8Hz,1H),6.91(d,J＝8.4Hz,1H),4.06(s,3H),3.63(t,J＝6.8Hz,2H),3.07(t,J＝8.0Hz,2H),1.79(quin,J＝7.6Hz,2H),1.55(quin,J＝6.8Hz,2H),1.30-1.45(br,15H)；MS.m/z430.2,[M+Na] +。
11-(8-methoxyl group-5-(trifluoromethyl) quinoline-2-base) 11-1-alcohol (C15)
YD:36％. 1HNMR(400MHz,d4-MeOD+CDCl 3)δ8.40(dq,J＝10.4,1.6Hz,1H),7.86(d,J＝8.4Hz,1H),7.58(d,J＝8.8Hz,1H),7.20(d,J＝8.0Hz,1H),4.11(s,3H),3.51(t,J＝6.8Hz,2H),3.00(t,J＝8.0Hz,2H),1.78(quin,J＝7.6Hz,2H),1.50(quin,J＝6.8Hz,2H),1.27-1.43(m,15H)；MS.m/z420.2,[M+Na] +。
11-(5,8-dimethoxy-quinoline-2-base) 11-1-alcohol (C16)
YD:31％； 1HNMR(400MHz,d4-MeOD)δ8.46(d,J＝8.4Hz,1H),7.38(d,J＝8.4Hz,1H),7.03(d,J＝8.4Hz,1H),6.82(d,J＝8.4Hz,1H),3.98(s,3H),3.94(s,3H),3.51(t,J＝6.8Hz,2H),2.95(t,J＝8.0Hz,2H),1.73(quin,J＝7.6Hz,2H),1.50(quin,J＝6.8Hz,2H),1.27-1.35(br,15H)；MS.m/z360.2,[M+H] +。
11-(8-methoxyl group-6-toluquinoline-2-base) 11-1-alcohol (C17)
YD:41％. 1HNMR(400MHz,CDCl 3)δ7.96(d,J＝8.4Hz,1H),7.30(t,J＝8.4Hz,1H),7.12(s,1H),6.87(s,1H),4.06(s,3H),3.63(t,J＝6.8Hz,2H),3.05(t,J＝7.6Hz,2H),2.50(s,3H),1.79(quin,J＝8.0Hz,2H),1.55(quin,J＝6.8Hz,2H),1.27-1.41(br,15H)；MS.m/z366.2,[M+Na] +。
11-(the fluoro-8-methoxy quinoline of 6--2-base) 11-1-alcohol (C18)
YD:41％； 1HNMR(400MHz,d4-MeOD)δ8.12(d,J＝8.4Hz,1H),7.44(d,J＝8.8Hz,1H),7.07(dd,J＝9.2,2.4Hz,1H),7.01(dd,J＝10.8,2.8Hz,1H),4.06(s,3H),3.52(t,J＝6.8Hz,2H),2.95(t,J＝8.0Hz,2H),1.75(quin,J＝7.6Hz,2H),1.48(quin,J＝7.2Hz,2H),1.19-1.35(m,15H)；MS.m/z348.2,[M+H] +。
11-(the chloro-8-methoxy quinoline of 6--2-base) 11-1-alcohol (C19)
YD:39％； 1HNMR(400MHz,d4-MeOD)δ8.11(d,J＝8.4Hz,1H),7.44-7.47(m,2H),7.13(d,J＝2.0Hz,1H),4.05(s,3H),3.52(t,J＝6.8Hz,2H),2.96(t,J＝8.0Hz,2H),1.76(quin,J＝7.2Hz,2H),1.50(quin,J＝6.8Hz,2H),1.28-1.36(br,15H)；MS.m/z360.2,[M+H] +。
11-(the fluoro-8-methoxy quinoline of 7--2-base) 11-1-alcohol (C20)
YD:32％； 1HNMR(400MHz,d4-MeOD)δ8.20(d,J＝8.8Hz,1H),7.60(dd,J＝8.8,5.6Hz,1H),7.39(dd,J＝8.8,1.6Hz,1H),7.01(d,J＝8.8Hz,1H),4.13(d,J＝1.2Hz,3H),3.52(t,J＝6.8Hz,2H),2.99(t,J＝7.6Hz,2H),1.80(quin,J＝7.6Hz,2H),1.48(quin,J＝6.8Hz,2H),1.29-1.42(m,15H)；MS.m/z348.2,[M+H] +。
11-(the chloro-8-methoxy quinoline of 7--2-base) 11-1-alcohol (C21)
YD:17％； 1HNMR(400MHz,d4-MeOD)δ8.20(d,J＝8.4Hz,1H),7.60(d,J＝8.8Hz,1H),7.50(d,J＝8.8Hz,1H),7.42(d,J＝8.4Hz,1H),4.08(s,3H),3.52(t,J＝6.8Hz,2H),2.99(t,J＝7.6Hz,2H),1.82(quin,J＝7.2Hz,2H),1.50(quin,J＝6.8Hz,2H),1.28-1.42(br,15H)；MS.m/z360.2,[M+H] +。
11-(chloro-6, the 8-dimethoxy-quinoline-2-bases of 5-) 11-1-alcohol (C22)
YD:32％； 1HNMR(400MHz,d4-MeOD)δ8.40(d,J＝8.8Hz,1H),7.46(d,J＝8.8Hz,1H),7.07(s,1H),4.08(s,3H),4.02(s,3H),3.51(t,J＝6.8Hz,2H),2.94(t,J＝7.6Hz,2H),1.74(quin,J＝7.6Hz,2H),1.50(quin,J＝6.8Hz,2H),1.27-1.34(br,15H)；MS.m/z394.2,[M+H] +。
11-(chloro-5, the 8-dimethoxy-quinoline-2-bases of 6-) 11-1-alcohol (C23)
YD:35％； 1HNMR(400MHz,d4-MeOD)δ8.38(d,J＝8.8Hz,1H),7.51(d,J＝8.4Hz,1H),7.12(s,1H),4.02(s,3H),3.94(s,3H),3.52(t,J＝6.4Hz,2H),2.97(t,J＝7.6Hz,2H),1.74(quin,J＝7.6Hz,2H),1.50(quin,J＝6.8Hz,2H),1.34-1.41(br,15H)；MS.m/z394.2,[M+H] +。
11-(the chloro-8-methoxy quinoline of 5,7-bis--2-base) 11-1-alcohol (C24)
YD:40％. 1HNMR(400MHz,CDCl 3)δ8.40(d,J＝8.4Hz,1H),7.59(d,J＝8.0Hz,1H),7.56(s,1H),7.39(d,J＝8.8Hz,1H),4.19(s,3H),3.63(t,J＝6.8Hz,2H),3.04(t,J＝7.6Hz,2H),1.84(quin,J＝7.2Hz,2H),1.55(quin,J＝6.8Hz,2H),1.27-1.40(br,15H)；MS.m/z420.2,[M+Na] +。
Embodiment 3 – prepares (8-ethoxyquinoline-2-base) and (8-isopropoxy quinoline-2-base) alkyl alcohol
Reagent and condition: (a) iodoethane or 2-N-PROPYLE BROMIDE, K 2cO 3, DMF, 60 DEG C, 14h.; (b) 1) LHMDS, THF, 0 DEG C, 1h.; 2) Br (CH 2) n-1oH, RT, 12-30h.
Method: at 60 DEG C, iodoethane (3.9g, 25.0mmol) or 2-N-PROPYLE BROMIDE (2.4g, 19.2mmol) are added into containing 2-methyl quinaldine red (3.0g, 18.8mmol) and K 2cO 3(6.5g, 47mmol; 5.2g, 37.6mmol) 30mlDMF stirred solution 14 hours.By reaction mixture with H 2o (200ml) quenching also extracts with EtOAc (50mlX2).By organic layer evaporation concentration under vacuum.Flash column chromatography chromatography method is utilized by resistates to carry out purifying with Hex/EA (6:1), and with hexane/EA recrystallize to obtain solid intermediate 8-oxyethyl group-2-toluquinoline (2.75g, 78%) and liquid 8-isopropoxy-2-toluquinoline (2.92g, 77%).LHMDS (2.2 equivalent) is processed 1 hour with the THF solution of the stirred solution of different intermediate (1 equivalent) at 0 DEG C.By the Br (CH of correspondence 2) n-1oH (1.1 – 1.2 equivalent) is added into reaction mixture, and makes temperature get back to RT to carry out 12 to 30 hours again.Decompression removes solvent.Flash column chromatography chromatography method is utilized by brown oil resistates to carry out purifying with Hex/EA or DCM/EA, and with hexane/EA recrystallize to provide Compound D and E.
9-(8-ethoxyquinoline-2-base)-1-alcohol in the ninth of the ten Heavenly Stems (D1)
YD:45％. 1HNMR(400MHz,CDCl 3)δ8.07(d,J＝8.0Hz,1H),7.34-7.42(m,3H),7.06(d,J＝8.4Hz,1H),4.35(q,J＝6.8Hz,2H),3.63(t,J＝6.8Hz,2H),3.11(br,2H),1.83(quin,J＝7.6Hz,2H),1.52-1.64(m,5H),1.26-1.46(br,11H)；MS.m/z338.0,[M+Na] +。
10-(8-ethoxyquinoline-2-base)-1-alcohol in the last of the ten Heavenly stems (D2)
YD:36％. 1HNMR(400MHz,d4-MeOD)δ8.16(d,J＝8.4Hz,1H),7.38-7.44(m,3H),7.14(dd,J＝7.2,1.6Hz,1H),4.29(q,J＝6.8Hz,2H),3.52(t,J＝6.8Hz,2H),2.99(t,J＝7.6Hz,2H),1.78(quin,J＝7.6Hz,2H),1.57(t,J＝7.6Hz,3H),1.50(t,J＝7.6Hz,2H),1.30-1.43(br,13H)；MS.m/z352.0,[M+Na] +。
11-(8-ethoxyquinoline-2-base) 11-1-alcohol (D3)
YD:43％. 1HNMR(400MHz,CDCl 3)δ8.03(d,J＝7.6Hz,1H),7.31-7.41(m,3H),7.04(d,J＝7.2Hz,1H),4.33(q,J＝7.2Hz,2H),3.62(t,J＝6.4Hz,2H),3.06(br,2H),1.81(quin,J＝8.0Hz,2H),1.51-1.61(m,6H),1.38-1.51(br,14H)；MS.m/z344.3,[M+H] +。
12-(8-ethoxyquinoline-2-base) 12-1-alcohol (D4)
YD:33％. 1HNMR(400MHz,CDCl 3)δ8.03(d,J＝8.4Hz,1H),7.31-7.39(m,3H),7.04(d,J＝7.6Hz,1H),4.33(q,J＝6.8Hz,2H),3.62(t,J＝6.4Hz,2H),3.05(t,J＝8.0Hz,2H),1.82(quin,J＝7.2Hz,2H),,1.53-1.62(m,5H),1.27-1.42(br,17H)；MS.m/z380.3,[M+Na] +。
13-(8-ethoxyquinoline-2-base) 13-1-alcohol (D5)
YD:43％. 1HNMR(400MHz,CDCl 3)δ8.04(d,J＝8.4Hz,1H),7.32-7.40(m,3H),7.04(d,J＝7.6Hz,1H),4.34(q,J＝6.8Hz,2H),3.62(t,J＝6.4Hz,2H),3.07(t,J＝8.0Hz,2H),1.82(quin,J＝7.6Hz,2H),1.52-1.62(m,5H),1.19-1.46(br,19H)；MS.m/z394.0,[M+Na] +。
14-(8-ethoxyquinoline-2-base) 14-1-alcohol (D6)
YD:35％. 1HNMR(400MHz,CDCl 3)δ8.00(d,J＝8.4Hz,1H),7.28-7.35(m,3H),7.02(d,J＝7.2Hz,1H),4.32(q,J＝6.8Hz,2H),3.61(t,J＝6.4Hz,2H),3.01(t,J＝8.0Hz,2H),1.80(quin,J＝7.6Hz,2H),1.52-1.60(m,5H),1.24-1.41(br,21H)；MS.m/z408.3,[M+Na] +。
15-(8-ethoxyquinoline-2-base) 15-1-alcohol (D7)
YD:33％. 1HNMR(400MHz,d4-MeOD)δ8.21(d,J＝8.4Hz,1H),7.40-7.47(m,3H),7.17(dd,J＝7.2,1.6Hz,1H),4.30(q,J＝7.2Hz,2H),3.52(t,J＝6.8Hz,2H),3.01(t,J＝7.6Hz,2H),1.78(quin,J＝7.6Hz,2H),1.57(t,J＝6.8Hz,3H),1.51(quin,J＝6.8Hz,2H),1.26-1.43(br,23H)；MS.m/z400.4,[M+Na] +。
11-(8-oxyethyl group-5-toluquinoline-2-base) 11-1-alcohol (D8)
YD:34％. 1HNMR(400MHz,CDCl 3)δ8.20(d,J＝8.8Hz,1H),7.36(d,J＝8.4Hz,1H),7.19(d,J＝7.6Hz,1H),6.94(d,J＝8.0Hz,1H),4.31(q,J＝6.8Hz,2H),3.63(t,J＝6.4Hz,2H),3.08(t,J＝8.0Hz,2H),2.57(s,3H),1.83(quin,J＝7.6Hz,2H),1.83(t,J＝7.6Hz,3H),1.57(quin,J＝7.2Hz,2H),1.41-1.45(m,2H),1.28-1.33(br,13H)；MS.m/z380.2,[M+Na] +。
11-(8-oxyethyl group-5-fluorine quinoline-2-base) 11-1-alcohol (D9)
YD:49％. 1HNMR(400MHz,d4-MeOD)δ8.33(d,J＝8.4Hz,1H),7.49(d,J＝8.8Hz,1H),7.12(t,J＝9.2Hz,1H),7.05(dd,J＝8.4,4.8Hz,1H),4.25(q,J＝7.2Hz,2H),3.51(t,J＝6.8Hz,2H),2.99(t,J＝8.0Hz,2H),1.77(quin,J＝7.2Hz,2H),1.55(t,J＝7.2Hz,3H),1.48-1.52(m,2H),1.28-1.46(br,15H)；MS.m/z384.2,[M+Na] +。
9-(the chloro-8-ethoxyquinoline of 5--2-base)-1-alcohol in the ninth of the ten Heavenly Stems (D10)
YD:34％. 1HNMR(400MHz,d4-MeOD)δ8.47(d,J＝8.8Hz,1H),7.55(d,J＝8.8Hz,1H),7.50(d,J＝8.4Hz,1H),7.10(d,J＝8.8Hz,1H),4.28(q,J＝6.8Hz,2H),3.51(t,J＝6.4Hz,2H),3.01(t,J＝8.0Hz,2H),1.76(quin,J＝7.6Hz,2H),1.56(t,J＝6.8Hz,3H),1.48-1.51(m,2H),1.31-1.46(br,11H)；MS.m/z350.2,[M+H] +。
11-(the chloro-8-ethoxyquinoline of 5--2-base) 11-1-alcohol (D11)
YD:38％. 1HNMR(400MHz,CDCl 3)δ8.35(d,J＝8.8Hz,1H),7.36(dd,J＝8.4,3.6Hz,1H),7.19(d,J＝2.4Hz,1H),6.88(d,J＝8.4Hz,1H),4.25(q,J＝7.2Hz,2H),3.56(t,J＝6.4Hz,2H),2.98(t,J＝8.0Hz,2H),1.76(quin,J＝8.0Hz,2H),1.45-1.54(m,5H),1.19-1.39(br,15H)；MS.m/z400.2,[M+Na] +。
15-(the chloro-8-ethoxyquinoline of 5--2-base) 15-1-alcohol (D12)
YD:38％. 1HNMR(400MHz,d4-MeOD+CDCl 3)δ8.47(d,J＝8.8Hz,1H),7.53(d,J＝8.8Hz,1H),7.49(d,J＝8.4Hz,1H),7.08(d,J＝8.4Hz,1H),4.28(q,J＝6.8Hz,2H),3.52(t,J＝6.8Hz,2H),3.01(t,J＝8.0Hz,2H),1.79(quin,J＝7.6Hz,2H),1.57(t,J＝6.8Hz,3H),1.49(quin,J＝6.8Hz,2H),1.25-1.41(br,23H)；MS.m/z434.3,[M+H] +。
11-(the bromo-8-ethoxyquinoline of 5--2-base) 11-1-alcohol (D13)
YD:33％. 1HNMR(400MHz,d4-MeOD)δ8.41(d,J＝8.8Hz,1H),7.67(d,J＝8.4Hz,1H),7.52(d,J＝8.8Hz,1H),7.04(d,J＝8.4Hz,1H),4.27(q,J＝7.2Hz,2H),3.52(t,J＝6.8Hz,2H),3.00(t,J＝8.0Hz,2H),1.77(quin,J＝7.6Hz,2H),1.56(t,J＝7.2Hz,3H),1.47-1.57(m,2H),1.27-1.39(br,15H)；MS.m/z444.2,[M+Na] +。
11-(the chloro-8-ethoxyquinoline of 5,7-bis--2-base) 11-1-alcohol (D14)
YD:34％. 1HNMR(400MHz,d4-MeOD)δ8.43(d,J＝8.8Hz,1H),7.64(s,1H),7.51(d,J＝8.4Hz,1H),4.39(q,J＝6.8Hz,2H),3.52(t,J＝6.8Hz,2H),3.00(t,J＝7.2Hz,2H),1.84(quin,J＝7.2Hz,2H),1.45-1.49(m,5H),1.27-1.36(br,15H)；MS.m/z434.2,[M+Na] +。
9-(8-isopropoxy quinoline-2-base)-1-alcohol in the ninth of the ten Heavenly Stems (E1)
YD:28％. 1HNMR(400MHz,d4-MeOD)δ8.07(d,J＝8.8Hz,1H),7.33-7.36(m,1H),7.31-7.33(m,2H),7.09(d,J＝7.2Hz,1H),4.79(m,1H),3.49(t,J＝6.8Hz,2H),2.93(t,J＝7.6Hz,2H),1.71(quin,J＝7.6Hz,2H),1.45-1.49(m,2H),1.41(d,J＝6Hz,6H),1.20-1.35(br,11H)；MS.m/z330.2,[M+H] +。
10-(8-isopropoxy quinoline-2-base)-1-alcohol in the last of the ten Heavenly stems (E2)
YD:36％. 1HNMR(400MHz,d4-MeOD)δ8.14(d,J＝8.8Hz,1H),7.40-7.43(m,1H),7.37-7.39(m,2H),7.16(dd,J＝6.8,2.0Hz,1H),4.83(m,1H),3.51(t,J＝6.8Hz,2H),2.98(t,J＝7.6Hz,2H),1.77(quin,J＝7.2Hz,2H),1.45-1.49(m,2H),1.41(d,J＝6Hz,6H),1.20-1.35(br,11H)；MS.m/z366.0,[M+Na] +。
11-(8-isopropoxy quinoline-2-base) 11-1-alcohol (E3)
YD:45％. 1HNMR(400MHz,CDCl 3)δ7.99(d,J＝8.4Hz,1H),7.34(d,J＝4.4Hz,2H),7.24-7.27(m,1H),7.09(t,J＝4.4Hz,1H),4.82(sept,J＝6Hz,1H),3.60(t,J＝6.8Hz,2H),3.00(t,J＝7.6Hz,2H),1.81(quin,J＝7.6Hz,2H),1.51-1.56(m,2H),1.47(d,J＝6Hz,6H),1.33-1.43(br,15H)；MS.m/z380.3,[M+Na] +。
12-(8-isopropoxy quinoline-2-base) 12-1-alcohol (E4)
YD:34％. 1HNMR(400MHz,CDCl 3)δ8.05(d,J＝7.6Hz,1H),7.30-7.39(m,3H),7.13(dd,J＝6.4,2.4Hz,1H),4.85(sept,J＝6Hz,1H),3.63(t,J＝6.8Hz,2H),3.09(br,2H),1.84(quin,J＝7.6Hz,2H),1.56(quin,J＝7.2Hz,2H),1.48(d,J＝6Hz,6H),1.27-1.47(br,17H)；MS.m/z394.3,[M+Na] +。
13-(8-isopropoxy quinoline-2-base) 13-1-alcohol (E5)
YD:34％. 1HNMR(400MHz,d4-MeOD)δ8.11(d,J＝8.4Hz,1H),7.35-7.41(m,3H),7.14(d,J＝7.2Hz,1H),4.81(br,1H),3.52(t,J＝6.8Hz,2H),2.96(t,J＝8.0Hz,2H),1.75(quin,J＝7.2Hz,2H),1.45-1.52(m,2H),1.43(d,J＝6.0Hz,6H),1.25-1.42(br,19H)；MS.m/z408.0,[M+Na] +。
14-(8-isopropoxy quinoline-2-base) 14-1-alcohol (E6)
YD:36％. 1HNMR(400MHz,d4-MeOD)δ8.13(d,J＝8.8Hz,1H),7.37-7.43(m,3H),7.16(dd,J＝7.2,1.6Hz,1H),4.86(br,1H),3.52(t,J＝6.8Hz,2H),2.98(t,J＝7.6Hz,2H),1.78(quin,J＝7.6Hz,2H),1.49-1.52(m,2H),1.46(d,J＝6.4Hz,6H),1.26-1.41(br,21H)；MS.m/z422.3,[M+Na] +。
15-(8-isopropoxy quinoline-2-base) 15-1-alcohol (E7)
YD:36％. 1HNMR(400MHz,CDCl 3)δ8.01(d,J＝8.4Hz,1H),7.27-7.36(m,3H),7.10-7.13(m,1H),4.82(sept,J＝4.1Hz,1H),3.61(t,J＝6.8Hz,2H),3.00(t,J＝6.4Hz,2H),1.81(quin,J＝7.6Hz,2H),1.52-1.55(m,2H),1.48(d,J＝2Hz,6H),1.31-1.47(br,21H)；MS.m/z436.3,[M+Na] +。
11-(8-isopropoxy-5-toluquinoline-2-base) 11-1-alcohol (E8)
YD:48％. 1HNMR(400MHz,CDCl 3)δ8.09(d,J＝8.4Hz,1H),7.26(d,J＝8.8Hz,1H),7.12(d,J＝8.0Hz,1H),6.97(t,J＝7.6Hz,1H),4.75(sept,J＝6Hz,1H),3.55(t,J＝6.8Hz,2H),3.00(t,J＝7.6Hz,2H),2.51(s,3H),1.81(t,J＝7.2Hz,2H),1.23-1.49(br,23H)；MS.m/z394.3,[M+Na] +。
11-(5-fluoro-8-isopropoxy quinoline-2-base) 11-1-alcohol (E9)
YD:46％. 1HNMR(400MHz,d4-MeOD)δ8.30(d,J＝8.8Hz,1H),7.44(d,J＝8.4Hz,1H),7.09(d,J＝4.8Hz,1H),4.79(m,1H),3.51(t,J＝6.8Hz,2H),2.97(t,J＝8.0Hz,2H),1.74(quin,J＝7.6Hz,2H),1.45-1.51(m,2H),1.42(d,J＝6.4Hz,6H),1.12-1.39(br,15H)；MS.m/z398.2,[M+Na] +。
9-(5-chloro-8-isopropoxy quinoline-2-base)-1-alcohol in the ninth of the ten Heavenly Stems (E10)
YD:46％. 1HNMR(400MHz,d4-MeOD)δ8.45(d,J＝8.8Hz,1H),7.52(d,J＝8.4Hz,1H),7.49(d,J＝8.4Hz,1H),7.12(d,J＝8.4Hz,1H),4.85(m,1H),3.51(t,J＝6.4Hz,2H),3.01(t,J＝8.0Hz,2H),1.78(quin,J＝7.6Hz,2H),1.49(quin,J＝6.4Hz,2H),1.45(d,J＝6.0Hz,6H),1.30-1.42(br,11H)；MS.m/z364.2,[M+H] +。
11-(5-chloro-8-isopropoxy quinoline-2-base) 11-1-alcohol (E11)
YD:46％. 1HNMR(400MHz,d4-MeOD)δ8.47(d,J＝8.4Hz,1H),7.53(d,J＝8.4Hz,1H),7.50(d,J＝8.4Hz,1H),7.13(d,J＝8.4Hz,1H),4.89(m,1H),3.52(t,J＝6.4Hz,2H),3.01(t,J＝7.2Hz,2H),1.79(quin,J＝7.6Hz,2H),1.48(quin,J＝6.8Hz,2H),1.41(d,J＝5.6Hz,6H),1.21～1.39(br,15H)；MS.m/z414.2,[M+Na] +。
15-(5-chloro-8-isopropoxy quinoline-2-base) 15-1-alcohol (E12)
YD:46％. 1HNMR(400MHz,d4-MeOD+CDCl 3)δ8.46(d,J＝8.8Hz,1H),7.51(d,J＝8.8Hz,1H),7.48(d,J＝8.8Hz,1H),7.11(d,J＝8.4Hz,1H),4.85(m,1H),3.52(t,J＝6.8Hz,2H),3.01(t,J＝8.0Hz,2H),1.79(quin,J＝7.2Hz,2H),1.51(quin,J＝6.8Hz,2H),1.46(d,J＝6.0Hz,6H),1.25-1.39(m,23H)；MS.m/z448.3,[M+H] +。
11-(5-bromo-8-isopropoxy quinoline-2-base) 11-1-alcohol (E13)
YD:40％. 1HNMR(400MHz,d4-MeOD)δ8.43(d,J＝8.8Hz,1H),7.69(d,J＝8.8Hz,1H),7.52(d,J＝8.4Hz,1H),7.10(d,J＝7.6Hz,1H),4.86(br,1H),3.52(t,J＝6.8Hz,2H),3.02(t,J＝7.6Hz,2H),1.79(quin,J＝7.2Hz,2H),1.50-1.52(m,2H),1.46(d,J＝6.0Hz,6H),1.28-1.41(br,15H)；MS.m/z458.2,[M+Na] +。
11-(5,7-bis-chloro-8-isopropoxy quinoline-2-base) 11-1-alcohol (E14)
YD:37％. 1HNMR(400MHz,CDCl 3)δ8.36(d,J＝8.4Hz,1H),7.56(d,J＝3.2Hz,1H),7.35(d,J＝8.4Hz,1H),5.13(m,1H),3.63(t,J＝6.8Hz,2H),3.00(t,J＝7.6Hz,2H),1.86(quin,J＝6.8Hz,2H),1.52-1.59(m,4H),1.27-1.44(br,20H)；MS.m/z448.4,[M+Na] +。
Embodiment 4 – prepares (8-cyclo propyl methoxy quinoline-2-base) alkyl alcohol derivative
Reagent and condition: (a) methylene radical Cyclopropyl Bromide, K 2cO 3, DMF, 60 DEG C, 13h.; (b) 1) LHMDS, THF, 0 DEG C, 1h.; 2) Br (CH 2) n-1oH, rt, 12-20h.
Method: at 60 DEG C, methylene radical Cyclopropyl Bromide (1.0g, 6.3mmol) is added into containing 2-methyl quinaldine red (1.0g, 6.3mmol) and K 2cO 3in the 25mlDMF of (2.5g, 18.1mmol) stirred solution 13 hours.By reaction mixture with H 2o (200ml) quenching also extracts with EtOAc (30mlX3).By organic layer evaporation concentration under vacuum, and flash column chromatography chromatography method is utilized by resistates to carry out purifying to provide the chloro-8-of intermediate 5-(cyclo propyl methoxy)-2-toluquinoline with Hex/EA (8:1 to 6:1).LHMDS (2.2 equivalent) is processed 1 hour with the THF solution containing intermediate (0.5g, 2.3mmol) stirred solution at 0 DEG C.By the Br (CH of correspondence 2) n-1oH (1.1 – 1.2 equivalent) is added into reaction mixture, and makes temperature get back to RT to carry out 12 to 20 hours again.Decompression removes solvent.Flash column chromatography chromatography method is utilized by brown oil resistates to carry out purifying with Hex/EA or DCM/EA, and with Hex/EA recrystallize to provide compound F 17-hydroxy-corticosterone.
9-(8-(cyclo propyl methoxy) quinoline-2-base)-1-alcohol in the ninth of the ten Heavenly Stems (F1)
YD:49％. 1HNMR(400MHz,d4-MeOD)δ8.15(d,J＝8.4Hz,1H),7.38-7.43(m,3H),7.14(dd,J＝5.6,3.2Hz,1H),4.06(d,J＝7.2Hz,2H),3.51(t,J＝6.8Hz,2H),3.00(t,J＝8.0Hz,2H),1.77(quin,J＝7.6Hz,2H),1.48-1.52(m,3H),1.32-1.47(m,11H),0.65-0.70(m,2H),0.34-0.45(m,2H)；MS.m/z342.2,[M+H] +。
10-(8-(cyclo propyl methoxy) quinoline-2-base)-1-alcohol in the last of the ten Heavenly stems (F2)
YD:43％. 1HNMR(400MHz,d4-MeOD)δ8.16(d,J＝8.4Hz,1H),7.40～7.43(m,3H),7.15(dd,J＝5.6,3.2Hz,1H),4.07(d,J＝7.2Hz,2H),3.52(t,J＝6.4Hz,2H),3.01(t,J＝8.0Hz,2H),1.80(quin,J＝7.6Hz,2H),1.47-1.53(m,3H),1.31-1.44(m,13H),0.67-0.69(m,2H),0.44-0.46(m,2H)；MS.m/z356.2,[M+H] +。
11-(8-(cyclo propyl methoxy) quinoline-2-base) 11-1-alcohol (F3)
YD:45％. 1HNMR(400MHz,CDCl 3)δ8.02(d,J＝8.4Hz,1H),7.30～7.38(m,2H),7.05(dd,J＝6.4,2.4Hz,1H),4.11(d,J＝6.8Hz,1H),3.63(t,J＝6.4Hz,2H),3.04(t,J＝8.0Hz,2H),1.83(quin,J＝7.6Hz,2H),1.48-1.59(m,3H),1.26-1.46(br,15H),0.67(dd,J＝13.2,5.6Hz,2H),0.44(dd,J＝13.2,5.6Hz,2H)；MS.m/z392.2,[M+Na] +。
12-(8-(cyclo propyl methoxy) quinoline-2-base) 12-1-alcohol (F4)
YD:36％. 1HNMR(400MHz,CDCl 3)δ8.01(d,J＝8.4Hz,1H),7.29-7.38(m,3H),7.06(dd,J＝6.0,2.4Hz,1H),4.11(d,J＝6.8Hz,1H),3.63(t,J＝6.4Hz,2H),3.04(t,J＝7.2Hz,2H),1.83(quin,J＝7.6Hz,2H),1.48-1.59(m,3H),1.27-1.47(br,17H),0.67(dd,J＝13.2,5.6Hz,2H),0.42-0.48(m,2H)；MS.m/z384.3,[M+H] +。
13-(8-(cyclo propyl methoxy) quinoline-2-base) 13-1-alcohol (F5)
YD:42％. 1HNMR(400MHz,d4-MeOD)δ8.14(d,J＝8.4Hz,1H),7.38～7.41(m,3H),7.05(dd,J＝5.6,3.2Hz,1H),4.05(d,J＝6.8Hz,2H),3.52(t,J＝6.4Hz,2H),2.99(t,J＝8.0Hz,2H),1.78(quin,J＝7.6Hz,2H),1.44-1.52(m,3H),1.26-1.40(m,19H),0.67(dd,J＝13.2,5.6Hz,2H),0.40-0.47(m,2H)；MS.m/z420.0,[M+Na] +。
14-(8-(cyclo propyl methoxy) quinoline-2-base) 14-1-alcohol (F6)
YD:37％. 1HNMR(400MHz,d4-MeOD)δ8.15(d,J＝8.8Hz,1H),7.39～7.42(m,3H),7.13(dd,J＝5.6,3.2Hz,1H),4.05(d,J＝6.8Hz,2H),3.52(t,J＝6.8Hz,2H),2.99(t,J＝7.6Hz,2H),1.78(quin,J＝7.6Hz,2H),1.44-1.52(m,3H),1.26-1.43(m,21H),0.65-0.69(m,2H),0.42(dd,J＝10.0,4.8Hz,2H)；MS.m/z434.3,[M+Na] +。
15-(8-(cyclo propyl methoxy) quinoline-2-base) 15-1-alcohol (F7)
YD:69％. 1HNMR(400MHz,d4-MeOD+CDCl 3)δ8.13(dd,J＝8.4,2.0Hz,1H),7.38(br,3H),7.11(d,J＝2.4Hz,1H),4.05(d,J＝6.8Hz,2H),3.52(t,J＝6.8Hz,2H),2.99(t,J＝8.0Hz,2H),1.78(quin,J＝7.2Hz,2H),1.46-1.52(m,3H),1.25-1.44(m,23H),0.63-0.69(m,2H),0.40-0.46(m,2H)；MS.m/z426.4,[M+H] +。
11-(8-(cyclo propyl methoxy)-5-toluquinoline-2-base) 11-1-alcohol (F8)
YD:45％. 1HNMR(400MHz,d4-MeOD)δ8.31(d,J＝8.8Hz,1H),δ7.44(d,J＝8.8Hz,1H),7.22(d,J＝8.0Hz,1H),7.02(d,J＝8.0Hz,1H),4.02(d,J＝7.2Hz,2H),3.52(t,J＝6.4Hz,2H),3.00(t,J＝8.0Hz,2H),2.57(s,3H),1.79(quin,J＝7.2Hz,2H),1.29-1.52(m,18H),0.65-0.68(m,2H),0.40-0.43(m,2H)；MS.m/z406.3,[M+Na] +。
11-(8-(cyclo propyl methoxy)-5-fluorine quinoline-2-base) 11-1-alcohol (F9)
YD:46％. 1HNMR(400MHz,d4-MeOD)δ8.36(d,J＝8.8Hz,1H),7.52(d,J＝8.8Hz,1H),7.07-7.15(m,2H),4.05(d,J＝6.8Hz,2H),3.53(t,J＝6.8Hz,2H),3.02(t,J＝7.6Hz,2H),1.79(quin,J＝7.6Hz,2H),1.42-1.49(m,3H),1.22-1.40(m,15H),0.65-0.69(m,2H),0.42(dd,J＝10.4,4.8Hz,2H)；MS.m/z410.2,[M+Na] +。
9-(the chloro-8-of 5-(cyclo propyl methoxy) quinoline-2-base)-1-alcohol in the ninth of the ten Heavenly Stems (F10)
YD:33％. 1HNMR(400MHz,d4-MeOD)δ8.48(d,J＝8.8Hz,1H),7.55(d,J＝8.8Hz1H),7.49(d,J＝8.4Hz,1H),7.11(d,J＝8.4Hz,1H),4.06(d,J＝6.8Hz,2H),3.51(t,J＝6.4Hz,2H),3.03(t,J＝8.0Hz,2H),1.83(t,J＝7.6Hz,2H),1.54-1.69(m,3H),1.27-1.48(br,15H),0.67-0.71(m,2H),0.43-0.46(m,2H)；MS.m/z376.2,[M+H] +。
11-(the chloro-8-of 5-(cyclo propyl methoxy) quinoline-2-base) 11-1-alcohol (F11)
YD:34％. 1HNMR(400MHz,CDCl 3)δ8.41(d,J＝8.8Hz,1H),7.43(d,J＝2.4Hz1H),7.41(d,J＝2.4Hz,1H),6.97(d,J＝8.4Hz,1H),4.09(d,J＝7.2Hz,2H),3.63(t,J＝6.4Hz,2H),3.05(t,J＝8.0Hz,2H),1.83(t,J＝7.6Hz,2H),1.54-1.69(m,3H),1.27-1.48(br,15H),0.67-0.71(m,2H),0.43-0.46(m,2H)；MS.m/z426.2,[M+Na] +。
15-(the chloro-8-of 5-(cyclo propyl methoxy) quinoline-2-base) 15-1-alcohol (F12)
YD:28％. 1HNMR(400MHz,d4-MeOD+CDCl 3)δ8.47(d,J＝8.8Hz,1H),7.54(d,J＝8.8Hz,1H),7.48(d,J＝8.4Hz,1H),7.10(d,J＝8.4Hz,1H),4.06(d,J＝6.8Hz,2H),3.52(t,J＝6.8Hz,2H),3.02(t,J＝7.6Hz,2H),1.79(quin,J＝7.6Hz,2H),1.46-1.52(m,2H),1.25-1.44(br,24H),0.65-0.69(m,2H),0.41-0.43(m,2H)；MS.m/z460.3,[M+Na] +。
11-(the bromo-8-of 5-(cyclo propyl methoxy) quinoline-2-base) 11-1-alcohol (F13)
YD:35％. 1HNMR(400MHz,d4-MeOD)δ8.42(d,J＝8.8Hz,1H),δ7.67(d,J＝8.4Hz,1H),7.53(d,J＝8.8Hz,1H),7.06(d,J＝8.4Hz,1H),4.05(d,J＝7.2Hz,2H),3.51(t,J＝6.4Hz,2H),3.02(t,J＝8.0Hz,2H),1.77(quin,J＝7.6Hz,2H),1.46-1.52(m,3H),1.28-1.44(m,15H),0.65-0.70(m,2H),0.42-0.45(m,2H)；MS.m/z470.2,[M+Na] +。
11-(the chloro-8-of 5,7-bis-(cyclo propyl methoxy) quinoline-2-base) 11-1-alcohol (F14)
YD:53％. 1HNMR(400MHz,d4-MeOD)δ8.47(d,J＝8.8Hz,1H),δ7.67(s,1H),7.53(d,J＝8.8Hz,1H),7.06(d,J＝8.4Hz,1H),4.23(d,J＝7.2Hz,2H),3.53(t,J＝6.4Hz,2H),3.02(t,J＝7.6Hz,2H),1.86(quin,J＝7.2Hz,2H),1.48-1.53(m,2H),1.29-1.38(m,16H),0.62(dd,J＝12.8,5.2Hz,2H),0.31(dd,J＝10.8,5.2Hz,2H)；MS.m/z460.2,[M+Na] +。
Embodiment 5 – prepares (5,7-dichloro-8-hydroxyquinoline-2-base) alkyl alcohol
Reagent and condition: (a) NCS, CHCl 3, rt, 48h.
Method: N-chloro-succinimide (0.3g, 2.25mmol) is added into the CHCl containing compd B stirred solution 3(20ml) in 48 hours.Reaction mixture to be poured in trash ice and with CH 2cl 2(20mlX2) extract.Utilized by extract column chromatography to carry out purifying with Hex/EA (3:1), and recrystallize is to obtain compound (0.18g, 49%).
The chloro-2-of 5,7-bis-(11-hydroxyl undecyl) quinoline-8-alcohol (G1)
YD:49％. 1HNMR(400MHz,CDCl 3)δ8.38(d,J＝8.8Hz,1H),7.51(s,1H),7.42(d,J＝8.8Hz,1H),3.63(t,J＝6.8Hz,2H),3.00(t,J＝7.6Hz,2H),1.82(quin,J＝7.2Hz,2H),1.56(quin,J＝7.6Hz,2H),1.27-1.38(br,15H)；MS.m/z382.0,[M-H] +。
Embodiment 6 – prepares (the chloro-8-methoxy quinoline of 5--2-base) alkyl alcohol or alkyl acetates
Reagent and condition: (a) HCl, ICl 3, ice HOAc, H 2o, 6h, rt.
Method: dense HCl (0.5mL/mmol) is added into (8-methoxy quinoline-2-base)-ol (1.0 equivalent) that various different long-chain is substituted under room temperature, and reddish yellow mixture is stirred 5 minutes.Dropwise by ICl 3dense HCl (2mL) solution of (1.5 equivalent) adds so far in mixture.In this clear yellow viscous mixture of stirred at ambient temperature 6 hours.Water is added wherein and carry out layering with EA.With normal saline washing organic layer, with anhydrous MgSO 4drying is also filtered, and removes solvent afterwards to obtain oily resistates, is utilized by oily resistates flash column chromatography chromatography method with CHCl 3carry out purifying to obtain H1 to H5.
10-(5-chloro-8-methoxy quinoline-2-base)-1-alcohol in the last of the ten Heavenly stems (H1a) and acetic acid 10-(the chloro-8-methoxy quinoline of 5--2-base) ester in the last of the ten Heavenly stems (H1b)
YD:61% and 10%.H1a: 1hNMR (200MHz, CDCl 3) δ 8.41 (d, J=8.68Hz, 1H), 7.42 (dd, J=8Hz, J=2Hz, 2H), 6.91 (d, J=8Hz, 1H), 4.03 (s, 3H), 3.59 (t, J=6Hz, 2H), 3.59 (t, J=4Hz, 2H), 1.73 (m, 2H), 1.48 (m, 2H), 1.25 (br, 12H); HRMS (EI): calculated value C 20h 28clNO 2: 349.1803, actual value: 349.1781.H1b: 1hNMR (400MHz, CDCl 3) δ 8.41 (d, J=8Hz, 1H), 7.42 (dd, J=8Hz, J=4Hz, 2H), 6.92 (d, J=8Hz, 1H), 4.06 (t, J=8Hz, 2H), 4.02 (s, 3H), 3.03 (t, J=8Hz, 2H), 2.02 (s, 3H), 1.79 (m, 2H), 1.59 (m, 2H), 1.40 (m, 2H), 1.23 (br, 12H); HRMS (FAB, M+H): calculated value C 22h 31clNO 3392.1992, actual value 392.1983.
11-(5-chloro-8-methoxy quinoline-2-base) 11-1-alcohol (H2a) and acetic acid 11-(the chloro-8-methoxy quinoline of 5--2-base) 11 esters (H2b)
YD:60% and 12%.H2a: 1hNMR (400MHz, CDCl 3) δ 8.43 (d, J=8.72Hz, 1H), 7.44 (dd, J=13.5Hz, J=5.3Hz, 2H), 6.94 (d, J=8.3Hz, 1H), 4.05 (s, 3H), 3.62 (t, J=6.6Hz, 2H), 3.07 (t, J=5.2Hz, 2H), 1.80 (m, 2H), 1.54 (m, 2H), 1.39 (m, 2H), 1.26 (br, 12H); HRMS (EI): calculated value C 21h 30clNO 2363.1960, actual value 363.1941.H2b: 1hNMR (400MHz, CDCl 3) δ 8.41 (d, J=8.6Hz, 1H), 7.42 (dd, J=8.3Hz, J=3.8Hz, 2H), 6.91 (d, J=8.4Hz, 1H), 4.06 (t, J=7.8Hz, 2H), 4.02 (s, 3H), 3.02 (t, J=7.8Hz, 2H), 2.01 (s, 3H), 1.78 (m, 2H), 1.58 (m, 2H), 1.39 (m, 2H), 1.22 (br, 12H); HRMS (EI): calculated value C 23h 32clNO 3405.2065, actual value 405.2044.
12-(5-chloro-8-methoxy quinoline-2-base) 12-1-alcohol (H3a) and acetic acid 12-(the chloro-8-methoxy quinoline of 5--2-base) ten diester (H3b)
YD:57% and 27%.H3a: 1hNMR (400MHz, CDCl 3) δ 8.46 (d, J=8.6Hz, 1H), 7.44 (dd, J=8.3Hz, J=6.9Hz, 2H), 6.94 (d, J=8.4Hz, 1H), 4.04 (s, 3H), 3.59 (t, J=6.6Hz, 2H), 3.11 (t, J=7.8Hz, 2H), 1.78 (m, 2H), 1.50 (m, 2H), 1.40 (m, 2H), 1.23 (br, 14H); HRMS (EI): calculated value C 22h 32clNO 2377.2116, actual value 377.2106.H3b: 1hNMR (200MHz, CDCl 3) δ 8.38 (d, J=8.7Hz, 1H), 7.40 (d, J=8.6Hz, 2H), 6.88 (d, J=8.4Hz, 1H), 4.03 (t, J=7.8Hz, 2H), 4.01 (s, 3H), 3.02 (t, J=7.8Hz, 2H), 1.99 (s, 3H), 1.76 (m, 2H), 1.59 (m, 2H), 1.20 (br, 16H); HRMS (FAB, M+H): calculated value C 24h 35clNO 3420.2305, actual value 420.2310.
13-(5-chloro-8-methoxy quinoline-2-base) 13-1-alcohol (H4a) and acetic acid 13-(the chloro-8-methoxy quinoline of 5--2-base) 13 esters (H4b)
YD:64% and 14%.H4a: 1hNMR (400MHz, CDCl 3) δ 8.46 (d, J=8.6Hz, 1H), 7.45 (dd, J=8.3Hz, J=6.9Hz, 2H), 6.94 (d, J=8.4Hz, 1H), 4.04 (s, 3H), 3.59 (t, J=6.6Hz, 2H), 3.11 (t, J=7.8Hz, 2H), 1.78 (m, 2H), 1.50 (m, 2H), 1.40 (m, 2H), 1.23 (br, 16H); HRMS (EI): calculated value C 23h 34clNO 2391.2273, actual value 391.2249.H4b: 1hNMR (400MHz, CDCl 3) δ 8.38 (d, J=8.6Hz, 1H), 7.40 (dd, J=8.5Hz, J=5.8Hz, 2H), 6.89 (d, J=8.4Hz, 1H), 4.01 (t, J=9.6Hz, 2H), 4.00 (s, 3H), 3.00 (t, J=7.9Hz, 2H), 1.99 (s, 3H), 1.75 (m, 2H), 1.58 (m, 2H), 1.38 (m, 2H), 1.22 (br, 16H); HRMS (FAB, M+H): calculated value C 25h 37clNO 3434.2462, actual value 434.2459.
Embodiment 7 – prepares (oxine-4-base) or (8-alkoxyl group quinolyl-4) alkyl alcohol
Reagent and condition: (a) methyl vinyl ketone, HCl, backflow. (b) MeI, K 2cO 3, acetone, rt, 8h; EtI or 2-N-PROPYLE BROMIDE or methylene radical Cyclopropyl Bromide, K 2cO 3, DMF, 60 DEG C, (c) 1) and LHMDS, THF, 0 DEG C, 1h.; 2) Br (CH 2) n-1oH, rt, (d) BnBr, KOH, EtOH, backflow. (e) H 2, Pd/C, MeOH, rt, 24h.
Method: pass through ring-closure reaction synthetic intermediate INT1 by 2-amino-phenol and methyl ethylene reactive ketone.INT1 and various alkyl halide are reacted provide 8-alkoxyl group-4-methylquinoline derivatives as intermediate.By the Br (CH of correspondence 2) n-1oH and intermediate reaction are to synthesize a series of compound J and I.Hydrogenation (the method illustrates in embodiment 1) is utilized to remove protecting group J, to obtain compound K.
11-(8-methoxy quinoline-4-base) 11-1-alcohol (I1)
YD:34％. 1HNMR(400MHz,CDCl 3)δ8.80(dd,J＝4.4,0.6Hz,1H),7.59(dd,J＝8.4,0.8Hz,1H),7.44-7.49(m,1H),7.03(d,J＝7.6Hz,1H),4.08(s,3H),3.63(t,J＝6.8Hz,2H),3.03(t,J＝7.6Hz,2H),1.74(quin,J＝7.6Hz,2H),1.55(quin,J＝7.2Hz,2H),1.23-1.45(br,15H)；MS.m/z329.9,[M+H] +。
11-(8-ethoxyquinoline-4-base) 11-1-alcohol (I2)
YD:42％.HNMR(400MHz,d4-MeOD)δ8.66(d,J＝8.4Hz,1H),7.64(d,J＝8.4Hz,1H),7.51(t,J＝8.0Hz,1H),7.37(d,J＝8.4Hz,1H),7.15(d,J＝7.6Hz,1H),4.27(q,J＝6.8Hz,2H),3.52(t,J＝6.8Hz,2H),3.08(d,J＝7.6Hz,2H),1.75(quin,J＝7.6Hz,2H),1.50-1.57(m,5H),1.21-1.49(br,15H)；MS.m/z366.2,[M+Na] +。
11-(8-isopropoxy quinolyl-4) 11-1-alcohol (I3)
YD:48％. 1HNMR(400MHz,d4-MeOD)δ8.65(d,J＝8.4Hz,1H),7.63(d,J＝7.6Hz,1H),7.51(d,J＝8.0Hz,1H),7.35(d,J＝4.4Hz,1H),7.17(d,J＝8.0Hz,1H),4.84(br,1H),3.52(t,J＝6.4Hz,2H),3.07(d,J＝7.6Hz,2H),1.74(br,2H),1.43-1.50(br,9H),1.29-1.34(br,14H)；MS.m/z380.3,[M+Na] +。
11-(8-(cyclo propyl methoxy) quinolyl-4) 11-1-alcohol (I4)
YD:53％. 1HNMR(400MHz,d4-MeOD)δ8.66(d,J＝8.4Hz,1H),7.63(d,J＝8.4Hz,1H),7.49(t,J＝8.4Hz,1H),7.36(d,J＝4.8Hz,1H),7.13(d,J＝7.6Hz,1H),4.03(d,J＝6.8Hz,1H),3.52(t,J＝6.8Hz,2H),3.06(d,J＝7.6Hz,2H),1.69-1.75(m,2H),1.28-1.52(br,18H),0.65-0.68(m,2H),0.42-0.43(m,2H)；MS.m/z392.2[M+Na] +。
11-(8-(benzyloxy) quinolyl-4) 11-1-alcohol (J1)
YD:46％. 1HNMR(400MHz,d4-MeOD)δ8.66(d,J＝8.4Hz,1H),7.64(d,J＝8.4Hz,1H),7.52(d,J＝7.2Hz,2H),7.45(t,J＝8.0Hz,1H),7.30-7.38(m,3H),7.26-7.28(m,1H),7.17(d,J＝7.6Hz,1H),5.37(s,2H),3.52(t,J＝6.4Hz,2H),3.06(t,J＝8Hz,2H),1.73(q,J＝7.6Hz,2H),1.50(t,J＝7.2Hz,2H),1.28-1.48(m,15H)；MS.m/z428.3,[M+Na] +。
12-(8-(benzyloxy) quinolyl-4) 12-1-alcohol (J2)
YD:46％. 1HNMR(400MHz,d4-MeOD)δ8.67(d,J＝4.4Hz,1H),7.65(d,J＝8.4Hz,1H),7.52(d,J＝7.2Hz,2H),7.45(t,J＝8.0Hz,1H),7.30-7.39(m,3H),7.27-7.30(m,1H),7.18(d,J＝8.0Hz,1H),5.38(s,2H),3.52(t,J＝6.4Hz,2H),3.08(t,J＝7.6Hz,2H),1.74(q,J＝7.6Hz,2H),1.49(t,J＝7.2Hz,2H),1.23-1.45(m,17H)；MS.m/z442.3,[M+Na] +。
4-(11-hydroxyl undecyl) quinoline-8-alcohol (K1)
YD:84％. 1HNMR(400MHz,d4-MeOD)δ8.63(d,J＝4.4Hz,1H),7.51(d,J＝8.4Hz,1H),7.40(t,J＝8.0Hz,1H),7.28(d,J＝4.0Hz,1H),7.06(d,J＝7.6Hz,1H),3.51(t,J＝6.8Hz,2H),3.02(t,J＝8.0Hz,2H),1.71(t,J＝7.6Hz,2H),1.50(quin,J＝6.8Hz,2H),1.12-1.31(br,15H)；MS.m/z316.2,[M+H] +。
4-(12-hydroxyl dodecyl) quinoline-8-alcohol (K2)
YD:86％. 1HNMR(400MHz,CDCl 3)δ8.52(d,J＝4.4Hz,1H),7.36(dd,J＝8.4,0.8Hz,1H),7.31(d,J＝7.6Hz,1H),7.13(d,J＝4.4Hz,1H),6.99(dd,J＝7.6,1.2Hz,1H),3.43(t,J＝6.8Hz,2H),2.89(t,J＝7.6Hz,2H),1.61(quin,J＝7.6Hz,2H),1.40(quin,J＝6.8Hz,2H),1.12-1.31(br,17H)；MS.m/z352.2,[M+Na] +。
Embodiment 8 – prepares (8-trifluoromethoxy quinoline-2-base) alkyl alcohol
Method: 2-trifluoro-methoxyaniline and crotonic aldehyde are reacted pass through ring-closure reaction synthetic intermediate.By intermediate and corresponding Br (CH 2) n-1oH (as mentioned above) reaction is to synthesize a series of compound L.
9-(8-(trifluoromethoxy) quinoline-2-base)-1-alcohol in the ninth of the ten Heavenly Stems (L1)
YD:41％. 1HNMR(400MHz,CDCl 3)δ8.06(dd,J＝8.4,1.2Hz,1H),7.70(d,J＝8.4Hz,1H),7.56(d,J＝7.6Hz,1H),7.43(d,J＝8.0Hz,1H),7.34(dd,J＝8.4,1.2Hz,1H),3.61(t,J＝6.4Hz,2H),3.01(t,J＝6.4Hz,2H),1.81-1.85(br,2H),1.53-1.56(br,2H),1.21-1.35(m,15H)；MS.m/z355.9,[M+H] +。
11-(8-(trifluoromethoxy) quinoline-2-base) 11-1-alcohol (L2)
YD:41％. 1HNMR(400MHz,d4-MeOD)δ8.26(t,J＝8.0Hz,1H),7.86(d,J＝7.6Hz,1H),7.64(t,J＝7.2Hz,1H),7.47-7.56(m,2H),3.51(t,J＝6.8Hz,2H),2.99(t,J＝6.4Hz,2H),1.79(quin,J＝6.8Hz,2H),1.50(quin,J＝6.8Hz,2H),1.21-1.35(m,15H)；MS.m/z406.2,[M+Na] +。
14-(8-(trifluoromethoxy) quinoline-2-base) 14-1-alcohol (L3)
YD:37％. 1HNMR(400MHz,d4-MeOD)δ8.27(d,J＝8.4Hz,1H),7.87(d,J＝8.0Hz,1H),7.65(t,J＝7.2Hz,1H),7.49-7.56(m,2H),3.52(t,J＝6.8Hz,2H),3.01(t,J＝7.6Hz,2H),1.82(quin,J＝7.2Hz,2H),1.51(quin,J＝6.8Hz,2H),1.27-1.37(m,21H)；MS.m/z448.2,[M+Na] +。
15-(8-(trifluoromethoxy) quinoline-2-base) 15-1-alcohol (L4)
YD:32％. 1HNMR(400MHz,d4-MeOD+CDCl 3)δ8.21(d,J＝8.4Hz,1H),7.81(d,J＝8.0Hz,1H),7.61(d,J＝7.6Hz,1H),7.51(d,J＝8.0Hz,1H),7.46(t,J＝8.4Hz,1H),3.52(t,J＝6.8Hz,2H),2.99(t,J＝7.6Hz,2H),1.80(quin,J＝7.6Hz,2H),1.50(quin,J＝7.2Hz,2H),1.15-1.41(br,23H)；MS.m/z462.2,[M+Na] +。
Example 9 – prepares 2-N-and replaces-8-hydroxyl/alkoxyl group quinoline
Reagent and condition: (a) SeO 2, dioxan, 50 to 80 DEG C; (b) N-methyl-prop ynamine or 2-(piperazine-1-base) ethanol or NH 2(CH 2) n-1OH, NaBH (OAc) 3, 1,2-ethylene dichloride, rt.
Method: dropwise dioxan (15ml) solution of 8-hydroxy-2-methylquinoline (6.0g, 37.7mmol) is added into SeO at 50 DEG C 2dioxan (80ml) stirred solution of (6.3g, 56.8mmol), and mixture is heated to 80 DEG C 20 hours again.Filter the mixture formed.Concentrated filtrate, and utilized by resistates column chromatography to carry out purifying to obtain oxine-2-carboxylic aldehyde (2.45g, 38%) derivative as intermediate with Hex/EA=(15:1 to 10:1).With amido alcohol, amido alkynes or other heterocycles, utilize reductive amination process by converted for N-substitution compound, to provide a series of compound.By the oxidation of 8-alkoxyl group-2-toluquinoline to provide 8-alkoxyl group quinoline-2-carboxylic aldehyde derivatives, afterwards and in the same way obtain compound M to O.
2-((4-(2-hydroxyethyl) piperazine-1-base) methyl) quinoline-8-alcohol (M1)
YD:76%. 1hNMR (400MHz, CDCl 3) δ 8.02 (d, J=8.4Hz, 1H), 7.43 (d, J=8.4Hz, 1H), 7.34 (t, J=8.0Hz, 1H), 7.22 (d, J=7.6Hz, 1H), 7.10 (d, J=6.8Hz, 1H), 3.73 (s, 2H), 3.61 (t, J=6.8Hz, 2H), 2.51 (t, J=5.6Hz, 10H); HRMS (ESI): calculated value [M+Na] +: 310.1526, actual value: 310.1527.
2-(4-((the chloro-8-methoxy quinoline of 5--2-base) methyl) piperazine-1-base) ethanol (M2)
YD:76％. 1HNMR(400MHz,CDCl 3)δ8.23(d,J＝8.8Hz,1H),7.59(d,J＝8.8Hz,1H),7.21(d,J＝8.4Hz,1H),6.68(d,J＝8.8Hz,1H),3.81(s,3H),3.72(s,2H),3.44(t,J＝4.8Hz,2H),2.35-2.38(m,10H)；MS.m/z336.1,[M+H] +。
2-(4-((the chloro-8-ethoxyquinoline of 5--2-base) methyl) piperazine-1-base) ethanol (M3)
YD:53％. 1HNMR(400MHz,CDCl 3)δ8.36(d,J＝8.8Hz,1H),7.68(d,J＝8.4Hz,1H),7.34(d,J＝8.4Hz,1H),6.83(d,J＝8.4Hz,1H),4.18(q,J＝6.8Hz,3H),3.84(s,2H),3.54(t,J＝5.2Hz,2H),2.45-2.50(br,10H),1.49(t,J＝6.8Hz,3H)；MS.m/z350.1,[M+H] +。
2-(4-((5-chloro-8-isopropoxy quinoline-2-base) methyl) piperazine-1-base) ethanol (M4)
YD:61％. 1HNMR(400MHz,d4-MeOD)δ8.52(d,J＝8.8Hz,1H),7.81(d,J＝8.8Hz,1H),7.53(d,J＝8.4Hz,1H),7.14(d,J＝8.4Hz,1H),4.87(m,1H),3.89(s,2H),3.67(t,J＝6.0Hz,2H),2.54-2.62(br,10H),1.45(t,J＝6.0Hz,6H)；MS.m/z364.1,[M+H] +。
2-(4-((the chloro-8-of 5-(cyclo propyl methoxy) quinoline-2-base) methyl) piperazine-1-base) ethane (M5)
YD:76％. 1HNMR(400MHz,d4-MeOD)δ8.40(d,J＝8.4Hz,1H),7.71(d,J＝8.8Hz,1H),7.42(d,J＝8.4Hz,1H),6.99(d,J＝8.4Hz,1H),3.97(d,J＝6.8Hz,2H),3.84(s,2H),3.65(t,J＝6.0Hz,2H),3.44(t,J＝4.8Hz,2H),2.56(br,8H),2.51(t,J＝4.8Hz,2H),1.37-1.43(m,1H),0.62-0.66(m,2H),0.37-0.40(m,2H)；MS.m/z376.2,[M+H] +。
2-(4-((the chloro-8-methoxy quinoline of 5,7-bis--2-base) methyl) piperazine-1-base) ethanol (M6)
YD:39％. 1HNMR(400MHz,d4-MeOD)δ8.53(d,J＝8.8Hz,1H),7.80(d,J＝8.8Hz,1H),7.70(s,1H),4.11(s,3H),3.89(s,2H),3.67(t,J＝6.0Hz,2H),2.63(br,8H),2.55(t,J＝6.0Hz,2H),1.93(s,1H)；MS.m/z370.1,[M+H] +。
2-(4-((the chloro-8-of 5,7-bis-(cyclo propyl methoxy) quinoline-2-base) methyl) piperazine-1-base) ethanol (M7)
YD:82％. 1HNMR(400MHz,CDCl 3)δ8.43(d,J＝8.8Hz,1H),7.71(d,J＝8.8Hz,1H),7.58(s,1H),4.22(d,J＝7.2Hz,2H),3.88(s,2H)3.61(t,J＝6.4Hz,2H),2.56(t,J＝5.2Hz,10H),1.41-1.44(m,1H),0.57-0.62(m,2H),0.33-0.37(m,2H)；MS.m/z410.1,[M+Na] +。
2-((methyl (Propargyl) amido) methyl) quinoline-8-alcohol (N1)
YD:49％. 1HNMR(400MHz,CDCl 3)δ8.08(d,J＝8.4Hz,1H),7.55(d,J＝8.4Hz,1H),7.40(t,J＝8.0Hz,1H),7.28(d,J＝8.0Hz,1H),7.15(d,J＝7.6Hz,1H),3.90(s,2H),3.41(d,J＝2.0Hz,2H),2.39(s,3H),2.31(d,J＝2.0Hz,1H)；MS.m/z249.1,[M+H] +。
The chloro-2-of 5-((methyl (Propargyl) amido) methyl) quinoline-8-alcohol (N2)
YD:38％. 1HNMR(400MHz,CDCl 3)δ8.47(d,J＝8.4Hz,1H),7.71(d,J＝8.8Hz,1H),7.47(d,J＝8.0Hz,1H),7.08(d,J＝8.4Hz,1H),3.93(s,2H),3.42(d,J＝2.0Hz,2H),2.40(s,3H),2.31(t,J＝2.0Hz,1H)；MS.m/z261.0,[M+H] +。
N-((the chloro-8-methoxy quinoline of 5--2-base) methyl)-N-methyl-prop-2-alkynes-1-amine (N3)
YD:52％. 1HNMR(400MHz,CDCl 3)δ8.48(d,J＝8.8Hz,1H),7.80(d,J＝8.8Hz,1H),7.46(d,J＝8.4Hz,1H),6.93(d,J＝8.4Hz,1H),4.05(s,3H),4.00(s,2H),3.42(d,J＝2.0Hz,2H),2.37(s,3H),2.27(t,J＝2.0Hz,1H),MS.m/z297.0,[M+Na] +。
N-((the chloro-8-ethoxyquinoline of 5--2-base) methyl)-N-methyl-prop-2-alkynes-1-amine (N4)
YD:64％. 1HNMR(400MHz,CDCl 3)δ8.48(d,J＝8.8Hz,1H),7.79(d,J＝8.8Hz,1H),7.46(d,J＝8.8Hz,1H),6.96(d,J＝8.4Hz,1H),4.32(t,J＝6.8Hz,2H),4.01(s,2H),3.45(d,J＝2.0Hz,2H),2.41(s,3H),2.28(t,J＝2.0Hz,1H),1.59(t,J＝6.8Hz,3H)；MS.m/z289.1,[M+H] +。
N-((5-chloro-8-isopropoxy quinoline-2-base) methyl)-N-methyl-prop-2-alkynes-1-amine (N5)
YD:76％. 1HNMR(400MHz,CDCl 3)δ8.47(d,J＝8.8Hz,1H),7.73(d,J＝8.8Hz,1H),7.46(d,J＝8.0Hz,1H),7.03(d,J＝8.4Hz,1H),4.80(m,1H),3.99(s,2H),3.44(d,J＝2.4Hz,2H),2.41(s,3H),2.28(t,J＝2.4Hz,1H),1.48(d,J＝6.4Hz,6H)；MS.m/z303.1,[M+H] +。
N-((the chloro-8-of 5-(cyclo propyl methoxy) quinoline-2-base) methyl)-N-methyl-prop-2-alkynes-1-amine (N6)
YD:58％. 1HNMR(400MHz,CDCl 3)δ8.48(d,J＝8.4Hz,1H),7.77(d,J＝8.8Hz,1H),7.45(d,J＝8.4Hz,1H),6.98(d,J＝8.4Hz,1H),4.09(d,J＝7.2Hz,2H),4.01(s,2H),3.45(d,J＝2.0Hz,2H),2.41(s,3H),2.28(t,J＝2.0Hz,1H),1.42～1.50(m,1H),0.65-0.70(m,2H),0.42-0.45(m,2H)；MS.m/z337.1,[M+Na] +。
N-((the chloro-8-methoxy quinoline of 5,7-bis--2-base) methyl)-N-methyl-prop-2-alkynes-1-amine (N7)
YD:58％. 1HNMR(400MHz,CDCl 3)δ8.47(d,J＝8.8Hz,1H),7.74(d,J＝8.8Hz,1H),7.60(s,1H),4.20(s,3H),3.99(s,2H),3.43(d,J＝2.0Hz,2H),2.41(s,3H),2.29(t,J＝2.0Hz,1H)；MS.m/z309.0,[M+H] +。
N-((the chloro-8-of 5,7-bis-(cyclo propyl methoxy) quinoline-2-base) methyl)-N-methyl-prop-2-alkynes-1-amine (N8)
YD:76％. 1HNMR(400MHz,CDCl 3)δ8.45(d,J＝8.8Hz,1H),7.71(d,J＝8.8Hz,1H),7.59(s,1H),4.25(d,J＝7.6Hz,2H),3.95(s,2H),3.40(d,J＝2.0Hz,2H),2.40(s,3H),2.28(t,J＝2.0Hz,1H),1.41-1.45(m,1H),0.57-0.62(m,2H),0.36(dd,J＝10.0,4.8Hz,2H)；MS.m/z371.0,[M+Na] +。
8-((5-chloro-8-methoxy quinoline-2-base) methyl amido) pungent-1-alcohol (O1)
YD:44％. 1HNMR(400MHz,d4-MeOD)δ8.55(d,J＝8.8Hz,1H),7.69(d,J＝8.8Hz,1H),7.58(d,J＝8.4Hz,1H),7.16(d,J＝8.4Hz,1H),4.07(s,5H),3.50(t,J＝6.8Hz,2H),2.63(t,J＝7.2Hz,2H),1.56(quin,J＝7.2Hz,2H),1.50(quin,J＝6.8Hz,2H),1.29-1.32(br,10H)；MS.m/z351.2,[M+H] +。
8-((5-chloro-8-ethoxyquinoline-2-base) methyl amido) pungent-1-alcohol (O2)
YD:41％. 1HNMR(400MHz,d4-MeOD)δ8.51(d,J＝8.8Hz,1H),7.66(d,J＝8.4Hz,1H),7.53(d,J＝8.4Hz,1H),7.12(d,J＝8.4Hz,1H),4.29(q,J＝6.8Hz,2H),4.07(s,2H),3.51(t,J＝6.8Hz,2H),2.64(t,J＝7.2Hz,2H),1.47-1.58(m,7H),1.31(br,9H)；MS.m/z365.2,[M+H] +。
8-((5-chloro-8-isopropoxy quinoline-2-base) methyl amido) pungent-1-alcohol (O3)
YD:31％. 1HNMR(400MHz,d4-MeOD)δ8.55(d,J＝8.8Hz,1H),7.66(d,J＝8.8Hz,1H),7.56(d,J＝8.4Hz,1H),7.19(d,J＝8.4Hz,1H),4.89(m,1H),4.15(s,2H),3.52(t,J＝6.4Hz,2H),2.71(t,J＝7.2Hz,2H),1.59(quin,J＝6.8Hz,2H)1.46-1.50(m,8H),1.33(br,9H)；MS.m/z379.2,[M+H] +。
8-((the chloro-8-of 5-(cyclo propyl methoxy) quinoline-2-base) methyl amido) pungent-1-alcohol (O4)
YD:29％. 1HNMR(400MHz,d4-MeOD)δ8.54(d,J＝8.4Hz,1H),7.67(d,J＝8.8Hz,1H),7.54(d,J＝8.4Hz,1H),7.15(d,J＝8.4Hz,1H),4.09(s+d,J＝6.8Hz,4H),3.51(t,J＝6.8Hz,2H),2.67(t,J＝7.2Hz,2H),1.59(quin,J＝7.2Hz,2H),1.43-1.51(m,3H),1.29-1.42(br,10H),0.66-0.89(m,2H),0.44(dd,J＝10.4,4.8Hz,2H)；MS.m/z391.2,[M+H] +。
8-((5,7-bis-chloro-8-methoxy quinoline-2-base) methyl amido) pungent-1-alcohol (O5)
YD:37％. 1HNMR(400MHz,d4-MeOD)δ8.54(d,J＝8.8Hz,1H),7.71(s,1H),7.65(d,J＝8.8Hz,1H),4.14(s,3H),4.12(s,2H),3.52(t,J＝6.8Hz,2H),2.70(t,J＝7.2Hz,2H),1.60(quin,J＝6.8Hz,2H),1.50(m,2H),1.33(br,9H)；MS.m/z385.1,[M+H] +。
8-((the chloro-8-of 5,7-bis-(cyclo propyl methoxy) quinoline-2-base) methyl amido) pungent-1-alcohol (O6)
YD:56％. 1HNMR(400MHz,d4-MeOD)δ8.51(d,J＝8.4Hz,1H),7.69(s,1H),7.61(d,J＝8.8Hz,1H),4.22(d,J＝7.2Hz,2H),4.10(s,2H),3.52(t,J＝6.8Hz,2H),2.68(t,J＝7.2Hz,2H),1.59(quin,J＝7.2Hz,2H),1.51(quin,J＝6.8Hz,2H),1.28-1.42(br,11H),0.55-0.60(m,2H),0.30-0.33(m,2H)；MS.m/z425.2,[M+H] +。
Own-1-the alcohol (P1) of 6-(two ((8-methoxy quinoline-2-base) methyl) amido)
1HNMR(400MHz,d4-MeOD)δ8.18(d,J＝8.4Hz,2H),7.80(d,J＝8.4Hz,2H),7.44(t,J＝8.0Hz,2H),7.38(d,J＝8.0Hz,2H),7.13(d,J＝7.2Hz,2H),4.02(s,6H),3.99(s,4H),3.40(t,J＝6.8Hz,2H),2.59(t,J＝6.8Hz,2H),1.56(quin,J＝6.8Hz,2H),1.41(quin,J＝6.8Hz,2H),1.27(quin,J＝7.6Hz,2H),1.18(quin,J＝6.8Hz,2H)；MS.m/z482.3,[M+Na] +。
After Figure 1A display utilizes congo red staining, C12 suppresses the microscopic analysis of A β aggegation under zine ion presence or absence condition.Figure 1B and Fig. 2 shows C12 and dissolves the A β aggegation carried out.The fA β that Fig. 3 A-B shows Compound C 12, CQ and C12 intermediate neuroprotective unit cell brings out from zinc.Only has Compound C 12 to the aggegation effective (Fig. 3 B) not containing zinc.The axon growth that the Compound C 12 that shows Fig. 4 causes on non-Differentiated PC12 cell brings out phenomenon.Fig. 5 shows the performance that quinoline increases GAP43.Fig. 6 shows Compound C 12 can improve learning performance with the dysmnesia mouse that B3 brings out for fA β.C12 and B3 (10mg/kg) increases the run duration of fA β diseased mice in roller-test.Fig. 7 A-D shows the study of Compound C 12 fA β diseased mice of Improving memory obstacle in Morris water maze test.For mouse, assess (Fig. 7 A) and total miles of relative movement (Fig. 7 B) during it climbs up total movement of hiding platform; And quantize its per-cent appearing at target area (Fig. 7 C), represent its relative time entering the region around hiding platform (total time compared to swimming); And assess average swim speed (Fig. 7 D) to differentiate to improve by motion unit is active the memory improvement caused.The Compound C 12 that is shown in Fig. 8 in dysmnesia fA β diseased mice, cause GAP43 to increase and fA β reduces.
The aforementioned description about exemplifying embodiments is only to illustrate and describing object, and not for be used for complete enumerate or the present invention be limited to know announcement aspect.With reference to after foregoing teachings, various change and modification can be had.
The selection of previous embodiment and example and description are to explain principle of the present invention and practical application thereof, to make those of ordinary skill in the art can utilize the present invention and various embodiment, and are carried out various modification to meet specific purposes.Under the prerequisite not departing from spirit of the present invention and scope, the technical field of the invention those of ordinary skill can be thought and other embodiments easily.Therefore, scope of the present invention should be determined by following claims, but not determined by exemplary embodiments as herein described and aforementioned explanation.
The reference that can comprise patent, patent application case and other open source literatures is quoted and is discussed in explanation of the present invention.These of reference are quoted and are discussed and are only used to illustrate description of the invention, and do not represent applicant and admit that these reference are prior art of the present invention.The all reference quoted and discuss in this specification sheets are all incorporated to herein as a reference with regard to its all the elements, and the scope being incorporated to reference is equal to these reference is distinctly incorporated to herein as a reference.
Claims (amendment according to treaty the 19th article)
1. formula (I) compound or its medical acceptable salt, solvate or hydrate, prodrug or metabolite:
(I) wherein:
R 1for hydrogen, (C 1-C 8) alkyl, (C 1-C 8) stretch alkyl (C 3-C 8) cycloalkyl, (C 1-C 8) alkylhalide group or (C 1-C 8) stretch alkyl (C 6-C 20) aryl;
R 2for hydrogen or halogen;
R 3for hydrogen, halogen, (C 1-C 8) alkyl or (C 1-C 8) alkoxyl group;
R 4for hydrogen, halogen, (C 1-C 8) alkyl, (C 1-C 8) alkoxyl group or (C 1-C 8) alkylhalide group;
R 5for hydrogen or (C 1-C 20) alkanol;
R 6for hydrogen; And
R 7for (C 1-C 20) alkanol, (C 1-C 8) stretch alkyl (C 3-C 8) heterocyclic radical (C 1-C 20) alkanol, (C 1-C 8) stretch alkyl (C 3-C 8) heterocyclic radical (C 1-C 20) alkyl, (C 1-C 8) stretch alkyl (C 1-C 6) alkyl amine group (C 1-C 6) alkynyl, (C 1-C 8) stretch alkyl amine group (C 1-C 20) alkanol or (C 1-C 8) stretch alkyl amine group (C 1-C 20) alkanol (C 1-C 8) stretch alkyl replace (C 3-C 20) heteroaryl;
(II) or wherein:
R 1, R 2, R 3, R 4and R 6separately as middlely in above-mentioned (I) to define;
R 5for (C 1-C 20) alkanol; And
R 7for hydrogen, (C 1-C 20) alkanol, (C 1-C 8) stretch alkyl (C 3-C 8) heterocyclic radical (C 1-C 20) alkanol, (C 1-C 8) stretch alkyl (C 3-C 8) heterocyclic radical (C 1-C 20) alkyl, (C 1-C 8) stretch alkyl (C 1-C 6) alkyl amine group (C 1-C 6) alkynyl, (C 1-C 8) stretch alkyl amine group (C 1-C 20) alkanol or (C 1-C 8) stretch alkyl amine group (C 1-C 20) alkanol (C 1-C 8) stretch alkyl replace (C 3-C 20) heteroaryl.
2. compound as claimed in claim 1,
(A) wherein:
R 1for hydrogen, CH 3, CH 2cH 3, CH (CH 3) 2, CH 2cH (CH 3) 2, CF 3or phenmethyl;
R 2for hydrogen, F or Cl;
R 3for hydrogen, F, Cl, CH 3or OCH 3;
R 4for hydrogen, F, Cl, Br, CH 3, OCH 3or CF 3;
R 5for hydrogen, (CH 2) 11oH or (CH 2) 12oH;
R 6for hydrogen; And
R 7for (CH 2) 9oH, (CH 2) 10oH, (CH 2) 11oH, (CH 2) 12oH, (CH 2) 13oH, (CH 2) 14oH, (CH 2) 15oH, CH 2(N (CH 2cH 2) 2n) CH 2cH 2oH, CH 2(N (CH 2cH 2) 2n) CH 2cH 3, CH 2n (CH 3) CH 2c ≡ CH, CH 2nH (CH 2) 8oH or CH 2n ((CH 2) 6oH) CH 2(8-methoxy quinoline-2-base);
(B) or wherein:
R 1, R 2, R 3, R 4and R 6separately as middlely in above-mentioned (A) to define;
R 5for (CH 2) 11oH or (CH 2) 12oH; And
R 7for hydrogen, (CH 2) 9oH, (CH 2) 10oH, (CH 2) 11oH, (CH 2) 12oH, (CH 2) 13oH, (CH 2) 14oH, (CH 2) 15oH, CH 2(N (CH 2cH 2) 2n) CH 2cH 2oH, CH 2(N (CH 2cH 2) 2n) CH 2cH 3, CH 2n (CH 3) CH 2c ≡ CH, CH 2nH (CH 2) 8oH or CH 2n ((CH 2) 6oH) CH 2(8-methoxy quinoline-2-base).
3. compound as claimed in claim 2, wherein
R 1for hydrogen, CH 3, CH 2cH 3, CH (CH 3) 2, CH 2cH (CH 3) 2, CH 2cH (CH 2) 2, CF 3or phenmethyl;
R 2, R 3, R 4, R 5and R 6respective is independently hydrogen; And
R 7for (CH 2) 9oH, (CH 2) 10oH, (CH 2) 11oH, (CH 2) 12oH, (CH 2) 13oH, (CH 2) 14oH, (CH 2) 15oH, CH 2(N (CH 2cH 2) 2n) CH 2cH 2oH or CH 2n (CH 3) CH 2c ≡ CH.
4. compound as claimed in claim 2, wherein
R 1for hydrogen, CH 3, CH 2cH 3, CH 2cH (CH 3) 2, CH 2cH (CH 2) 2or CH (CH 3) 2;
R 2, R 3, R 5and R 6respective is independently hydrogen;
R 4for CH 3, F, Cl, Br, CF 3or OCH 3; And
R 7for (CH 2) 9oH, (CH 2) 10oH, (CH 2) 11oH, (CH 2) 12oH, (CH 2) 13oH, (CH 2) 15oH, (CH 2) 10oCOCH 3, (CH 2) 11oCOCH 3, (CH 2) 12oCOCH 3, (CH 2) 13oCOCH 3, CH 2nH (CH 2) 8oH, CH 2(N (CH 2cH 2) 2n) CH 2cH 2oH, CH 2(N (CH 2cH 2) 2n) CH 2cH 3or CH 2n (CH 3) CH 2c ≡ CH.
5. compound as claimed in claim 2, wherein
R 1for hydrogen, CH 3, CH 2cH 3, CH (CH 2) 2or CH 2cH (CH 2) 2;
R 2, R 4respective is independently Cl;
R 3, R 5and R 6respective is independently hydrogen; And
R 7for (CH 2) 11oH, CH 2nH (CH 2) 8oH or CH 2n (CH 3) CH 2c ≡ CH.
6. compound as claimed in claim 2, wherein
R 1for hydrogen, CH 3, CH 2cH 3, CH 2cH (CH 3) 2, CH 2cH (CH 2) 2, CH (CH 3) 2or phenmethyl;
R 2, R 3, R 4, R 6and R 7respective is independently hydrogen; And
R 5for (CH 2) 11oH or (CH 2) 12oH.
7. compound as claimed in claim 2, wherein
R 1for CH 3;
R 2, R 5and R 6respective is independently hydrogen;
R 3and R 4respective is independently OCH 3or Cl; And
R 7for (CH 2) 11oH.
8. compound as claimed in claim 2, it is selected from following formed group:
9-(8-(benzyloxy) quinoline-2-base)-1-alcohol in the ninth of the ten Heavenly Stems,
10-(8-(benzyloxy) quinoline-2-base)-1-alcohol in the last of the ten Heavenly stems,
11-(8-(benzyloxy) quinoline-2-base) 11-1-alcohol,
12-(8-(benzyloxy) quinoline-2-base) 12-1-alcohol,
13-(8-(benzyloxy) quinoline-2-base) 13-1-alcohol,
14-((8-(benzyloxy) quinoline-2-base) 14-1-alcohol,
15-(8-(benzyloxy) quinoline-2-base) 15-1-alcohol,
11-(8-(benzyloxy)-5-toluquinoline-2-base) 11-1-alcohol,
11-(8-(benzyloxy)-6-toluquinoline-2-base) 11-1-alcohol,
11-(8-(benzyloxy)-5-fluorine quinoline-2-base) 11-1-alcohol,
11-(8-(benzyloxy)-5-chloroquinoline-2-base) 11-1-alcohol,
2-(9-hydroxyl nonyl) quinoline-8-alcohol,
2-(10-hydroxy decyl) quinoline-8-alcohol,
2-(11-hydroxyl undecyl) quinoline-8-alcohol,
2-(12-hydroxyl dodecyl) quinoline-8-alcohol,
2-(13-hydroxyl tridecyl) quinoline-8-alcohol,
2-(14-hydroxyl tetradecyl) quinoline-8-alcohol,
2-(15-hydroxyl pentadecyl) quinoline-8-alcohol,
2-(11-hydroxyl undecyl)-5-toluquinoline-8-alcohol,
2-(11-hydroxyl undecyl)-6-toluquinoline-8-alcohol,
The chloro-2-of 5-(11-hydroxyl undecyl) quinoline-8-alcohol,
9-(8-methoxy quinoline-2-base)-1-alcohol in the ninth of the ten Heavenly Stems,
10-(8-methoxy quinoline-2-base)-1-alcohol in the last of the ten Heavenly stems,
11-(8-methoxy quinoline-2-base) 11-1-alcohol,
12-(8-methoxy quinoline-2-base) 12-1-alcohol,
13-(8-methoxy quinoline-2-base) 13-1-alcohol,
14-((8-methoxy quinoline-2-base) 14-1-alcohol,
15-(8-methoxy quinoline-2-base) 15-1-alcohol,
11-(8-methoxyl group-5-toluquinoline-2-base) 11-1-alcohol,
11-(the fluoro-8-methoxy quinoline of 5--2-base) 11-1-alcohol,
12-(the fluoro-8-methoxy quinoline of 5--2-base) 12-1-alcohol,
9-(the chloro-8-methoxy quinoline of 5--2-base)-1-alcohol in the ninth of the ten Heavenly Stems,
11-(the chloro-8-methoxy quinoline of 5--2-base) 11-1-alcohol,
15-(the chloro-8-methoxy quinoline of 5--2-base) 15-1-alcohol,
11-(the bromo-8-methoxy quinoline of 5--2-base) 11-1-alcohol,
11-(8-methoxyl group-5-(trifluoromethyl) quinoline-2-base) 11-1-alcohol,
11-(5,8-dimethoxy-quinoline-2-base) 11-1-alcohol,
11-(8-methoxyl group-6-toluquinoline-2-base) 11-1-alcohol,
11-(the fluoro-8-methoxy quinoline of 6--2-base) 11-1-alcohol,
11-(the chloro-8-methoxy quinoline of 6--2-base) 11-1-alcohol,
11-(the fluoro-8-methoxy quinoline of 7--2-base) 11-1-alcohol,
11-(the chloro-8-methoxy quinoline of 7--2-base) 11-1-alcohol,
11-(chloro-6, the 8-dimethoxy-quinoline-2-bases of 5-) 11-1-alcohol,
11-(chloro-5, the 8-dimethoxy-quinoline-2-bases of 6-) 11-1-alcohol,
11-(the chloro-8-methoxy quinoline of 5,7-bis--2-base) 11-1-alcohol,
9-(8-ethoxyquinoline-2-base)-1-alcohol in the ninth of the ten Heavenly Stems,
10-(8-ethoxyquinoline-2-base)-1-alcohol in the last of the ten Heavenly stems,
11-(8-ethoxyquinoline-2-base) 11-1-alcohol,
12-(8-ethoxyquinoline-2-base) 12-1-alcohol,
13-(8-ethoxyquinoline-2-base) 13-1-alcohol,
14-((8-ethoxyquinoline-2-base) 14-1-alcohol,
15-(8-ethoxyquinoline-2-base) 15-1-alcohol,
11-(8-oxyethyl group-5-toluquinoline-2-base) 11-1-alcohol,
11-(8-oxyethyl group-5-fluorine quinoline-2-base) 11-1-alcohol,
9-(the chloro-8-ethoxyquinoline of 5--2-base)-1-alcohol in the ninth of the ten Heavenly Stems,
11-(the chloro-8-ethoxyquinoline of 5--2-base) 11-1-alcohol,
15-(the chloro-8-ethoxyquinoline of 5--2-base) 15-1-alcohol,
11-(the bromo-8-ethoxyquinoline of 5--2-base) 11-1-alcohol,
11-(the chloro-8-ethoxyquinoline of 5,7-bis--2-base) 11-1-alcohol,
9-(8-isopropoxy quinoline-2-base)-1-alcohol in the ninth of the ten Heavenly Stems,
10-(8-isopropoxy quinoline-2-base)-1-alcohol in the last of the ten Heavenly stems,
11-(8-isopropoxy quinoline-2-base) 11-1-alcohol,
12-(8-isopropoxy quinoline-2-base) 12-1-alcohol,
13-(8-isopropoxy quinoline-2-base) 13-1-alcohol,
14-((8-isopropoxy quinoline-2-base) 14-1-alcohol,
15-(8-isopropoxy quinoline-2-base) 15-1-alcohol,
11-(8-isopropoxy-5-toluquinoline-2-base) 11-1-alcohol,
11-(5-fluoro-8-isopropoxy quinoline-2-base) 11-1-alcohol,
9-(5-chloro-8-isopropoxy quinoline-2-base)-1-alcohol in the ninth of the ten Heavenly Stems,
11-(5-chloro-8-isopropoxy quinoline-2-base) 11-1-alcohol,
15-(5-chloro-8-isopropoxy quinoline-2-base) 15-1-alcohol,
11-(5-bromo-8-isopropoxy quinoline-2-base) 11-1-alcohol,
15-(5-chloro-8-isopropoxy quinoline-2-base) 15-1-alcohol,
11-(5-bromo-8-isopropoxy quinoline-2-base) 11-1-alcohol,
11-(5,7-bis-chloro-8-isopropoxy quinoline-2-base) 11-1-alcohol,
9-(8-(cyclo propyl methoxy) quinoline-2-base)-1-alcohol in the ninth of the ten Heavenly Stems,
10-(8-(cyclo propyl methoxy) quinoline-2-base)-1-alcohol in the last of the ten Heavenly stems,
11-(8-(cyclo propyl methoxy) quinoline-2-base) 11-1-alcohol,
12-(8-(cyclo propyl methoxy) quinoline-2-base) 12-1-alcohol,
13-(8-(cyclo propyl methoxy) quinoline-2-base) 13-1-alcohol,
14-((8-(cyclo propyl methoxy) quinoline-2-base) 14-1-alcohol,
15-(8-(cyclo propyl methoxy) quinoline-2-base) 15-1-alcohol,
11-(8-(cyclo propyl methoxy)-5-toluquinoline-2-base) 11-1-alcohol,
11-(8-(cyclo propyl methoxy)-5-fluorine quinoline-2-base) 11-1-alcohol,
9-(the chloro-8-of 5-(cyclo propyl methoxy) quinoline-2-base)-1-alcohol in the ninth of the ten Heavenly Stems,
11-(the chloro-8-of 5-(cyclo propyl methoxy) quinoline-2-base) 11-1-alcohol,
15-(the chloro-8-of 5-(cyclo propyl methoxy) quinoline-2-base) 15-1-alcohol,
11-(the bromo-8-of 5-(cyclo propyl methoxy) quinoline-2-base) 11-1-alcohol,
11-(the chloro-8-of 5,7-bis-(cyclo propyl methoxy) quinoline-2-base) 11-1-alcohol,
The chloro-2-of 5,7-bis-(11-hydroxyl undecyl) quinoline-8-alcohol,
10-(the chloro-8-methoxy quinoline of 5--2-base)-1-alcohol in the last of the ten Heavenly stems,
Acetic acid 10-(the chloro-8-methoxy quinoline of 5--2-base) ester in the last of the ten Heavenly stems,
11-(the chloro-8-methoxy quinoline of 5--2-base) 11-1-alcohol,
Acetic acid 11-(the chloro-8-methoxy quinoline of 5--2-base) 11 esters,
12-(the chloro-8-methoxy quinoline of 5--2-base) 12-1-alcohol,
Acetic acid 12-(the chloro-8-methoxy quinoline of 5--2-base) ten diester,
13-(the chloro-8-methoxy quinoline of 5--2-base) 13-1-alcohol,
Acetic acid 13-(the chloro-8-methoxy quinoline of 5--2-base) 13 esters,
11-(8-methoxy quinoline-4-(-Ji) 11-1-alcohol,
11-(8-ethoxyquinoline-4-(-Ji) 11-1-alcohol,
11-(8-isopropoxy quinoline-4-(-Ji) 11-1-alcohol,
11-(8-(cyclo propyl methoxy) quinoline-4-(-Ji) 11-1-alcohol,
11-(8-(benzyloxy) quinoline-4-(-Ji) 11-1-alcohol,
12-(8-(benzyloxy) quinoline-4-(-Ji) 12-1-alcohol,
4-((11-hydroxyl undecyl) quinoline-8-alcohol,
4-((12-hydroxyl dodecyl) quinoline-8-alcohol,
9-(8-(trifluoromethoxy) quinoline-2-base)-1-alcohol in the ninth of the ten Heavenly Stems,
11-(8-(trifluoromethoxy) quinoline-2-base) 11-1-alcohol,
14-((8-(trifluoromethoxy) quinoline-2-base) 14-1-alcohol,
15-(8-(trifluoromethoxy) quinoline-2-base) 15-1-alcohol,
2-((4-((2-hydroxyethyl) piperazine-1-base) methyl) quinoline-8-alcohol,
2-(4-(((the chloro-8-methoxy quinoline of 5--2-base) methyl) piperazine-1-base) ethanol,
2-(4-(((the chloro-8-ethoxyquinoline of 5--2-base) methyl) piperazine-1-base) ethanol,
2-(4-(((5-chloro-8-isopropoxy quinoline-2-base) methyl) piperazine-1-base) ethanol,
2-(4-(((the chloro-8-of 5-(cyclo propyl methoxy) quinoline-2-base) methyl) piperazine-1-base) ethane,
2-(4-(((the chloro-8-methoxy quinoline of 5,7-bis--2-base) methyl) piperazine-1-base) ethanol,
2-(4-(((the chloro-8-of 5,7-bis-(cyclo propyl methoxy) quinoline-2-base) methyl) piperazine-1-base) ethanol,
2-((methyl (Propargyl) amido) methyl) quinoline-8-alcohol,
The chloro-2-of 5-((methyl (Propargyl) amido) methyl) quinoline-8-alcohol,
N ((the chloro-8-methoxy quinoline of 5--2-base) methyl)-N-methyl-prop-2-alkynes-1-amine,
N ((the chloro-8-ethoxyquinoline of 5--2-base) methyl)-N-methyl-prop-2-alkynes-1-amine,
N ((5-chloro-8-isopropoxy quinoline-2-base) methyl)-N-methyl-prop-2-alkynes-1-amine,
N ((the chloro-8-of 5-(cyclo propyl methoxy) quinoline-2-base) methyl)-N-methyl-prop-2-alkynes-1-amine,
N ((the chloro-8-methoxy quinoline of 5,7-bis--2-base) methyl)-N-methyl-prop-2-alkynes-1-amine,
N ((the chloro-8-of 5,7-bis-(cyclo propyl methoxy) quinoline-2-base) methyl)-N-methyl-prop-2-alkynes-1-amine,
8-((5-chloro-8-methoxy quinoline-2-base) methyl amido) pungent-1-alcohol,
8-((5-chloro-8-ethoxyquinoline-2-base) methyl amido) pungent-1-alcohol,
8-((5-chloro-8-isopropoxy quinoline-2-base) methyl amido) pungent-1-alcohol,
8-((the chloro-8-of 5-(cyclo propyl methoxy) quinoline-2-base) methyl amido) pungent-1-alcohol,
8-((5,7-bis-chloro-8-methoxy quinoline-2-base) methyl amido) pungent-1-alcohol,
8-((the chloro-8-of 5,7-bis-(cyclo propyl methoxy) quinoline-2-base) methyl amido) pungent-1-alcohol and
Own-1-the alcohol of 6-(two ((8-methoxy quinoline-2-base) methyl) amido).
9. prepare a method for compound described in claim 1, comprising:
(1) by formula (II) compound
Wherein:
R 2, R 3, R 4, R 5and R 6respective is independently hydrogen; Or
R 2, R 4, R 5and R 6independently be hydrogen and R separately 3for CH 3; Or
R 2, R 3, R 5and R 6independently be hydrogen and R separately 4for CH 3, F, Cl or Br; Or
R 2, R 5, R 6respective is independently hydrogen, R 3for OCH 3and R 4for Cl; Or
R 2, R 4for Cl and R 3, R 5, R 6respective is independently hydrogen,
React, to obtain formula (III) compound at about room temperature is to about 80 DEG C in a basic solution with toluene bromide, methyl iodide, iodoethane, 2-N-PROPYLE BROMIDE or methylene radical Cyclopropyl Bromide
Wherein:
R 1for CH 3, CH 2cH 3, CH (CH 3) 2, CH 2cH (CH 3) 2or phenmethyl; And
R 2, R 3, R 4, R 5and R 6respective is independently hydrogen; Or
R 2, R 4, R 5and R 6independently be hydrogen and R separately 3for CH 3; Or
R 2, R 3, R 5and R 6independently be hydrogen and R separately 4for CH 3, F, Cl or Br; Or
R 2, R 5, R 6respective is independently hydrogen, R 3for OCH 3and R 4for Cl; Or
R 2, R 4for Cl and R 3, R 5, R 6respective is independently hydrogen;
(2) by formula (III) compound and two (trimethyl silicon based) amido lithium and monobromo (C 1-C 20) alkanol reacts, to obtain formula (I) compound in tetrahydrofuran (THF) at 0 DEG C
Wherein:
R 1for CH 3, CH 2cH 3, CH (CH 3) 2, CH 2cH (CH 3) 2or phenmethyl;
R 2, R 3, R 4, R 5and R 6respective is independently hydrogen; Or
R 2, R 4, R 5and R 6independently be hydrogen and R separately 3for CH 3; Or
R 2, R 3, R 5and R 6independently be hydrogen and R separately 4for CH 3, F, Cl or Br; Or
R 2, R 5, R 6respective is independently hydrogen, R 3for OCH 3and R 4for Cl; Or R 3for Cl and R 4for OCH 3or
R 2, R 4for Cl and R 3, R 5, R 6respective is independently hydrogen; And
R 7for (CH 2) 9oH, (CH 2) 10oH, (CH 2) 11oH, (CH 2) 12oH, (CH 2) 13oH or (CH 2) 15oH,
(3) wherein R is incited somebody to action 1for formula (I) compound of phenmethyl, at room temperature reacted in methyl alcohol by palladium carbon under pressure with hydrogen, or react at 0 DEG C in methylene dichloride with boron trichloride, to obtain formula (I) compound
R 1, R 2, R 3, R 4, R 5and R 6respective is independently hydrogen; Or
R 1, R 2, R 4, R 5and R 6independently be hydrogen and R separately 3for CH 3; Or
R 1, R 2, R 3, R 5and R 6independently be hydrogen and R separately 4for CH 3, F, Cl or Br; Or
R 1, R 2, R 5, R 6respective is independently hydrogen, R 3for OCH 3and R 4for Cl; R 3for Cl and R 4for OCH 3; Or
R 2, R 4for Cl and R 1, R 3, R 5, R 6respective is independently hydrogen; And
R 7for (CH 2) 9oH, (CH 2) 10oH, (CH 2) 11oH, (CH 2) 12oH, (CH 2) 13oH or (CH 2) 15oH; Or
(4) wherein R is incited somebody to action 1, R 2, R 3, R 4, R 5and R 6independently be hydrogen and R separately 7for (CH 2) 11formula (I) compound of OH, with N-chloro-succinimide in CHCl 3in at room temperature react, to provide formula (I) compound, wherein R 1, R 3, R 5and R 6respective is independently hydrogen, R 2and R 4independently be chlorine and R separately 7for (CH 2) 11oH; Or
(5) wherein R is incited somebody to action 1for methyl, R 2, R 3, R 4, R 5and R 6independently be hydrogen and R separately 7for (CH 2) 11oH, (CH 2) 12oH or (CH 2) 13formula (I) compound of OH, with concentrated hydrochloric acid, ICl 3and glacial acetic acid reacts, to provide formula (I) compound, wherein R 1for methyl, R 2, R 3, R 5and R 6respective is independently hydrogen, R 4for Cl and R 7for (CH 2) 10oH, (CH 2) 11oH, (CH 2) 12oH, (CH 2) 13oH, (CH 2) 15oH, (CH 2) 10oCOCH 3, (CH 2) 11oCOCH 3, (CH 2) 12oCOCH 3or (CH 2) 13oCOCH 3; Or
(6) 2-amino-phenol and methyl vinyl ketone are reacted in hydrochloric acid, to obtain formula (INT-1) compound
(7) formula (INT-1) compound and methyl iodide, iodoethane, 2-N-PROPYLE BROMIDE, methylene radical Cyclopropyl Bromide or toluene bromide are reacted in basic solution, to provide formula (III) compound,
Wherein R 10for methyl, ethyl, 2-propyl group, methylene radical cyclopropyl or phenmethyl;
(8) wherein R is incited somebody to action 10for formula (III) compound of methyl, ethyl, 2-propyl group, methylene radical cyclopropyl or phenmethyl, react at 0 DEG C in tetrahydrofuran (THF) with two (trimethyl silicon based) amido lithium and the bromo-undecyl alcohol of 11-or 12-bromine lauryl alcohol, to obtain formula (I) compound, wherein R 1for methyl, ethyl, 2-propyl group, methylene radical cyclopropyl or phenmethyl; R 2, R 3, R 4, R 6and R 7respective is independently hydrogen; And R 5for (CH 2) 11oH or (CH 2) 12oH;
(9) wherein R is incited somebody to action 1for phenmethyl; R 2, R 3, R 4, R 6and R 7respective is independently hydrogen; And R 5for (CH 2) 11oH or (CH 2) 12formula (I) compound of OH, is at room temperature reacted by palladium carbon under pressure with hydrogen in methyl alcohol, to obtain formula (I) compound, wherein R 1for hydrogen; R 2, R 3, R 4, R 6and R 7respective is independently hydrogen; And R 5for (CH 2) 11oH or (CH 2) 12oH; Or
(10) 2-trifluoro-methoxyaniline and crotonic aldehyde are reacted, to obtain 2-methyl-8-trifluoromethoxy quinoline, by it with two (trimethyl silicon based) amido lithium and monobromo (C 1-C 20) alkanol processes, to obtain formula (I) compound, wherein R in tetrahydrofuran (THF) at 0 DEG C 1for trifluoromethyl; R 2, R 3, R 4, R 5and R 6respective is independently hydrogen; And R 7for (CH 2) 10oH, (CH 2) 11oH, (CH 2) 12oH, (CH 2) 13oH or (CH 2) 15oH; Or
(11) by the 8-hydroxy-2-methylquinoline compound of the same form (IV), wherein R 1for hydrogen, methyl, ethyl, 2-propyl group or methylene radical cyclopropyl,
React at an elevated temperature in dioxan with tin anhydride, to provide the same form (VI) compound, R 1for hydrogen, methyl, ethyl, 2-propyl group or methylene radical cyclopropyl
(12) wherein R is incited somebody to action 1for formula (VI) compound of hydrogen, methyl, ethyl, 2-propyl group or methylene radical cyclopropyl, react with N-methyl-prop ynamine, to obtain formula (I) compound, wherein R 1for hydrogen, CH 3, CH 2cH 3, CH 2cH (CH 3) 2, CH 2cH (CH 2) 2or CH (CH 3) 2, R 2, R 3, R 4, R 5and R 6respective is independently hydrogen; And R 7for CH 2n (CH 3) CH 2c ≡ CH; Or
(13) by R 1for formula (VI) compound of hydrogen, methyl, ethyl, 2-propyl group or methylene radical cyclopropyl, react with 2 (piperazine-1-base) ethanol, to obtain the same form (I) compound, wherein R 1for hydrogen, CH 3, CH 2cH 3, CH 2cH (CH 3) 2, CH 2cH (CH 2) 2or CH (CH 3) 2, R 2, R 3, R 4, R 5and R 6respective is independently hydrogen; And R 7for CH 2(N (CH 2cH 2) 2n) CH 2cH 2oH; Or
(14) by formula (VI) compound and an amido (C 1-C 20) alkanol carries out reacting to obtain the same form (I) compound, wherein R 1for hydrogen, CH 3, CH 2cH 3, CH 2cH (CH 3) 2, CH 2cH (CH 2) 2or CH (CH 3) 2; R 2, R 3, R 4, R 5and R 6respective is independently hydrogen; And R 7for CH 2nH (CH 2) 8oH or CH 2n ((CH 2) 6oH) CH 2(8-methoxy quinoline-2-base).
10. a constituent, comprises the compound according to any one of claim 1 to 8 or its medical acceptable salt, solvate or hydrate, prodrug or the metabolite of a treatment significant quantity, and medical acceptable thinner or a supporting agent.
11. 1 kinds of constituents being used for the treatment of neurodegenerative disorders, comprise the compound according to any one of claim 1 to 8 or its medical acceptable salt, solvate or hydrate, prodrug or the metabolite of a treatment significant quantity, and medical acceptable thinner or a supporting agent.
12. constituents being used for the treatment of neurodegenerative disorders as claimed in claim 11, wherein this neurodegenerative disorders is selected from the group be made up of following disease: Alzheimer's disease, amyotrophic lateral sclerosis, cognitive dissonance, ischemia apoplexy, cerebral paralysis, apoplexy, hemorrhagic stroke, storehouse Jia Shi disease, spongiform encephalopathy becomes, mad cow syndrome, dementia, melancholia, Down syndrome, epilepsy, Frontotemporal Dementia, Tourette syndrome, Ha Sishi disease, Heng Dingdunshi disease, Lewy body disease, Parkinson's disease, cognitive disorder, learning disorder, macular diseases, dysmnesia, multiple sclerosis, multiple systems atrophy, motor neurone disease, kirschner disease, gradual core is benumbed, pseudodementia disease, retinopathy, senile dementia, the nerve degeneration that schizophrenia transient anoxia brings out, traumatic brain injury and Spinal injury.
13. constituents being used for the treatment of neurodegenerative disorders as claimed in claim 11, wherein this neurodegenerative disorders is Alzheimer's disease.
Compound according to any one of 14. 1 kinds of claims 1 to 8 is for the preparation of the purposes of a neurodegenerative disorders medicine for treatment thing.
15. purposes as claimed in claim 14, wherein this medicine is for being used for the treatment of Alzheimer's disease.
Illustrate or state (amendment according to treaty the 19th article)
The revised comment that Based PC T treaty is the 19th article
According to Patent Cooperation Treaty the 19th article, submit on text basis at international application, applicant have modified claim 1-2 more clearly to define claimed invention scope.In addition, applicant also have modified claim 9 to correct numbering and errors in text.
The amendment basis of claim 1-2 is found in former claim 1-2, and the amendment basis of claim 9 is found in specification sheets embodiment 5, which describe add N-chloro-succinimide with compd B at CHCl 3in react.Described amendment does not exceed the scope that former specification sheets and claims are recorded.
Existing appended claims replaces page and amendment contrast page, would like to ask Your Excellency auditor and examines according to amended claims.

Claims (15)

1. formula (I) compound or its medical acceptable salt, solvate or hydrate, prodrug or metabolite:
Wherein
R 1for hydrogen, (C 1-C 8) alkyl, (C 1-C 8) stretch alkyl (C 3-C 8) cycloalkyl, (C 1-C 8) alkylhalide group or (C 1-C 8) stretch alkyl (C 6-C 20) aryl;
R 2for hydrogen or halogen;
R 3for hydrogen, halogen, (C 1-C 8) alkyl or (C 1-C 8) alkoxyl group;
R 4for hydrogen, halogen, (C 1-C 8) alkyl, (C 1-C 8) alkoxyl group or (C 1-C 8) alkylhalide group;
R 5for hydrogen or (C 1-C 20) alkanol;
R 6for hydrogen; And
R 7for hydrogen, (C 1-C 20) alkanol, (C 1-C 8) stretch alkyl (C 3-C 8) heterocyclic radical (C 1-C 20) alkanol, (C 1-C 8) stretch alkyl (C 3-C 8) heterocyclic radical (C 1-C 20) alkyl, (C 1-C 8) stretch alkyl (C 1-C 6) alkyl amine group (C 1-C 6) alkynyl, (C 1-C 8) stretch alkyl amine group (C 1-C 20) alkanol or (C 1-C 8) stretch alkyl amine group (C 1-C 20) alkanol (C 1-C 8) stretch alkyl replace (C 3-C 20) heteroaryl.
2. compound as claimed in claim 1, wherein
R 1for hydrogen, CH 3, CH 2cH 3, CH (CH 3) 2, CH 2cH (CH 3) 2, CF 3or phenmethyl;
R 2for hydrogen, F or Cl;
R 3for hydrogen, F, Cl, CH 3or OCH 3;
R 4for hydrogen, F, Cl, Br, CH 3, OCH 3or CF 3;
R 5for hydrogen, (CH 2) 11oH or (CH 2) 12oH;
R 6for hydrogen; And
R 7for hydrogen, (CH 2) 9oH, (CH 2) 10oH, (CH 2) 11oH, (CH 2) 12oH, (CH 2) 13oH, (CH 2) 14oH, (CH 2) 15oH, CH 2(N (CH 2cH 2) 2n) CH 2cH 2oH, CH 2(N (CH 2cH 2) 2n) CH 2cH 3, CH 2n (CH 3) CH 2c ≡ CH, CH 2nH (CH 2) 8oH or CH 2n ((CH 2) 6oH) CH 2(8-methoxy quinoline-2-base).
3. compound as claimed in claim 2, wherein
R 1for hydrogen, CH 3, CH 2cH 3, CH (CH 3) 2, CH 2cH (CH 3) 2, CH 2cH (CH 2) 2, CF 3or phenmethyl;
R 2, R 3, R 4, R 5and R 6respective is independently hydrogen; And
R 7for (CH 2) 9oH, (CH 2) 10oH, (CH 2) 11oH, (CH 2) 12oH, (CH 2) 13oH, (CH 2) 14oH, (CH 2) 15oH, CH 2(N (CH 2cH 2) 2n) CH 2cH 2oH or CH 2n (CH 3) CH 2c ≡ CH.
4. compound as claimed in claim 2, wherein
R 1for hydrogen, CH 3, CH 2cH 3, CH 2cH (CH 3) 2, CH 2cH (CH 2) 2or CH (CH 3) 2;
R 2, R 3, R 5and R 6respective is independently hydrogen;
R 4for CH 3, F, Cl, Br, CF 3or OCH 3; And
R 7for (CH 2) 9oH, (CH 2) 10oH, (CH 2) 11oH, (CH 2) 12oH, (CH 2) 13oH, (CH 2) 15oH, (CH 2) 10oCOCH 3, (CH 2) 11oCOCH 3, (CH 2) 12oCOCH 3, (CH 2) 13oCOCH 3, CH 2nH (CH 2) 8oH, CH 2(N (CH 2cH 2) 2n) CH 2cH 2oH, CH 2(N (CH 2cH 2) 2n) CH 2cH 3or CH 2n (CH 3) CH 2c ≡ CH.
5. compound as claimed in claim 2, wherein
R 1for hydrogen, CH 3, CH 2cH 3, CH (CH 2) 2or CH 2cH (CH 2) 2;
R 2, R 4respective is independently Cl;
R 3, R 5and R 6respective is independently hydrogen; And
R 7for (CH 2) 11oH, CH 2nH (CH 2) 8oH or CH 2n (CH 3) CH 2c ≡ CH.
6. compound as claimed in claim 2, wherein
R 1for hydrogen, CH 3, CH 2cH 3, CH 2cH (CH 3) 2, CH 2cH (CH 2) 2, CH (CH 3) 2or phenmethyl;
R 2, R 3, R 4, R 6and R 7respective is independently hydrogen; And
R 5for (CH 2) 11oH or (CH 2) 12oH.
7. compound as claimed in claim 2, wherein
R 1for CH 3;
R 2, R 5and R 6respective is independently hydrogen;
R 3and R 4respective is independently OCH 3or Cl; And
R 7for (CH 2) 11oH.
8. compound as claimed in claim 2, it is selected from following formed group:
9-(8-(benzyloxy) quinoline-2-base)-1-alcohol in the ninth of the ten Heavenly Stems,
10-(8-(benzyloxy) quinoline-2-base)-1-alcohol in the last of the ten Heavenly stems,
11-(8-(benzyloxy) quinoline-2-base) 11-1-alcohol,
12-(8-(benzyloxy) quinoline-2-base) 12-1-alcohol,
13-(8-(benzyloxy) quinoline-2-base) 13-1-alcohol,
14-((8-(benzyloxy) quinoline-2-base) 14-1-alcohol,
15-(8-(benzyloxy) quinoline-2-base) 15-1-alcohol,
11-(8-(benzyloxy)-5-toluquinoline-2-base) 11-1-alcohol,
11-(8-(benzyloxy)-6-toluquinoline-2-base) 11-1-alcohol,
11-(8-(benzyloxy)-5-fluorine quinoline-2-base) 11-1-alcohol,
11-(8-(benzyloxy)-5-chloroquinoline-2-base) 11-1-alcohol,
2-(9-hydroxyl nonyl) quinoline-8-alcohol,
2-(10-hydroxy decyl) quinoline-8-alcohol,
2-(11-hydroxyl undecyl) quinoline-8-alcohol,
2-(12-hydroxyl dodecyl) quinoline-8-alcohol,
2-(13-hydroxyl tridecyl) quinoline-8-alcohol,
2-(14-hydroxyl tetradecyl) quinoline-8-alcohol,
2-(15-hydroxyl pentadecyl) quinoline-8-alcohol,
2-(11-hydroxyl undecyl)-5-toluquinoline-8-alcohol,
2-(11-hydroxyl undecyl)-6-toluquinoline-8-alcohol,
The chloro-2-of 5-(11-hydroxyl undecyl) quinoline-8-alcohol,
9-(8-methoxy quinoline-2-base)-1-alcohol in the ninth of the ten Heavenly Stems,
10-(8-methoxy quinoline-2-base)-1-alcohol in the last of the ten Heavenly stems,
11-(8-methoxy quinoline-2-base) 11-1-alcohol,
12-(8-methoxy quinoline-2-base) 12-1-alcohol,
13-(8-methoxy quinoline-2-base) 13-1-alcohol,
14-((8-methoxy quinoline-2-base) 14-1-alcohol,
15-(8-methoxy quinoline-2-base) 15-1-alcohol,
11-(8-methoxyl group-5-toluquinoline-2-base) 11-1-alcohol,
11-(the fluoro-8-methoxy quinoline of 5--2-base) 11-1-alcohol,
12-(the fluoro-8-methoxy quinoline of 5--2-base) 12-1-alcohol,
9-(the chloro-8-methoxy quinoline of 5--2-base)-1-alcohol in the ninth of the ten Heavenly Stems,
11-(the chloro-8-methoxy quinoline of 5--2-base) 11-1-alcohol,
15-(the chloro-8-methoxy quinoline of 5--2-base) 15-1-alcohol,
11-(the bromo-8-methoxy quinoline of 5--2-base) 11-1-alcohol,
11-(8-methoxyl group-5-(trifluoromethyl) quinoline-2-base) 11-1-alcohol,
11-(5,8-dimethoxy-quinoline-2-base) 11-1-alcohol,
11-(8-methoxyl group-6-toluquinoline-2-base) 11-1-alcohol,
11-(the fluoro-8-methoxy quinoline of 6--2-base) 11-1-alcohol,
11-(the chloro-8-methoxy quinoline of 6--2-base) 11-1-alcohol,
11-(the fluoro-8-methoxy quinoline of 7--2-base) 11-1-alcohol,
11-(the chloro-8-methoxy quinoline of 7--2-base) 11-1-alcohol,
11-(chloro-6, the 8-dimethoxy-quinoline-2-bases of 5-) 11-1-alcohol,
11-(chloro-5, the 8-dimethoxy-quinoline-2-bases of 6-) 11-1-alcohol,
11-(the chloro-8-methoxy quinoline of 5,7-bis--2-base) 11-1-alcohol,
9-(8-ethoxyquinoline-2-base)-1-alcohol in the ninth of the ten Heavenly Stems,
10-(8-ethoxyquinoline-2-base)-1-alcohol in the last of the ten Heavenly stems,
11-(8-ethoxyquinoline-2-base) 11-1-alcohol,
12-(8-ethoxyquinoline-2-base) 12-1-alcohol,
13-(8-ethoxyquinoline-2-base) 13-1-alcohol,
14-((8-ethoxyquinoline-2-base) 14-1-alcohol,
15-(8-ethoxyquinoline-2-base) 15-1-alcohol,
11-(8-oxyethyl group-5-toluquinoline-2-base) 11-1-alcohol,
11-(8-oxyethyl group-5-fluorine quinoline-2-base) 11-1-alcohol,
9-(the chloro-8-ethoxyquinoline of 5--2-base)-1-alcohol in the ninth of the ten Heavenly Stems,
11-(the chloro-8-ethoxyquinoline of 5--2-base) 11-1-alcohol,
15-(the chloro-8-ethoxyquinoline of 5--2-base) 15-1-alcohol,
11-(the bromo-8-ethoxyquinoline of 5--2-base) 11-1-alcohol,
11-(the chloro-8-ethoxyquinoline of 5,7-bis--2-base) 11-1-alcohol,
9-(8-isopropoxy quinoline-2-base)-1-alcohol in the ninth of the ten Heavenly Stems,
10-(8-isopropoxy quinoline-2-base)-1-alcohol in the last of the ten Heavenly stems,
11-(8-isopropoxy quinoline-2-base) 11-1-alcohol,
12-(8-isopropoxy quinoline-2-base) 12-1-alcohol,
13-(8-isopropoxy quinoline-2-base) 13-1-alcohol,
14-((8-isopropoxy quinoline-2-base) 14-1-alcohol,
15-(8-isopropoxy quinoline-2-base) 15-1-alcohol,
11-(8-isopropoxy-5-toluquinoline-2-base) 11-1-alcohol,
11-(5-fluoro-8-isopropoxy quinoline-2-base) 11-1-alcohol,
9-(5-chloro-8-isopropoxy quinoline-2-base)-1-alcohol in the ninth of the ten Heavenly Stems,
11-(5-chloro-8-isopropoxy quinoline-2-base) 11-1-alcohol,
15-(5-chloro-8-isopropoxy quinoline-2-base) 15-1-alcohol,
11-(5-bromo-8-isopropoxy quinoline-2-base) 11-1-alcohol,
15-(5-chloro-8-isopropoxy quinoline-2-base) 15-1-alcohol,
11-(5-bromo-8-isopropoxy quinoline-2-base) 11-1-alcohol,
11-(5,7-bis-chloro-8-isopropoxy quinoline-2-base) 11-1-alcohol,
9-(8-(cyclo propyl methoxy) quinoline-2-base)-1-alcohol in the ninth of the ten Heavenly Stems,
10-(8-(cyclo propyl methoxy) quinoline-2-base)-1-alcohol in the last of the ten Heavenly stems,
11-(8-(cyclo propyl methoxy) quinoline-2-base) 11-1-alcohol,
12-(8-(cyclo propyl methoxy) quinoline-2-base) 12-1-alcohol,
13-(8-(cyclo propyl methoxy) quinoline-2-base) 13-1-alcohol,
14-((8-(cyclo propyl methoxy) quinoline-2-base) 14-1-alcohol,
15-(8-(cyclo propyl methoxy) quinoline-2-base) 15-1-alcohol,
11-(8-(cyclo propyl methoxy)-5-toluquinoline-2-base) 11-1-alcohol,
11-(8-(cyclo propyl methoxy)-5-fluorine quinoline-2-base) 11-1-alcohol,
9-(the chloro-8-of 5-(cyclo propyl methoxy) quinoline-2-base)-1-alcohol in the ninth of the ten Heavenly Stems,
11-(the chloro-8-of 5-(cyclo propyl methoxy) quinoline-2-base) 11-1-alcohol,
15-(the chloro-8-of 5-(cyclo propyl methoxy) quinoline-2-base) 15-1-alcohol,
11-(the bromo-8-of 5-(cyclo propyl methoxy) quinoline-2-base) 11-1-alcohol,
11-(the chloro-8-of 5,7-bis-(cyclo propyl methoxy) quinoline-2-base) 11-1-alcohol,
The chloro-2-of 5,7-bis-(11-hydroxyl undecyl) quinoline-8-alcohol,
10-(the chloro-8-methoxy quinoline of 5--2-base)-1-alcohol in the last of the ten Heavenly stems,
Acetic acid 10-(the chloro-8-methoxy quinoline of 5--2-base) ester in the last of the ten Heavenly stems,
11-(the chloro-8-methoxy quinoline of 5--2-base) 11-1-alcohol,
Acetic acid 11-(the chloro-8-methoxy quinoline of 5--2-base) 11 esters,
12-(the chloro-8-methoxy quinoline of 5--2-base) 12-1-alcohol,
Acetic acid 12-(the chloro-8-methoxy quinoline of 5--2-base) ten diester,
13-(the chloro-8-methoxy quinoline of 5--2-base) 13-1-alcohol,
Acetic acid 13-(the chloro-8-methoxy quinoline of 5--2-base) 13 esters,
11-(8-methoxy quinoline-4-(-Ji) 11-1-alcohol,
11-(8-ethoxyquinoline-4-(-Ji) 11-1-alcohol,
11-(8-isopropoxy quinoline-4-(-Ji) 11-1-alcohol,
11-(8-(cyclo propyl methoxy) quinoline-4-(-Ji) 11-1-alcohol,
11-(8-(benzyloxy) quinoline-4-(-Ji) 11-1-alcohol,
12-(8-(benzyloxy) quinoline-4-(-Ji) 12-1-alcohol,
4-((11-hydroxyl undecyl) quinoline-8-alcohol,
4-((12-hydroxyl dodecyl) quinoline-8-alcohol,
9-(8-(trifluoromethoxy) quinoline-2-base)-1-alcohol in the ninth of the ten Heavenly Stems,
11-(8-(trifluoromethoxy) quinoline-2-base) 11-1-alcohol,
14-((8-(trifluoromethoxy) quinoline-2-base) 14-1-alcohol,
15-(8-(trifluoromethoxy) quinoline-2-base) 15-1-alcohol,
2-((4-((2-hydroxyethyl) piperazine-1-base) methyl) quinoline-8-alcohol,
2-(4-(((the chloro-8-methoxy quinoline of 5--2-base) methyl) piperazine-1-base) ethanol,
2-(4-(((the chloro-8-ethoxyquinoline of 5--2-base) methyl) piperazine-1-base) ethanol,
2-(4-(((5-chloro-8-isopropoxy quinoline-2-base) methyl) piperazine-1-base) ethanol,
2-(4-(((the chloro-8-of 5-(cyclo propyl methoxy) quinoline-2-base) methyl) piperazine-1-base) ethane,
2-(4-(((the chloro-8-methoxy quinoline of 5,7-bis--2-base) methyl) piperazine-1-base) ethanol,
2-(4-(((the chloro-8-of 5,7-bis-(cyclo propyl methoxy) quinoline-2-base) methyl) piperazine-1-base) ethanol,
2-((methyl (Propargyl) amido) methyl) quinoline-8-alcohol,
The chloro-2-of 5-((methyl (Propargyl) amido) methyl) quinoline-8-alcohol,
N ((the chloro-8-methoxy quinoline of 5--2-base) methyl)-N-methyl-prop-2-alkynes-1-amine,
N ((the chloro-8-ethoxyquinoline of 5--2-base) methyl)-N-methyl-prop-2-alkynes-1-amine,
N ((5-chloro-8-isopropoxy quinoline-2-base) methyl)-N-methyl-prop-2-alkynes-1-amine,
N ((the chloro-8-of 5-(cyclo propyl methoxy) quinoline-2-base) methyl)-N-methyl-prop-2-alkynes-1-amine,
N ((the chloro-8-methoxy quinoline of 5,7-bis--2-base) methyl)-N-methyl-prop-2-alkynes-1-amine,
N ((the chloro-8-of 5,7-bis-(cyclo propyl methoxy) quinoline-2-base) methyl)-N-methyl-prop-2-alkynes-1-amine,
8-((5-chloro-8-methoxy quinoline-2-base) methyl amido) pungent-1-alcohol,
8-((5-chloro-8-ethoxyquinoline-2-base) methyl amido) pungent-1-alcohol,
8-((5-chloro-8-isopropoxy quinoline-2-base) methyl amido) pungent-1-alcohol,
8-((the chloro-8-of 5-(cyclo propyl methoxy) quinoline-2-base) methyl amido) pungent-1-alcohol,
8-((5,7-bis-chloro-8-methoxy quinoline-2-base) methyl amido) pungent-1-alcohol,
8-((the chloro-8-of 5,7-bis-(cyclo propyl methoxy) quinoline-2-base) methyl amido) pungent-1-alcohol and
Own-1-the alcohol of 6-(two ((8-methoxy quinoline-2-base) methyl) amido).
9. prepare a method for compound described in claim 1, comprising:
(15) by formula (II) compound
Wherein:
R 2, R 3, R 4, R 5and R 6respective is independently hydrogen; Or
R 2, R 4, R 5and R 6independently be hydrogen and R separately 3for CH 3; Or
R 2, R 3, R 5and R 6independently be hydrogen and R separately 4for CH 3, F, Cl or Br; Or
R 2, R 5, R 6respective is independently hydrogen, R 3for OCH 3and R 4for Cl; Or
R 2, R 4for Cl and R 3, R 5, R 6respective is independently hydrogen,
React, to obtain formula (III) compound at about room temperature is to about 80 DEG C in a basic solution with toluene bromide, methyl iodide, iodoethane, 2-N-PROPYLE BROMIDE or methylene radical Cyclopropyl Bromide
Wherein:
R 1for CH 3, CH 2cH 3, CH (CH 3) 2, CH 2cH (CH 3) 2or phenmethyl; And
R 2, R 3, R 4, R 5and R 6respective is independently hydrogen; Or
R 2, R 4, R 5and R 6independently be hydrogen and R separately 3for CH 3; Or
R 2, R 3, R 5and R 6independently be hydrogen and R separately 4for CH 3, F, Cl or Br; Or
R 2, R 5, R 6respective is independently hydrogen, R 3for OCH 3and R 4for Cl; Or
R 2, R 4for Cl and R 3, R 5, R 6respective is independently hydrogen;
(16) by formula (III) compound and two (trimethyl silicon based) amido lithium and monobromo (C 1-C 20) alkanol reacts, to obtain formula (I) compound in tetrahydrofuran (THF) at 0 DEG C
Wherein:
R 1for CH 3, CH 2cH 3, CH (CH 3) 2, CH 2cH (CH 3) 2or phenmethyl;
R 2, R 3, R 4, R 5and R 6respective is independently hydrogen; Or
R 2, R 4, R 5and R 6independently be hydrogen and R separately 3for CH 3; Or
R 2, R 3, R 5and R 6independently be hydrogen and R separately 4for CH 3, F, Cl or Br; Or
R 2, R 5, R 6respective is independently hydrogen, R 3for OCH 3and R 4for Cl; Or R 3for Cl and R 4for OCH 3or
R 2, R 4for Cl and R 3, R 5, R 6respective is independently hydrogen; And
R 7for (CH 2) 9oH, (CH 2) 10oH, (CH 2) 11oH, (CH 2) 12oH, (CH 2) 13oH or (CH 2) 15oH,
(17) wherein R is incited somebody to action 1for formula (I) compound of phenmethyl, at room temperature reacted in methyl alcohol by palladium carbon under pressure with hydrogen, or react at 0 DEG C in methylene dichloride with boron trichloride, to obtain formula (I) compound
R 1, R 2, R 3, R 4, R 5and R 6respective is independently hydrogen; Or
R 1, R 2, R 4, R 5and R 6independently be hydrogen and R separately 3for CH 3; Or
R 1, R 2, R 3, R 5and R 6independently be hydrogen and R separately 4for CH 3, F, Cl or Br; Or
R 1, R 2, R 5, R 6respective is independently hydrogen, R 3for OCH 3and R 4for Cl; R 3for Cl and R 4for OCH 3; Or
R 2, R 4for Cl and R 1, R 3, R 5, R 6respective is independently hydrogen; And
R 7for (CH 2) 9oH, (CH 2) 10oH, (CH 2) 11oH, (CH 2) 12oH, (CH 2) 13oH or (CH 2) 15oH; Or
(18) wherein R is incited somebody to action 1, R 2, R 3, R 4, R 5and R 6independently be hydrogen and R separately 7for (CH 2) 11formula (I) compound of OH, at room temperature reacts in methyl chloride with N-chloro-succinimide, to provide formula (I) compound, wherein R 1, R 3, R 5and R 6respective is independently hydrogen, R 2and R 4independently be chlorine and R separately 7for (CH 2) 11oH; Or
(19) wherein R is incited somebody to action 1for methyl, R 2, R 3, R 4, R 5and R 6independently be hydrogen and R separately 7for (CH 2) 11oH, (CH 2) 12oH or (CH 2) 13formula (I) compound of OH, with concentrated hydrochloric acid, ICl 3and glacial acetic acid reacts, to provide formula (I) compound, wherein R 1for methyl, R 2, R 3, R 5and R 6respective is independently hydrogen, R 4for Cl and R 7for (CH 2) 10oH, (CH 2) 11oH, (CH 2) 12oH, (CH 2) 13oH, (CH 2) 15oH, (CH 2) 10oCOCH 3, (CH 2) 11oCOCH 3, (CH 2) 12oCOCH 3or (CH 2) 13oCOCH 3; Or
(20) 2-amino-phenol and methyl vinyl ketone are reacted in hydrochloric acid, to obtain formula (INT-1) compound
(21) formula (INT-1) compound and methyl iodide, iodoethane, 2-N-PROPYLE BROMIDE, methylene radical Cyclopropyl Bromide or toluene bromide are reacted in basic solution, to provide formula (III) compound,
Wherein R 10for methyl, ethyl, 2-propyl group, methylene radical cyclopropyl or phenmethyl;
(22) wherein R is incited somebody to action 10for formula (III) compound of methyl, ethyl, 2-propyl group, methylene radical cyclopropyl or phenmethyl, react at 0 DEG C in tetrahydrofuran (THF) with two (trimethyl silicon based) amido lithium and the bromo-undecyl alcohol of 11-or 12-bromine lauryl alcohol, to obtain formula (I) compound, wherein R 1for methyl, ethyl, 2-propyl group, methylene radical cyclopropyl or phenmethyl; R 2, R 3, R 4, R 6and R 7respective is independently hydrogen; And R 5for (CH 2) 11oH or (CH 2) 12oH;
(23) wherein R is incited somebody to action 1for phenmethyl; R 2, R 3, R 4, R 6and R 7respective is independently hydrogen; And R 5for (CH 2) 11oH or (CH 2) 12formula (I) compound of OH, is at room temperature reacted by palladium carbon under pressure with hydrogen in methyl alcohol, to obtain formula (I) compound, wherein R 1for hydrogen; R 2, R 3, R 4, R 6and R 7respective is independently hydrogen; And R 5for (CH 2) 11oH or (CH 2) 12oH; Or
(24) 2-trifluoro-methoxyaniline and crotonic aldehyde are reacted, to obtain 2-methyl-8-trifluoromethoxy quinoline, by it with two (trimethyl silicon based) amido lithium and monobromo (C 1-C 20) alkanol processes, to obtain formula (I) compound, wherein R in tetrahydrofuran (THF) at 0 DEG C 1for trifluoromethyl; R 2, R 3, R 4, R 5and R 6respective is independently hydrogen; And R 7for (CH 2) 10oH, (CH 2) 11oH, (CH 2) 12oH, (CH 2) 13oH or (CH 2) 15oH; Or
(25) by the 8-hydroxy-2-methylquinoline compound of the same form (IV), wherein R 1for hydrogen, methyl, ethyl, 2-propyl group or methylene radical cyclopropyl,
React at an elevated temperature in dioxan with tin anhydride, to provide the same form (VI) compound, R 1for hydrogen, methyl, ethyl, 2-propyl group or methylene radical cyclopropyl
(26) wherein R is incited somebody to action 1for formula (VI) compound of hydrogen, methyl, ethyl, 2-propyl group or methylene radical cyclopropyl, react with N-methyl-prop ynamine, to obtain formula (I) compound, wherein R 1for hydrogen, CH 3, CH 2cH 3, CH 2cH (CH 3) 2, CH 2cH (CH 2) 2or CH (CH 3) 2, R 2, R 3, R 4, R 5and R 6respective is independently hydrogen; And R 7for CH 2n (CH 3) CH 2c ≡ CH; Or
(27) by R 1for formula (VI) compound of hydrogen, methyl, ethyl, 2-propyl group or methylene radical cyclopropyl, react with 2 (piperazine-1-base) ethanol, to obtain the same form (I) compound, wherein R 1for hydrogen, CH 3, CH 2cH 3, CH 2cH (CH 3) 2, CH 2cH (CH 2) 2or CH (CH 3) 2, R 2, R 3, R 4, R 5and R 6respective is independently hydrogen; And R 7for CH 2(N (CH 2cH 2) 2n) CH 2cH 2oH; Or
(28) by formula (VI) compound and an amido (C 1-C 20) alkanol carries out reacting to obtain the same form (I) compound, wherein R 1for hydrogen, CH 3, CH 2cH 3, CH 2cH (CH 3) 2, CH 2cH (CH 2) 2or CH (CH 3) 2; R 2, R 3, R 4, R 5and R 6respective is independently hydrogen; And R 7for CH 2nH (CH 2) 8oH or CH 2n ((CH 2) 6oH) CH 2(8-methoxy quinoline-2-base).
10. a constituent, comprises the compound according to any one of claim 1 to 8 or its medical acceptable salt, solvate or hydrate, prodrug or the metabolite of a treatment significant quantity, and medical acceptable thinner or a supporting agent.
11. 1 kinds of constituents being used for the treatment of neurodegenerative disorders, comprise the compound according to any one of claim 1 to 8 or its medical acceptable salt, solvate or hydrate, prodrug or the metabolite of a treatment significant quantity, and medical acceptable thinner or a supporting agent.
12. constituents being used for the treatment of neurodegenerative disorders as claimed in claim 11, wherein this neurodegenerative disorders is selected from the group be made up of following disease: Alzheimer's disease, amyotrophic lateral sclerosis, cognitive dissonance, ischemia apoplexy, cerebral paralysis, apoplexy, hemorrhagic stroke, storehouse Jia Shi disease, spongiform encephalopathy becomes, mad cow syndrome, dementia, melancholia, Down syndrome, epilepsy, Frontotemporal Dementia, Tourette syndrome, Ha Sishi disease, Heng Dingdunshi disease, Lewy body disease, Parkinson's disease, cognitive disorder, learning disorder, macular diseases, dysmnesia, multiple sclerosis, multiple systems atrophy, motor neurone disease, kirschner disease, gradual core is benumbed, pseudodementia disease, retinopathy, senile dementia, the nerve degeneration that schizophrenia transient anoxia brings out, traumatic brain injury and Spinal injury.
13. constituents being used for the treatment of neurodegenerative disorders as claimed in claim 11, wherein this neurodegenerative disorders is Alzheimer's disease.
Compound according to any one of 14. 1 kinds of claims 1 to 8 is for the preparation of the purposes of a neurodegenerative disorders medicine for treatment thing.
15. purposes as claimed in claim 14, wherein this medicine is for being used for the treatment of Alzheimer's disease.
CN201380075030.2A 2013-04-02 2013-04-02 Multi-functional quinoline as anti-nerve degeneration agent Expired - Fee Related CN105452224B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2013/034960 WO2014163622A1 (en) 2013-04-02 2013-04-02 Multifunctional quinoline derivatives as anti-neurodegenerative agents

Publications (2)

Publication Number Publication Date
CN105452224A true CN105452224A (en) 2016-03-30
CN105452224B CN105452224B (en) 2017-12-26

Family

ID=51658752

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201380075030.2A Expired - Fee Related CN105452224B (en) 2013-04-02 2013-04-02 Multi-functional quinoline as anti-nerve degeneration agent

Country Status (9)

Country Link
EP (1) EP2981525A4 (en)
JP (1) JP6153179B2 (en)
KR (1) KR101802048B1 (en)
CN (1) CN105452224B (en)
AU (1) AU2013385618B2 (en)
BR (1) BR112015024472A2 (en)
IL (1) IL241295A0 (en)
RU (1) RU2642466C2 (en)
WO (1) WO2014163622A1 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101725326B1 (en) * 2015-04-23 2017-04-12 대한민국 A novel isolated midroorganism having antibiotic activity and a production method of pseudane using the same
CN105949120B (en) * 2016-05-27 2018-07-24 广东工业大学 A kind of application of four teeth chelating type list quinoline and preparation method thereof and metal ion control agent as neurodegenerative disease
KR102281647B1 (en) * 2020-12-09 2021-07-30 메디케어제약 주식회사 Method of producing a derivative-piperazine
CN113527200B (en) * 2021-05-27 2022-12-02 北京斯利安药业有限公司 Preparation method of cloquinadol

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060089380A1 (en) * 2002-07-16 2006-04-27 Prana Biotechnology Ltd. 8-Hydroxy quinoline derivatives
US20090227626A1 (en) * 2005-08-04 2009-09-10 Palumed S.A. Novel polyquinoline derivatives and therapeutic use thereof
CN101611009A (en) * 2006-07-25 2009-12-23 伊维沃制药股份有限公司 Quinoline
US20110301163A1 (en) * 2008-10-06 2011-12-08 The Johns Hopkins University Quinoline compounds as inhibitors of angiogenesis, human methionine aminopeptidase, and sirt1, and methods of treating disorders

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3682927A (en) * 1968-06-15 1972-08-08 Massimo Carissimi 5,7-bichloro-8-hydroxy-2-acetylamino quinoline
GB9127306D0 (en) * 1991-12-23 1992-02-19 Boots Co Plc Therapeutic agents
ES2094567T3 (en) * 1992-10-27 1997-01-16 Janssen Pharmaceutica Nv DERIVATIVES OF 4-QUINOLINYL WITH ANTI-HELICOBACTER ACTIVITY.
AU720643B2 (en) * 1996-08-13 2000-06-08 P.N. Gerolymatos S.A. Use of the chelating agent clioquinol for the manufacture of a pharmaceutical composition for the treatment of Alzheimer's disease
JP3588126B2 (en) * 1997-07-07 2004-11-10 興和株式会社 Diamine derivatives and pharmaceuticals containing the same
FR2819507B1 (en) * 2001-01-17 2007-09-28 Inst Rech Developpement Ird SUBSTITUTED QUINOLINES FOR THE TREATMENT OF PROTOZOAN AND RETROVIRUS CO-INFECTIONS
PL209872B1 (en) 2002-03-27 2011-10-31 Glaxo Group Ltd Quinoline derivatives and their use as 5-ht6 ligands
WO2003093240A1 (en) 2002-04-30 2003-11-13 Yungjin Pharmaceutical Co., Ltd. Quinoline derivatives as caspase-3 inhibitor, preparation for producing the same and pharmaceutical composition comprising the same
WO2004076386A2 (en) * 2003-02-25 2004-09-10 Topotarget Uk Limited Carbamic acid compounds comprising a bicyclic heteroaryl group as hdac inhibitors
GB0322510D0 (en) 2003-09-25 2003-10-29 Glaxo Group Ltd Novel compounds
WO2005035534A1 (en) * 2003-10-08 2005-04-21 Ono Pharmaceutical Co., Ltd. Heterocyclic bicyclo ring and heterocyclic tricyclo ring compounds and drugs comprising the same
US20050131042A1 (en) * 2003-12-11 2005-06-16 Flentge Charles A. HIV protease inhibiting compounds
US8969349B2 (en) * 2010-05-26 2015-03-03 Sunovion Pharmaceuticals Inc. Substituted quinoxalines and quinoxalinones as PDE-10 inhibitors
CN102526052B (en) * 2012-01-19 2013-10-09 华南师范大学 Application of 2-gylcosyl chinoline compound in preparing acetylcholine esterase resisting medicines

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060089380A1 (en) * 2002-07-16 2006-04-27 Prana Biotechnology Ltd. 8-Hydroxy quinoline derivatives
US20090227626A1 (en) * 2005-08-04 2009-09-10 Palumed S.A. Novel polyquinoline derivatives and therapeutic use thereof
CN101611009A (en) * 2006-07-25 2009-12-23 伊维沃制药股份有限公司 Quinoline
US20110301163A1 (en) * 2008-10-06 2011-12-08 The Johns Hopkins University Quinoline compounds as inhibitors of angiogenesis, human methionine aminopeptidase, and sirt1, and methods of treating disorders

Also Published As

Publication number Publication date
RU2015137621A (en) 2017-05-11
KR20150136070A (en) 2015-12-04
EP2981525A1 (en) 2016-02-10
JP2016515617A (en) 2016-05-30
BR112015024472A2 (en) 2017-07-18
AU2013385618A1 (en) 2015-09-24
JP6153179B2 (en) 2017-06-28
WO2014163622A1 (en) 2014-10-09
IL241295A0 (en) 2015-11-30
AU2013385618B2 (en) 2017-01-05
RU2642466C2 (en) 2018-01-25
EP2981525A4 (en) 2016-12-21
CN105452224B (en) 2017-12-26
KR101802048B1 (en) 2017-12-28
WO2014163622A8 (en) 2014-11-13

Similar Documents

Publication Publication Date Title
JP6297655B2 (en) Polycyclic compounds and methods of use thereof
TWI394743B (en) Bicyclic azabicyclic carboxamide derivatives, preparation and therapeutic use thereof
JP2000514804A (en) 3-Ureido-pyridofuran and -pyridothiophene for the treatment of inflammatory processes
JPH07501337A (en) quinolone derivatives
EP0737671A2 (en) Aromatic hydroxamic acid compounds, their production and use
CA3132120C (en) Heteroaryl compounds and methods of use thereof
PT1765795E (en) Alkynyl derivatives as modulators of metabotropic glutamate receptors
CN101903372A (en) Heteroaryl derivatives as orexin receptor antagonists
CN105452224A (en) Multifunctional quinoline derivatives as anti-neurodegenerative agents
AU2009269842B2 (en) Use of indole derivatives as NURR-1 activators for treating Parkinson's disease
CN106573907A (en) Novel quinoline derivatives and their use in neurodegenerative diseases
DE102004024504A1 (en) Novel cylopenta [b] benzofuran derivatives and their use
RU2144028C1 (en) Improved methods of synthesis of 6,9-bis-[(2-aminoethyl)- -amino]benzo[g]isoquinoline-5,10-dione maleate
CN103333216A (en) 5alpha-6-ketone-cholestane analogue and applications thereof
BG62403B1 (en) Isoquinoline derivatives in their capacity of therapeutical forms
IL128902A (en) N-(2- benzothiazolyl)-1- piperidineethanamine derivatives, their preparation and pharmaceutical compositions comprising them
CN107737126B (en) Application of coumarin-dithiocarbamate derivative in pharmacy
JPH06507387A (en) Novel ureas and thioureas, their production and therapeutic applications
US9302992B2 (en) Multifunctional quinoline derivatives as anti-neurodegenerative agents
CN113956249B (en) Brain-targeted AChE inhibitor prodrug, and preparation method and application thereof
CN114380883B (en) Aminoalkoxy tripterine derivative, preparation method and application
JP2648434B2 (en) Pharmaceutical composition containing quinoline or quinazoline derivative
TWI543969B (en) Multifunctional quinoline derivatives as anti-neurodegenerative agents
WO2009153897A1 (en) Stemonamide synthesis intermediate and pharmaceutical composition for prevention and/or treatment of cancer
CN116457355A (en) 2-amino-3-carbonyl imidazopyridines and pyrazolopyridines compounds

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C41 Transfer of patent application or patent right or utility model
CB02 Change of applicant information

Address after: Taipei City, Taiwan, China

Applicant after: ANNJI PHARMACEUTICAL Co.,Ltd.

Address before: Taipei City, Taiwan, China

Applicant before: Ricky Biotechnology New Pharmaceutical Co.,Ltd.

Address after: Taipei City, Taiwan, China

Applicant after: ANNJI PHARMACEUTICAL Co.,Ltd.

Address before: Taipei City, Taiwan, China

Applicant before: ANNJI PHARMACEUTICAL Co.,Ltd.

COR Change of bibliographic data
TA01 Transfer of patent application right

Effective date of registration: 20160621

Address after: Taipei City, Taiwan, China

Applicant after: Ricky Biotechnology New Pharmaceutical Co.,Ltd.

Address before: Taipei City, Taiwan, China

Applicant before: ANNJI PHARMACEUTICAL Co.,Ltd.

GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20171226

Termination date: 20190402

CF01 Termination of patent right due to non-payment of annual fee